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Abstract 
Neurodegenerative diseases are characterized by the progressive loss of specific neurons in selected 
regions of the nervous system. The main clinical manifestation (movement disorders, cognitive 
impairment, and/or psychiatric disturbances) depends on the neuron population being primarily affected. 
Parkinson's disease (PD) is a common movement disorder, whose aetiology remains mostly unknown. 
Progressive loss of dopaminergic neurons in the Substantia Nigra causes an impairment of the motor 
control. Some of the pathogenetic mechanisms causing the progressive deterioration of these neurons 
are not specific for PD but are shared by other neurodegenerative diseases, like Alzheimer's disease (AD) 
and amyotrophic lateral sclerosis (ALS).  
In this context, the main aim of the present thesis is to dissect specific and common pathways of 
neurodegeneration, in order to focus on PD specific mechanisms and to delineate a PD macromolecular 
landscape, eliminating common signs of neuronal loss. The different projects developed during my Ph.D. 
programme aimed to achieve this final goal. 
First of all, to distinguish between general and PD-specific patterns of neurodegeneration, a meta-analysis 
of the literature of all quantitative proteomics investigations of neuronal alterations in different models 
of PD, AD, and ALS was performed (Meta-Neuro project). Afterwards, all proteomics data were merged 
with genetics information retrieved from the DisGeNET database. By using open-source bioinformatics 
tools, it was possible to identify biological processes specifically affected in PD, i.e., proteolysis, 
mitochondrion organization and mitophagy. Moreover, four cellular component complexes were found 
to be mostly involved in the pathogenesis: the proteasome complex, the protein phosphatase 2A, the 
chaperonins CCT complex and the complex III of the respiratory chain. Eventually, this analysis 
highlighted a close relationship between PD and ALS.  
In order to dissect the particular relationship between PD and ALS, the ProLyPALS project aimed at the 
analysis of ALS patients showing parkinsonian signs and symptoms (ALS-PD), who may evidence those 
proteins and biochemical pathways altered by both diseases. Indeed, the frequency of extrapyramidal 
symptoms in ALS patients is significantly higher than in the general population. To study these complex 
and multifactorial pathologies, a holistic approach may give a global view on the pathogenetic processes 
at the basis of neurodegeneration. The nature of samples available for this kind of studies is an issue in 
  
neuroscience research. In this project, peripheral blood mononuclear cells (PBMCs) were considered a 
good cellular model for a better understanding of ALS and PD, because of the easiness of sampling, their 
ability to patrol what is happening at the central level and the involvement of the immune system in the 
pathogeneses. The ultimate goal of this approach was the characterization of ALS-PD patients, based on 
a model constructed from the differences evidenced in the PBMCs proteome of ALS and PD subjects. 
Therefore, ALS and PD proteomes were used to construct the predictive model and ALS-PD subjects 
were predicted as ALS or PD, depending on the discriminant function previously generated. Total 
proteins from PBMCs lysates of each patient were separated through two-dimensional electrophoresis 
(2-DE). Around 400 spots in each 2-DE map were matched. Consequently, the 54 spots able to better 
discriminate between ALS and PD patients were selected by Wilcoxon test. Among them, 33 spots were 
selected to build a Linear Discriminant model, as the one with the best sensibility and specificity. The 
proteins at the basis of the model were identified by LC-MS/MS. The role of each feature contributing 
to the discriminating function was investigated, to evidence the biochemical pathways specifically altered 
by one of the two pathologies. Some of them have already been associated with either disease, for 
example a feature selected by the model was the Cu,Zn-superoxide dismutase-1 (SOD1), linked to familial 
ALS, whereas another one, fibrinogen, was already found to be reduced in T-lymphocytes of PD patients. 
Eventually, the model was used to predict the classification of the ALS-PD patients. Four ALS-PD 
subjects were classified as ALS patients, while five subjects resulted to be more similar to PD patients. 
Their classification as PD subjects instead of ALS can be due to several factors: early appearance of 
parkinsonism, severity of parkinsonian signs, familiarity with PD, mutations in genes commonly involved 
in PD. 
Mitochondria seem to have a pivotal role in PD pathogenesis. Several pieces of evidence are present in 
the literature and emerged by the results of the two first projects of the present thesis (Meta-Neuro and 
ProLyPALS projects). Many neurodegenerative diseases are only associated with alterations at the 
mitochondrial level, whereas the impairment of the mitochondrial quality control could be a primary 
event in PD pathogenesis. Indeed, several molecular pathways implicated in PD aetiology converge on 
mitochondria. To focus on the main mitochondrial processes involved in PD, PD-specific proteins 
obtained by the meta-analysis (Meta-Neuro project) were mapped on the functional mitochondrial 
human proteome network (MitoNet project). This network was built retrieving information from 
neXtProt, the reference database for the Human Proteome Project (HPP) metrics, about both nodes 
(mitochondrial proteins) and edges (gold binary interactions). This analysis highlighted that 31% of PD-
specific proteins were mitochondrial proteins or associated with mitochondria. Moreover, the over-
representation analysis highlighted the central role of mitophagy, mitochondrial protein import and 
mitochondrial transport as PD specific pathways. 
  
At the end of my Ph.D. programme, I tried to make a step forward in the use of bioinformatics tools to 
investigate PD specific mechanisms. In particular, I aimed at the generation of a dynamic model of the 
“PD mitochondrion”, to describe mathematically what happens in mitochondria of PD patients. The 
proposed model focused on a particular type of cellular model of PD (human neuroblastoma cells treated 
with mitochondrial toxins). The model adopted a fuzzy logic-based formalism that allows the temporal 
simulation of the system and the representation of heterogeneous cellular components and processes. To 
this purpose, preliminary data were collected about several proteins involved in mitochondrial dynamics, 
such as mitophagy, fusion and fission. Next steps will be the generation of many other wet results and 
their integration, to generate membership functions of the fuzzy-model, with the final aim to use the 
virtual “PD mitochondrion” as a simulation platform. 
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1.1 
Introduction 
 
 
 
 
 
From reductionism to systems biology  
Methodological reduction is based on the idea that complex biological systems could be explained by 
investigating their individual components. A common example of this type of strategy is the dissection 
of biological systems into their constituent parts (Strange, 2004), for instance, the investigation of 
cellular populations or organs is used to comprehend the organism status and the study of cellular 
biochemical components is exploited to understand cell phenotype. This method drove the research 
in the last half of the 20th century and it has been effective in explaining the chemical basis of numerous 
living processes.  
However, biological systems are clearly much more than the sum of their parts and the behaviour of 
complex physiological processes cannot be explained, or even predicted, by studying how the parts 
work in isolation. For instance, PARK7 gene encodes for DJ-1 protein (Protein/nucleic acid deglycase 
DJ-1) that plays an important role in cell protection against oxidative stress and cell death, acting as 
oxidative stress sensor and redox-sensitive chaperone and protease. Deletions and loss-of-function 
mutations in the human PARK7 gene have been associated with several diseases such as a familiar 
form of Parkinson's disease (PD) (Tang et al., 2006), amyotrophic lateral sclerosis (ALS) (Annesi et 
al., 2005) and dementia (Rizzu et al., 2004). Furthermore, an increase of DJ-1 level promotes cell 
survival (Kim et al., 2005) and it is involved in advanced stage ovarian carcinomas (Davidson et al., 
2008), in renal carcinoma (Sitaram et al., 2009) and in prostate cancers (Tillman et al., 2007). In all 
these pathologies, DJ-1 function and/or level are altered, but this alteration leads to different clinical 
features. Therefore, other factors, such as the specific cellular type, the micro- and macro-environment 
and epigenetic factors influence the epiphenomenon. Thus, interactions between the individual parts 
of given system, as well as influences from environmental factors and the genetic background, give 
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rise to a systems behaviour, which are absent in the individual components (Alm and Arkin, 2003; 
Van Regenmortel, 2004). Emergent properties have their own causal powers, which are not be 
predicted from lower-level (as it happens for resultant properties). For instance, the experience of pain 
can alter human behaviour, but the biochemical pathways activated in the neurons (lower-level) in the 
perception of pain are not the cause of the altered behaviour, as the pain itself has causal efficacy 
(Morowitz, 2002). Reductionists advocate the idea of “upward causation” by which molecular states 
bring about higher-level phenomena. The hierarchical structure present in biological systems implies 
that what happens at a certain scale (e.g. at the cellular level) is strongly linked to the other scales (e.g. 
at the tissue level). These levels interact in many ways: negative feedback and feed-forward control. 
Therefore, it is impossible to predict the whole phenomenon by linear mathematical models that 
disregard cooperativity and non-additive effects, but it is necessary the adoption of multi-scale 
mathematical methods, where the output of each model being the input of another model that 
operates on a different scale.  
Moreover, biological systems present other essential properties:  
- Robustness: the capability of systems to adapt and be impervious to change in the 
environment, thanks, for example, to the presence of redundant components that can act as a 
backup when individual components fail (Kitano, 2002). 
- Modularity: biological systems are composed of subsystems communicating with each other 
even if they are physically and functionally insulated. Thus, the failure of one module does not 
necessarily spread to other modules (Alm and Arkin, 2003).  
- Biological systems are open: they are able to exchange matter and energy with their 
environment, so they are not in thermodynamic equilibrium.  
For all the above-mentioned reasons, systems biology has emerged as the successor of reductionism 
(Kitano, 2002; Kitano, 2002; Pennisi, 2003, Bizzarri et al., 2013). 
The aim of systems biology is to integrate experimental data to build predictive models, whose 
numerical simulations can elucidate the emergent properties of the system in both physiological and 
pathological conditions (Medina, 2013; Noble, 2011; Longo et al., 2012). Mathematical modelling 
helps in revealing possible counterintuitive mechanisms and in generating new hypotheses that can be 
tested in laboratory. Simulation of the temporal evolution can show the system dynamics in a wide 
variety of perturbed conditions, considerably reducing the cost and time of experiments. The iterative 
process (Figure 1.1) of prediction, computational simulation and experimental validation allows to 
refine the model, in order to obtain the most accurate depiction of the real system, along with clarity, 
simplicity and a reduced number of free parameters (Fasano et al., 2016; Bartoccio and Liò, 2016). 
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Figure 1.1: Schematic representation of the iterative process of construction and validation of a mathematical model. Data 
from in silico analysis are compared to the experimental ones, in order to formulate new hypotheses and refine the first 
model draft. A validated model is the starting point for a deeper and predictive computational analysis. 
 
To formulate a mathematical model that describes the system, it is essential to know elements and 
dynamics activated in response to specific environmental or genetic perturbations and supplement 
this information to identify the rules of system control and regulation. To these purposes, several tools 
can be used, such as pathway and network analysis (Fasano et al., 2016).  
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Pathway analysis 
Biological knowledge has been organized in several databases, which encode biological knowledge of 
molecular mechanisms, proteins sequences, proteolytic peptides and proteins interactions data (Table 
1.1). 
Table 1.1: Main protein databases. 
Database name URL Reference 
Uniprot http://www.uniprot.org/ Chen et al., 2017 
neXtProt http://www.nextprot.org/ Gaudet et al., 2017 
UniGene https://www.ncbi.nlm.nih.gov/unigene/ 
NCBI Resource 
Coordinators, 2018 
RefSeq https://www.ncbi.nlm.nih.gov/refseq/ O'Leary et al., 2016 
GenBank https://www.ncbi.nlm.nih.gov/genbank/ Benson et al., 2005 
MissingProteinPedia http://missingproteins.org/ Baker et al., 2017 
Human Protein Atlas https://www.proteinatlas.org/ Thul and Lindskog, 2018 
MEROPS https://www.ebi.ac.uk/merops/ Rawlings et al., 2018 
Pride https://www.ebi.ac.uk/pride/archive/ Vizcaíno et al., 2016 
ProteomeXchange http://www.proteomexchange.org/ Deutsch et al., 2017 
Peptide Atlas http://www.peptideatlas.org/ Deutsch et al., 2015 
STRING https://string-db.org/ Szklarczyk et al., 2017 
BioGRID https://thebiogrid.org/ 
Chatr-Aryamontri et al., 
2017 
IMEX https://www.imexconsortium.org/ Orchad et al., 2012 
IntAct https://www.ebi.ac.uk/intact/ Orchard et al., 2015 
Gene Ontology 
consortium 
http://geneontology.org/ 
The Gene Ontology 
Consortium, 2017 
WIKIPATHWAY https://www.wikipathways.org/index.php/WikiPathways Slenter et al., 2018 
Pathway Commons http://www.pathwaycommons.org/pc/ Cerami et al., 2010 
Reactome https://reactome.org/ Fabregat et al., 2018 
KEGG https://www.genome.jp/kegg/ Kanehisa et al., 2017 
 
Many databases have become accessible in the last decade (Khatri et al., 2012; Ramanan et al., 2012) 
and some of them provide platforms to directly analyse proteomics data, such as pathway databases 
(e.g. Reactome (Fabregat et al., 2018) and KEGG (Kanehisa et al., 2017) databases) (Goh et al., 2012). 
Relevant functional relations may be obtained also from the Gene Ontology (GO) database, in which 
gene functions are described in terms of three different main aspects: the molecular function (MF), 
the cellular component (CC) and the biological process (BP) (The GO Consortium, 2017). Other 
possible platforms for the interpretation of proteomics data are secondary databases (which collect 
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information from other public pathway databases), such as Pathway Commons (Cerami et al., 2010) 
and WIKIPATHWAYS (Slenter et al., 2018). 
Using data stored in pathway databases, it is possible to analyse lists of proteins resulting from 
proteomics studies. The analysis of pathways can be used to generate a hypothesis, through an 
inductive method, and to attribute an expectation value to it (Khatri et al., 2012). To this purpose an 
over-representation analysis (ORA) can be performed to functionally explain changes at protein level. 
In the ORA, the hypergeometric test (Fisher’s test) is normally used to compute a p value for each 
over/under-represented pathway. Fisher’s test is a conditional test, where the p value for an over-
represented pathway is calculated from the number of differentially expressed proteins in the 
experimental list and in a reference database, assigned or not to a given pathway (Fasano et al., 2016).  
 
Network analysis  
Based on the rationale that interacting proteins share common functions or take part to common 
processes, it is possible to build biological networks. The biological network is a graph defined by two 
sets: a set of nodes, representing biological components (such as proteins, genes) and a set of edges, 
that connect nodes, representing physical or functional interactions.  
Networks can be analysed using several topological measures that can help elucidate potential 
therapeutic targets and/or biomarkers (degree of connectivity, betweenness centrality and clustering 
coefficient) (Santiago and Potashkin, 2014). Eventually, protein networks may be further analysed in 
terms of pathways to show how protein clusters are functionally linked to specific processes (Wu et 
al., 2014; Laukens et al., 2015).  
Several software is available to generate and visualize biological networks. Cytoscape is the most used, 
since it provides an open-source environment for network generation, visualization and analysis 
(Shannon et al., 2003). Moreover, several modules are available to customize the Cytoscape 
environment, in particular tools to perform the ORA on networks or to analyse topological elements 
(clusters or subnetworks). In addition to Cytoscape, other open-source platforms are available to 
visualize and analyse networks, such as Gephi – The Open Graph Viz Platform –for network 
manipulation (Bastian et al., 2009) and Pajek, for large networks (Mrvar and Batagelj, 2016). 
To build a biological network, information present in public databases that store molecular interaction 
data can be used (e.g., BioGRID (Chatr-Aryamontri et al., 2017), IntAct (Orchard et al., 2015), and 
STRING (Szklarczyk et al., 2017)). Each of them has advantaged and disadvatages (Table 1.2). Several 
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efforts have been made to put under a single consortium (the IMEx consortium) the whole 
information available on protein–protein interactions (PPI) (Orchad et al., 2012) (Table 1.2).  
Table 1.2: Advantages and disadvantages of main open source PPI databases. 
Database 
name 
Advantages Disadvantages 
IMEx 
• Contains physical interactions data 
• Contains data of several organisms 
• Is a secondary database  
• Contains data of several public interaction 
database (e.g., IntAct, BioGRID and 
Uniprot) 
• A plugin in Cytoscape is available 
• Redundant information 
• The user is overwhelmed with too 
much information 
• No quality control of data available 
• A graphical software is necessary 
to visualize the network 
IntAct 
• Contains physical interactions data 
• All interactions are derived from literature 
curation or direct user submissions 
• A plugin in Cytoscape is available 
• The user is overwhelmed with too 
much information 
• No quality control of data available 
• A graphical software is necessary 
to visualize the network 
STRING 
• Contains physical and functional 
interactions data 
• Contains data of several organisms 
• Is a secondary database  
• Contains data of several public interaction 
databases (e.g., IntAct, BioGRID) 
• Computes the PPI enrichment p value. It 
indicates that the network has significantly 
more interactions than expected 
• Performs an ORA using GO, KEGG and 
proteins domains databases (PFAM) 
• The user is overwhelmed with too 
much information 
• No quality control of data available 
 
neXtProt 
• Contains physical interactions data 
• Is a secondary database  
• Contains data of several public interaction 
database (e.g., IntAct, Uniprot) 
• Provides only highest and good quality 
data 
• Data deemed of a lower quality do not 
integrate 
• Provides only data about human 
proteins 
• No plugin in Cytoscape is available 
to directly generate the network 
• Information is manually curated 
(operator-dependent and delayed 
update with respect to 
automatically annotated database) 
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Logic modelling 
A graph can be a good representation of a biological systems, but it can provide only a static view of 
the underlying system. To overcome this drawback, two main modelling approaches are currently 
being utilized: mechanism-based models and logic-based models (Le Novère, 2015).  
Mechanism-based models allow to predict the behaviour of a specific system and to track its dynamics 
by fixed system parameters. All the parameters (e.g., diffusion, binding and reaction kinetics, 
concentrations of system's components) (Würstle et al., 2014) must be experimentally measured or 
inferred to specify the model.  For example, a mechanism-based model was used to describe the 
glucose-insulin system and all major physiological processes involved in plasma glucose homeostasis 
(Figure 1.2) (Cobelli et al., 2014). 
 
 
 
Figure 1.2: Pictorial layout of the physiological components in the glucose-insulin system model (taken from Cobelli et al., 
2014). 
 
All parameters of this model (e.g., insulin secretion in the pancreas, glucose uptake in peripheral tissues, 
glucose production) have been obtained through the evaluation of insulin and glucose dynamics in 
serum and plasma (Cobelli et al., 2014). Mechanism-based model requires a huge amount of 
biochemical quantitative information. To overcome this limitation, logic-based models are currently 
emerging as an alternative to study biological events (Wynn et al., 2012).  
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Logic-based models are graphs based on (1) edges, (2) nodes and (3) logical rules (Morris et al., 2010). 
The interactions between the components of the system can be physical or functional and edges can 
be added also using qualitative data (Morris et al., 2010). Moreover, nodes can represent different 
types of information, from the presence of a protein to the activation of a biochemical pathway or the 
occurrence of a phenotype. Logical rules can contain one or more logic operator (e.g. NOT, AND, 
OR). Each rule should correctly describe an interaction existing in the real biological system, to make 
the whole model predictive. Evaluation of logical rules provides the output value of each node based 
on the values of input nodes (Wynn et al., 2012). Various types of logic-based model exist, differing 
in (1) how they handle time during simulation and (2) how they describe nodes (discrete states or 
continuous states).  
(1) In logic-based models, simulation is usually performed in discrete time steps using a synchronous 
or asynchronous update (Wynn et al., 2012). In models that adopt a synchronous update method, all 
nodes are updated at the same time according to the values of their input nodes at the previous time 
step, thus the state of the network is always entirely determined by its state at the previous step. 
Conversely, in the asynchronous method, a randomly selected node is updated thanks to the state of 
the network and therefore its next state is non-deterministic. The asynchronous update method is 
thought to be closer to the real biological systems, but it requires to run many simulations to obtain 
probability distributions of output states according to given input states (Wynn et al., 2012). 
(2) In the logic-based model the description of variables can be represented as discrete states (using 
Boolean logic) or continuous states (using fuzzy logic). Among logic-based models, Boolean models 
are the simplest and widely used. In Boolean logic the variables can assume only two discrete state, 
often represented as 0 and 1 (active/inactive, present/not present) (Wynn et al., 2012; Würstle et al., 
2014). Describing all species as either \on" or \off" is clearly an unrealistic way to represent many 
biomolecular phenomena, which often exist in multiple states and do not show discrete transitions 
between one state and the other (Figure 1.3 A). This limitation can be overcome by a fuzzy logic 
approach. Fuzzy logic represents multi-state variables in a continuous way. In this way, intermediate 
states can be described (Figure 1.3 B). For these reasons, fuzzy logic is a suitable formalism to model 
qualitative knowledge on cellular processes, such as high or low expression of a gene, high or low 
activity of an enzyme, high or low concentration of a molecule, as well as their intermediate values. 
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Figure 1.3: Comparison between discrete sets (A) and fuzzy sets (B), described by membership functions. Discrete sets 
have sharp boundaries and an input can either belong or not to a set, while fuzzy sets have smooth boundaries and an 
input can belong to a set up to a certain degree. 
 
The membership degree of a fuzzy set is defined by a membership function. Membership functions 
describe the smooth transition from a region of inputs that is outside the set to a region that is inside 
the set. A linguistic variable is also defined for each of the smooth transitions.  For example, in Figure 
1.3, the linguistic variables are defined as “Cold”, “Warm” and “Hot”. Linguistic variables are 
meaningful terms (for example, “High” or “Low” for a fuzzy set representing the activation state of 
a gene), taken directly from natural language. Linguistic variables relate a common qualitative 
description typical of human language, to a quantitative one, represented by membership functions. 
Moreover, linguistic variables allow to express knowledge on the state of the node in a human-readable 
and easily comprehensible way, through the formulation of fuzzy “IF-THEN” rules. Fuzzy IF-THEN 
rules are the basic tool to capture the basic knowledge of the system and represent the interactions 
existing between the nodes of the modelled system. They appear in the form “\IF <antecedent> 
THEN <consequent>", where antecedent describes a condition and consequent describes the 
conclusion that can be drawn when the condition holds. For instance, considering the following rules: 
• IF Glucose is Low THEN Glycolysis is Low 
• IF Glucose is High THEN Glycolysis is High 
where “High” and “Low” are linguistic variables associated with suitable membership functions. 
Together, these two rules describe a positive regulation of glucose on glycolysis output. The use of 
linguistic variables in fuzzy logic rules allows to represent situations in which the condition is satisfied 
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only to a certain degree, in contrast to classic logic rules, where a condition is either fully satisfied or 
not. 
 
Proteomics approaches  
Systems biology aims at studying a biological system as a whole. Therefore, disciplines that consider 
biological systems in a global way are the natural source of data for systems biology. “Omic” 
technologies are high-throughput and provide a holistic view of the molecules that constitute cells, 
tissues or organisms. They aim at the universal detection of genes (genomics), mRNA 
(transcriptomics), proteins (proteomics) and metabolites (metabolomics) in a specific biological 
sample, in an untargeted and unbiased manner. These techniques have many advantages: they can 
simultaneously consider several molecules, they are highly standardisable and easily automatized, in 
order to process many biological samples (Shalhoub et al., 2014; Hosp and Mann, 2017).  
The term proteomics describes the study and the characterization of the proteome (complete set of 
proteins present in a cell, organ or organism at a given time), which conveys a snapshot of what is 
happening in the system under determined conditions. Indeed, environmental and cellular changes 
cause alterations in proteins expression, in their abundance, in their cellular or tissue localization, in 
their post-translational modifications (Villoslada et al., 2009). Proteomics approaches can be used for 
proteome profiling, for comparative expression analysis of two or more protein samples, for the 
localization and the identification of post-translational modifications and for the study of PPI. A wide 
range of proteomic approaches is available, such as gel-based applications and gel-free high 
throughput screening technologies.  
Even if proteomics has to be considered a global approach, it is far from properly detecting all the 
alterations occurring in a certain condition, mainly for technical reasons. For instance, in the shotgun 
approach, based on data-dependent acquisition (DDA), only peptides with an intense signal are 
fragmented and thus identified by mass spectrometry (MS). Moreover, other limitations in current 
proteomics studies are the statistical analysis (e.g., univariate vs. multivariate analysis, parametric vs. 
nonparametric analysis, multiple testing correction), the sample size (lack of an appropriate power 
analysis), the conservation of samples and confounding factors not appropriately taken into account 
(e.g., age, gender, administered drugs, clinical anamnesis of subjects recruited for translational studies) 
(Fasano et al., 2016).  
In quantitative proteomics, two approaches are possible: gel-based and gel-free (Jorrin-Novo et al., 
2018; Winter et al., 2018). Independently for the strategy chosen, the quantitation of proteomes is 
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difficult and presents some issues. Gel-based approaches are top-down. Therefore, they directly 
analyse proteins. On the contrary, gel-free technologies analyse peptides and are bottom-up 
approaches. In the first case, the extrapolation of protein abundance is complicated by the presence 
of multiple proteoforms (Jorrin-Novo et al., 2018). Therefore, changes wrongly attributed to protein 
amounts may be due to post-translational modifications. Even in the second approach, extrapolating 
protein abundance from peptides is not trivial, since the information on both the identity and the 
amount of each protein is obtained by the peptide-to-protein mapping.  
 
Gel-based techniques: two-dimensional gel electrophoresis (2-DE) 
The two-dimensional gel electrophoresis (2-DE) entails the separation of proteins based on their 
isoelectric point (pI) (first dimension, by isoelectric focusing (IEF)) and their molecular weight (MW) 
(second dimension). During the IEF, proteins migrate through a thin gel-strip embedded with 
immobilized pH gradients. Migration ends when proteins reach their pI. Proteins are then separated 
in the second dimension (orthogonal direction) by Sodium Dodecyl Sulfate Poly-Acrylamide Gel 
Electrophoresis (SDS-PAGE), where SDS imparts a net negative charge, allowing proteins to separate 
according to MW. Proteins can be visualized using visible stains such as Coomassie blue and silver 
staining, or fluorescent stains such as Sypro ruby or Ru(II) tris (bathophenanthroline disulfonate) 
(RuBPs) staining. Although RuBPs and silver staining have a comparable sensitivity, RuBPs has good 
linearity, high contrast and is compatible with MS analysis. This colorant is excited by UV light of 
wave length around 473/488 nm. After detection of the proteins in the gels, the resulting images are 
quantitatively analysed to determine proteoforms (spots) changing in the experimental conditions. 
Those spots are excised and submitted to in-gel digestion (generally with trypsin). The resulting 
peptides are then eluted and analysed by MS (Rabilloud and Lelong, 2011).  
2-DE analysis provides several types of information about the hundreds of proteins investigated 
simultaneously, including MW, pI and abundance, as well as possible post-translational modifications. 
2-DE is extensively used but mostly for qualitative experiments. Indeed, this method falls short of 
reproducibility, it unlikely detects low abundant and hydrophobic proteins, proteins with pI < 3 or pI 
> 10 and with MW < 10 kDa or MW> 150 kDa. However, 2-DE is the only technique that can be 
routinely applied for parallel quantitative expression profiling of complex protein mixtures, such as 
whole cell and tissue lysates, and the most widely used method for efficiently separating proteins, their 
variants and modifications (Chandramouli and Qian, 2009). 
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Gel-free techniques: MS-based proteomics 
Gel-free, or MS-based, proteomics techniques are emerging as the method of choice for quantitatively 
compare proteomes (Anjo et al., 2017). Label-free quantitative MS methods are based either on 
spectral counting or on peptide precursor ion intensities that are obtained using the first analyser of a 
tandem mass spectrometer. Peptides are identified across different liquid chromatography (LC) runs 
based on their specific retention time coordinates and precise mass to charge (m/z) values, which in 
principle allows the quantification of all the peptides detected from a biological sample that are within 
the sensitivity range of a MS analyser, independently for MS/MS acquisition. Starting from the peptide 
sequences obtained, proteins are identified using protein sequence databases. The stochastic precursor 
selection of DDA leads to under sampling of low abundant peptides. This results in missing peptide 
identification and reduces the number of quantifiable proteins. To overcome this limit, data-
independent acquisition (DIA) was introduced as an alternative. In DIA, the entire set of peptide 
precursors (without a pre-selection of the precursor ions in each cycle time) is fragmented. This 
approach complicates the analysis in a classical database search strategy. Therefore, spectral libraries 
obtained by an extensive analysis of the same/similar samples by DDA are normally generated to be 
used in the search analysis (Koopmans et al., 2018). On the other hand, label-based proteomics relies 
on various isotopic labelling strategies, such as isotope-coded affinity tag (ICAT), stable Isotope 
Labelling by/with Amino acids in Cell culture (SILAC) and isobaric Tags for Relative and Absolute 
Quantitation (iTRAQ) (Ross et al., 2004).  
 
Neurodegenerative diseases 
“Neurodegenerative disease” is a collective term for a range of conditions that primarily affect 
neurons, in the brain (e.g., Alzheimer’s disease (AD) and PD), or at the periphery (e.g., motor neurons 
in ALS).  
 
Alzheimer’s disease 
AD is the most common chronic neurodegenerative disease that affects approximately 35 million 
people worldwide (Honig et al., 2018). The prevalence of AD is generally estimated around 6% in 
people over 65 years of age (Burns and Iliffe, 2009). 
Early stages of AD are characterized by impairment of memory (e.g., misplacing objects, forgetting 
conversations, problems remembering names and missing appointments) and of 
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visuoconstructional/visuospatial drawing (e.g., clock drawing and copying of geometric figures). 
Language deficits are the second most prominent cognitive manifestation of AD (e.g., dysnomia, verbal 
paraphasias, and word-finding difficulty) and in some cases they can be the initial clinical symptoms 
(López et al., 2008). 
AD is characterized by extracellular plaques containing amyloid beta (Aβ) and intracellular 
neurofibrillary tangles containing hyperphosphorylated tau protein, along with synaptic and neuronal 
loss (Querfurth and La Ferla, 2010). Two different forms of AD have been described: sporadic and 
familial. In familial AD several mutations were reported such as those in the genes of Aβ A4 protein 
(APP), Presenilin-1 (PSEN1) and Presenilin-2 (PSEN2) (Minati et al., 2009). The investigation of the 
cellular function and toxicity of genes linked to monogenic forms of AD provided advances in the 
understanding of the molecular pathogenesis of sporadic forms. APP is a cell surface receptor and its 
functions are relevant to neurite growth, neuronal adhesion and axonogenesis (Chen and Bodles, 
2007). Sequential cleavage by β-secretase (BACE) and γ-secretase produces the Aβ peptide fragment 
that aggregates into clumps called "plaques" in the brains of AD patients (PSEN1 and PSEN2 are 
catalytic subunits of the γ-secretase complex). Moreover, alteration of abundance of proteins involved 
in the degradation of Aβ and in APP intracellular trafficking (Insulin-degrading enzyme (IDE) and 
Ubiquilin-1 (UBQLN1)) were reported (Minati et al., 2009). Furthermore, epigenetic mechanisms are 
involved in AD pathogenesis (Day and Sweatt, 2011), in particular an over methylation of DNA and 
histone modification have been described (Day and Sweatt, 2011; Ghavami et al., 2014). 
AD has been used as a reference disease for the purposes of the present thesis, since it is the most 
common neurodegenerative disease and it is the most studied one. Moreover, it is considered a non-
motor neurodegenerative disorder. However, motor signs can be observed in AD. They may result 
from different underlying mechanisms, although specific factors that influence their occurrence or 
rate of progression are not clear (Scarmeas et al., 2011). Data about their frequencies have a large 
variability (frequency of motor signs in AD ranged from 6% to >50%) (Scarmeas et al., 2011). Some 
of this inconsistency derives from methodologic differences, including variable definitions of motor 
signs.  
 
Proteomics of Alzheimer’s disease 
Proteomics studies in the literature are mainly focused on AD cellular and animal models and on post-
mortem human brain samples. The analysis of the proteome of transgenic mice expressing N-terminal 
truncated Aβ highlighted alterations in several proteins involved in the mTOR/p70S6K signalling 
pathway and in the Rhokinase (ROCK, a downstream effector of the small GTPase Rho). These 
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molecular alterations preceded the onset of behavioural symptoms (Yang et al., 2013). Using a label-
based approach (SILAC), it was also possible to study proteome changes in BV2 rat microglia, with 
Aβ fibrils. The expression of thirteen proteins were significantly regulated by Aβ (six proteins were 
up-regulated and 7 were down-regulated). Several of these proteins were cell membrane proteins 
involved in the PPAR signalling pathway and lysosomes functionality (KEGG pathway analysis) (Ma 
et al., 2013). Proteomics approaches allowed researchers to identified post-translational modification 
involved in AD pathogenesis. In particular, Zahid and co-workers, using a phosphoprotein-sensitive 
staining after 2-DE protein separation, observed alterations in the phosphorylation pattern in the 
Substantia Nigra (SN) and the cortex from AD cases and control subjects. They identified changes in 
the phosphorylation level of several proteins involved in energy metabolism pathways (e.g., glycolysis) 
(Zahid et al., 2012). The same investigators reported a focused analysis of S-nitrosylated proteins in 
hippocampus, SN and cortex from AD cases and control subjects, where 45 proteins involved in 
metabolism, signalling, apoptosis and redox regulation were endogenously S-nitrosylated (KEGG and 
Reactome pathway analysis) (Zahid et al., 2013). 
 
Parkinson’s disease 
PD is the most common neurodegenerative disorder after AD (Gibrat et al., 2009). The prevalence of 
PD is generally estimated around 1% in people over 65 years of age (de Lau and Breteler, 2006). The 
prevalence increases with age, with a slightly higher incidence in men with respect to women.  
PD is characterized by the presence of a motor symptomatology (bradykinesia, rest tremor, rigidity 
and postural disturbances). In addition to the motor symptomatology of PD, some non-motor 
symptoms such as hyposmia, REM sleep behaviour disorder (Janković et al., 2015), personality 
changes, pain, paraesthesia and depression may be present and may even manifest years before the 
motor symptoms (Nutt and Wooten, 2005). Urinary disturbances, orthostatic hypotension and 
neuropsychiatric disturbances (dementia, hallucinations and delirium) usually become evident several 
years after the onset of the disease (Chaudhuri et al., 2005). Late-onset motor symptoms include 
postural instability and falls, freezing of gait, speech and swallowing difficulties. 
The pathophysiology of PD involves the loss of dopaminergic neurons of the SN leading to 
denervation of the nigrostriatal tract and the significant reduction of dopamine (DA) at the striatal 
level. The degeneration of these dopaminergic neurons, which normally contain a considerable 
amount of neuromelanin (Dickson, 2012), produces the depigmentation of the SN. This process is 
usually associated with the presence of ubiquitin- and α-synuclein-positive cytoplasmic inclusions, 
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known as Lewy bodies (LB), within surviving dopaminergic neurons (Goedert, et al., 2013). The most 
abundant protein in LBs is α-synuclein (α-syn) (Stefanis, 2012):  
As there are no definitive biological or imaging markers, diagnosis is based on stringent clinical criteria 
such as Movement Disorder Society (MDS) of the Unified Parkinson's Disease Rating Scale (MDS-
UPDRS). It is a rating tool to follow the longitudinal course of PD. It is made up of the I) mentation, 
behaviour, and mood, II) activities of daily living and III) motor sections. All the parameters are 
evaluated by interview and a score is assigned to each category (from 0, normal situation, to 4, 
complete loss of function) (Goetz et al., 2007). Although, the diagnosis is made exclusively on a clinical 
basis, there are diagnostic tools that can be used to confirm the presence of dopaminergic denervation 
at the striatal level, thus lending support to the clinical diagnosis. These include fluorodopa positron 
emission tomography (FDOPA-PET) and DAT imaging with radionuclide tracers by means of single 
photon emission tomography (DAT-SPECT). In PD, substantial reductions in tracer uptake is 
observed.  
Since diagnosis is mainly clinical and supporting tools are invasive, radioactive and expensive, a lot of 
ongoing research is devoted to the discovery of peripheral biomarkers to develop new diagnostic 
devices. Several evidences support the rationale to search for peripheral biomarkers of PD as early 
reporters of central neurodegeneration. For example, up-regulation and/or genetic/post-translational 
modifications of PD-related proteins should be highlight even at the peripheral level. T lymphocytes 
are the population of immune cells that could better reflect some of the alterations that impair the 
function of SN dopaminergic neurons that are primarily involved in PD pathogenesis. T lymphocytes 
express some dopaminergic features (receptors, transporters, vesicles) and DA plays an active role in 
their functions, as the activation and the differentiation of various T subtypes (Pacheco et al., 2009). 
Indeed, neurochemical and neuroimaging studies have shown a decreased immunoreactivity for the 
DA receptor in neuronal as well as in PBMCs of PD patients. In addition, the same alterations in the 
level of enzymes involved in the oxidative phosphorylation reported in the spinal cord of PD patients 
have been detected in their PBMCs (Ladd et al., 2014). Thus, peripheral blood lymphocytes may 
represent sensitive reporters of PD pathogenesis (Fasano et al., 2008).  
Since most symptoms of PD are caused by the lack of DA in the brain, many PD drugs are aimed at 
either temporarily replenishing or mimicking the action of DA. Over the past half century, several 
progresses have been made in the treatment of PD, but levodopa, a DA precursor (L-
dihydroxyphenylalanine, L-DOPA), remains the most potent drug for controlling PD symptoms. 
However, chronic oral treatment with L-DOPA is associated with the development of motor 
complications: fluctuations in motor performance, reflecting rises and falls of L-DOPA plasma levels 
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(“on”/ “off” states), involuntary movements and painful dystonia. Another important category of 
antiparkinsonian drugs is represented by DA agonists, which can be used as monotherapy or in 
combination with L-DOPA. They exert their action by directly activating DA receptors, bypassing the 
presynaptic synthesis of DA. The activation of D2-like receptors (especially D3) is important for 
antiparkinsonian effects of DA agonists, although concurrent D1-like and D2-like stimulation is 
required to produce optimal physiological and behavioural effects (Jankovic and Aguilar, 2008). Some 
commonly used DA agonists in the clinical practice are Ropinirole, Pramipexole and Rotigotine. Other 
strategies to prolong DA response make use of inhibitors of enzymes that metabolize DA, such as 
catechol-O-methyltransferase (COMT) and monoamine oxidase (MAO). When used in a combined 
therapy, they extend the duration of action of L-DOPA. However, COMT inhibitors are used with 
caution because of hepatic side effects (Benabou and Waters, 2003). 
The view of aetiological factors in PD has changed remarkably. From a purely sporadic disease, PD 
is now considered a multifactorial disorder, since both environmental and genetic factors contribute 
to the onset (Schapira and Jenner, 2011). Genetic predisposition or susceptibility is one of the major 
contributors to the underlying cause (Gasser, 2009). Epidemiological studies suggest that sporadic PD 
accounts for 85% of cases (Sun et al., 2006), whereas the remaining 15% are familial forms of PD 
(Schulte and Gasser, 2011). In the past decade, there has been an explosion of knowledge about the 
genetics of PD and 18 PD-related gene loci have been identified (Crosiers et al., 2011, Lunati et al., 
2018). The most relevant are reported in Table 1.3. 
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Table 1.3: Some PD-related genes. 
Gene Protein function 
SNCA  
may be involved in the regulation of DA release and transport. Induces fibrillization of microtubule-
associated protein tau. 
LRRK2  
positively regulates autophagy through a calcium-dependent activation of the CaMKK/AMPK signalling 
pathway.  
PARK2 
RING domain-containing E3 ubiquitin ligase involved in proteasome- dependent degradation of proteins 
and in mitophagy. 
PINK1 
protects against mitochondrial dysfunction during cellular stress by phosphorylating mitochondrial 
proteins. Involved in the clearance of damaged mitochondria via selective autophagy (mitophagy) by 
mediating activation and translocation of Parkin. 
GBA 
lysosomal enzyme involved in glycolipid metabolism. Homozygous mutations cause an accumulation of 
glucocerebroside that results in a wide spectrum of symptoms, known as Gaucher disease. However, GBA 
mutations in one allele have been found to increase the risk of developing PD.  
PARK7 
plays an important role in cell protection against oxidative stress and cell death, acting as oxidative stress 
sensor and redox-sensitive chaperone and protease. 
VPS35 
Vacuolar protein sorting-associated protein 35, component of the retromer cargo-recognition complex, is 
critical for the endosome-trafficking and the trans Golgi recycling of membrane-associated proteins. 
EIF4G1 
Eukaryotic translation initiation factor 4Gamma1, which is ubiquitous and abundantly expressed in 
different tissues. It operates as a scaffold protein that interacts with many initiation factors, including 
PABP, eIF3, two eIF4F components (eIF4E and RNA helicase eIF4A) and with the 40S ribosome. 
 
The investigation of the cellular function and toxicity of genes linked to monogenic forms of PD 
provided advances in the understanding of the molecular pathogenesis of sporadic PD. Indeed, the 
progressive deterioration of vulnerable SN neurons in both sporadic and genetic PD forms may arise 
from cellular disturbances caused by alteration of DA metabolism, misfolding and aggregation of the 
synaptic protein α-syn (Luk et al., 2012), disruption of the autophagy-lysosome system (Moors et al., 
2016), mitochondrial dysfunction (Bondi et al., 2016), endoplasmic reticulum stress (Mercado et al., 
2016), dysregulation of calcium homeostasis (Rivero-Ríos et al., 2014), neuroinflammation and 
oxidative stress (Blesa et al., 2015).  
The environmental factor that most strongly relates to the onset of PD is the aging process. Aging 
can lead to irreversible cellular damage, weakening cellular repair machinery and predisposing people 
to neurodegenerative diseases (Hindle, 2010). Mitochondrial toxins are other environmental factors 
that shed light on the influence of environment on PD pathogenesis. There has been increasing 
interest in 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine/1-methyl-4-phenylpyridinium MPTP/MPP+ 
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and rotenone. MPTP is a toxic molecule that is able to cross the blood-brain-barrier. Once MPTP 
enters in the glial cells, it is metabolized to MPP+ by the monoamine oxidase enzyme. Then, MPP+ 
accumulates in the mitochondria of the dopaminergic neurons thanks to the DAT (Ramsay et al., 
1986). In vitro and in vivo studies demonstrated that, at the mitochondrial level, this toxin inhibits the 
activity of the complex I of the electron transport chain, thus leading to lower ATP production, 
increased reactive oxygen species (ROS) generation, mitophagy impairment and neuronal cell death 
(Gao et al., 2015; Navarro-Yepes et al., 2016). Rotenone is a lipophilic molecule that crosses the blood-
brain barrier and biological membranes without using a specific receptor or transporter. Once in 
neuronal cells, rotenone inhibits the complex I of the mitochondrial electron-transport-chain, thus 
causing high ROS generation, lower ATP production and apoptotic cell death (Johnson and 
Bobrovskaya, 2015). After these discoveries, MPTP and rotenone toxins became of common use in 
research in several in vitro and in vivo models, in order to recapitulate the sporadic PD pathology. 
Despite mitochondrial toxins are widely used in research, the parkinsonism induced by these 
compounds results from an acute toxic insult and differs from the slow and progressive disease 
process that characterize sporadic PD. The initial causes of the degeneration of dopaminergic neurons 
in PD is still unknown but altered DA homeostasis might be a key factor in the early steps of the 
pathogenesis (Alberio et al., 2012; Herrera et al., 2017). DA is synthesized starting from tyrosine and 
it is immediately stored in monoaminergic synaptic vesicles thanks to the vesicular monoaminergic 
transporter-2 (VMAT- 2). Since DA can auto-oxidize at neutral pH, when it accumulates in the 
cytosol, its auto-oxidation produces quinone species and hydrogen peroxide (Segura-Aguilar et al., 
2014). The most abundant quinone species are DA quinones and amino chrome (Herrera et al, 2017). 
DA quinone forms adducts with several proteins (e.g., Parkin), while amino chrome induces and 
stabilizes the formation of neurotoxic protofibrils of α-syn (Conway et al., 2001), causes dysfunction 
of the proteasome system (Zhou and Lim, 2009) and prevents the fusion of autophagy vacuoles with 
lysosomes (Paris et al., 2010). It has been demonstrated that α-syn plays an important role in DA 
homeostasis and that protofibrils of α-syn can modify the permeability of vesicles by forming pores, 
thus causing the leakage of DA from synaptic vesicles to the cytoplasm (Hastings, 2009) (Figure 1.4).  
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Figure 1.4: When DA is not properly stored in synaptic vesicles, it accumulates in the cytosol, thus forming quinones and 
increasing the ROS production. DA quinone forms adducts with several mitochondrial proteins and stabilizes the 
formation of α-syn neurotoxic protofibrils. In this way, altered DA homeostasis causes cellular oxidative stress and 
apoptotic cell death. 
 
On this basis, several efforts have been made to develop cellular models for DA toxicity. Altered DA 
homeostasis in mice with reduced VMAT2 expression is enough to cause DA-mediated toxicity and 
progressive loss of DA neurons (Caudle et al., 2007). A cellular model often used in neurodegeneration 
research is the catecholaminergic SH-SY5Y human neuroblastoma cell line. This cell model expresses 
the DAT and DA receptors and is able to form storage vesicles, although the low activity of the 
VMAT2 impairs DA storage into vesicles (Mena et al., 1989). For this reason, SH-SY5Y cytoplasmic 
DA concentration may be increased by administering DA in the culture medium (Alberio et al., 2010). 
 
Proteomics of Parkinson’s disease 
Pathogenesis of PD is still under investigation, due to its complexity in terms of current knowledge 
of genetic risk factors and the occurrence of several clinical phenotypes. Thus, cellular models, animal 
models, and post-mortem specimens from human subjects provide complementary resources. Among 
cellular models, the human neuroblastoma cell line SH-SY5Y has been widely used to recapitulate 
early stages of PD pathogenesis and to investigate mitochondrial dynamics in PD. Isolated 
mitochondria from SH-SY5Y exposed to a DA concentration able to induce oxidative stress were 
analysed by two different quantitative proteomics approaches (2-DE and shotgun proteomics). 
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Network analysis (IntAct) of results suggested a possible alteration of the NF-κB signalling pathway, 
and the hypothesis was further confirmed by the luciferase gene reporter assay (Alberio et al., 2010). 
Pathway analysis of mitochondrial proteins affected by DA revealed the over-representation of the 
Parkinson Disease and the Parkin– ubiquitin proteasomal system pathways and of gene ontologies 
associated with the generation of precursor metabolites and energy, unfolded protein response and 
programmed cell death. These alterations have been interpreted in part as the result of a direct effect 
of DA on mitochondria (e.g., alteration of mitochondrial proteases activity) and in part as the effect of 
the activation of cellular processes on mitochondria (e.g., regulation of programmed cell death) 
(Alberio et al., 2014). Moreover, high-resolution proteomic characterization of human SN from PD 
donors led to the identification of several differentially expressed proteins. The ORA of over-
expressed proteins displayed the enrichment of cytoskeletal remodelling. On the other hand, an ORA 
of under-expressed proteins highlighted several pathways associated to energy metabolism and 
mitochondrial activities, intracellular transport processes, synaptic activities or translation (Licker et 
al., 2014). 
 
Amyotrophic lateral sclerosis  
ALS is an adult-onset, fatal, neurodegenerative disease, affecting motor neurons of the primary motor 
cortex, the central trunk and the spinal cord. The typical symptoms of this disease include muscle 
weakening, with gradual and irreversible loss of voluntary movements control, dysphagia (inability to 
swallow) and dysarthria (problems with word articulation) (Kiernan et al., 2011). These symptoms are 
due to the involvement of upper and lower motor neurons (Saccon et al, 2013).  
The worldwide annual incidence of ALS is about 1.9 per 100,000, with a relatively similar rate in 
Caucasian populations and lower rates in African, Asian and Hispanic populations (Arthur et al., 2016). 
Men have a greater risk of developing ALS than women (Ingre et al., 2015). The death occurs typically 
after 2-4 years from the pathology onset, due to the impairment in respiratory muscles. Only 5–10% 
of patients survive beyond 10 years (Chiò et al., 2009). 
Two different forms of ALS have been described: sporadic ALS, with an age at onset from 58 and 63 
years (Logroscino et al., 2010), and familial ALS, characterized by an earlier onset, approximately 
around 40 to 55 years (Ingre et al, 2015). About 10-15% of patients have a family history of ALS 
(Byrne et al., 2011). 
The inheritance patterns of ALS vary depending on the mutation, although there is often a Mendelian 
pattern and high penetrance in familial ALS. The two major genetic contributors known to date are 
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the Cu,Zn-superoxide dismutase-1 (SOD1) gene and the C9ORF72 gene, even if many other genes 
have been associated to ALS so far, e.g., TARDBP (encoding for TAR DNA-binding protein 43), FUS 
(encoding for RNA-binding protein FUS), ANG (encoding for Angiogenin), OPTN (codifying for 
Optineurin), SETX (encoding for Senatassin) and VAPB (encoding for vesicle associated membrane 
protein B) (Andersen and Al-Chalabi, 2011; Turner et al., 2013) (Table 1.4). 
 
Table 1.4: Some of the most common ALS-related genes. 
Gene Protein function 
SOD1 
(ALS1) 
destroys radicals which are normally produced within cells. 
C9ORF72 
(FTDALS1) 
is a negative regulator of autophagy initiation, of mTORC1 signalling and endosomal trafficking. 
TARDBP 
(ALS10) 
is a regulator of transcription and splicing. It is involved in neuronal plasticity and maintenance of 
dendritic integrity. 
FUS 
(ALS6) 
is involved in neuronal plasticity and maintenance of dendritic integrity, by transporting messenger RNA 
to dendritic spines for local translation. 
ANG 
(ALS9) 
hydrolyses cellular tRNAs, resulting in decreased protein synthesis. 
OPTN 
(ALS12) 
interacts with adenovirus E3-14.7K protein and may use tumor necrosis factor-alpha or Fas-ligand 
pathways to mediate apoptosis, inflammation or vasoconstriction. It is involved in cellular 
morphogenesis and membrane trafficking, vesicle trafficking, and transcription activation through its 
interactions with the RAB8, huntingtin, and transcription factor IIIA proteins. 
SETX 
(ALS4) 
is involved in both DNA and RNA processing.  
VAPB 
(ALS8) 
is a type IV membrane protein, found in plasma and intracellular vesicle membranes. It interacts with 
VAPA, VAMP1 and VAMP2 and may be involved in vesicle trafficking. 
VCP 
(ALS14) 
plays a role in protein degradation, intracellular membrane fusion, DNA repair and replication, 
regulation of the cell cycle, and activation of the NF-kappa B pathway.  
CHMP2B 
(ALS17) 
is a component of the Endosomal Sorting Complex Required for Transport II that functions in the 
recycling or degradation of cell surface receptors. 
 
Investigations of ALS genes have delineated pathogenic roles for recurring themes. First, the motor 
neuron death usually entails deposition of aggregated proteins, often ubiquitinated and predominantly 
cytoplasmic. Second, in ALS, the levels and functions of RNA and RNA-binding proteins are 
abnormal. Aggregates of protein and RNA are detected both in motor neurons and non-neuronal 
cells, such as astrocytes and microglia. Third, most cases entail some disturbance of neuronal 
cytoskeletal architecture and function. Additionally, in almost all cases, motor neuron death is 
influenced by non-neuronal cells and cells involved in neuroinflammation. A defining feature of motor 
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neurons is the length of their axons, rendering them highly dependent on intracellular transport 
mechanisms to maintain normal structure and function. Critical in sustaining this extraordinary 
architecture is the cytoskeleton and associated molecular scaffolds and motors. Moreover, several 
processes have been postulated to have a role in ALS pathogenesis, such as, increased nitrative stress, 
intracellular calcium dysregulation and glutamatergic dysfunction. Glutamate-mediated excitotoxicity 
is characterized by an over activation of post synaptic receptors (NMDA ionotropic and AMPA 
receptors) by glutamate, which is the main excitatory neurotransmitter of the central nervous system. 
The toxic action of glutamate may rise from the permanence of this neurotransmitter in the inter 
synaptic space, because of a reduction in the expression of glutamate transporters by glial cells (Staats 
and VanDen Bosch, 2009). Glutamic excitotoxicity can lead to neurodegeneration through the 
activation of calcium dependent enzymatic pathways, ROS generation and an increase of pro-
inflammatory mediators (Hensley et al., 2006).  
The discovery of the glutamatergic alteration was the major turning point in the development of the 
pharmacotherapeutic approach to ALS leading to the introduction of riluzole, a benzothiazole 
derivative. It inhibits the glutamatergic transmission, either at a presynaptic or post synaptic level, 
through modulation of the ionotropic glutamate receptors (Cheah et al., 2010) and it can protect 
neurons, increasing the patients’ survival.  
ALS diagnosis is based on specific criteria known as El Escorial criteria (Agosta et al., 2015). These 
criteria are: 1) signs of degeneration of lower motor neurons, which are in the spinal cord and 
brainstem, by clinical examination or specialized testing; 2) signs of degeneration of upper motor 
neurons, which are in the brain, by clinical examination; 3) progressive spread of signs within a region 
to other regions; and 4) the absence of evidence of other disease processes that might explain the 
observed clinical and electrophysiological signs. If ALS is suspected, the next step is usually an 
electromyogram (EMG), to highlight signs of suffering of the second motor neuron in the muscles of 
arms and legs. Additional tests may include Nuclear Magnetic Resonance (NMR), to exclude other 
brain and spinal cord diseases, and the lumbar puncture, to exclude other neurological illnesses. 
Finally, to clarify the diagnosis in atypical cases, the muscle and nerve biopsy is adopted.  
To recognize the different stages of ALS, several staging scales are utilized: Revised ALS Functional 
Rating Scale (ALSFRS-R), King’s clinical staging and Milano-Torino (MiToS) functional staging (Chiò 
et al., 2012; Roche et al., 2012). The most commonly used is the ALSFRS, which is a validated 
questionnaire-based scale. Patient scores (from 4, normal situation, to 0, complete loss of function) 
are assigned to various tasks (speech, salivation, swallowing, handwriting, cutting food and handling 
utensils, dressing and hygiene, turning in bed and adjusting bed clothes, walking, climbing stairs, 
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dyspnoea, orthopnoea and respiratory insufficiency). By using these data, clinicians can evaluate four 
domains: gross motor tasks, fine motor tasks, bulbar functions and respiratory function.  
 
Proteomics of amyotrophic lateral sclerosis 
Deep proteomics characterization and ORA were employed to assess the suitability of several cell 
lines and primary motor neuron cultures as cell models for ALS, by identifying cellular pathways 
functionally relevant in motor neurons (Hornburg et al., 2014). Comparative proteomics profiling of 
cerebrospinal fluid (CSF) from sporadic ALS, healthy control and other neurological disease subjects 
led to the relative quantification of 1712 CSF proteins. The ORA of proteins up-regulated highlighted 
the activation of the “acute inflammatory response” and the “regulation of inflammatory response” 
in sporadic ALS CSF samples, whereas over-expressed proteins were involved in the “synapse 
organization” and the “extracellular matrix organization” (Collins et al., 2015).  
 
Amyotrophic lateral sclerosis patients with parkinsonian signs 
Several evidences support the existence of common pathogenetic mechanisms at the basis of different 
neurodegenerative disorders. Thus, it is not surprising that the progression of a neurodegenerative 
disease can lead to the manifestation of other brain pathologies, caused by the same altered processes. 
This explain why the simultaneous occurrence of more than one neurodegenerative pathology (usually 
called comorbidity) in the same patient is a quite common phenomenon, especially with the worsening 
of the cardinal pathology. In some patients with ALS, extrapyramidal symptoms and signs, typical of 
PD, due to nigrostriatal dysfunction have been reported (ALS-PD patients) (Park et al., 2011; Belin et 
al., 2015). The association between ALS and parkinsonism, although rare, occurs more frequently than 
expected by chance. Indeed, the frequency of PD symptoms in ALS patients is significantly higher 
than in the general population (Körner et al., 2013). Some authors reported that ALS is associated 
with parkinsonism with a frequency ranging from 5% to 17% (Manno et al., 2013). In addition, 
epidemiological studies showed a higher prevalence of parkinsonism in family members of ALS 
patients (Takahashi et al., 1993). The mean age at the onset of this overlapping syndrome is almost 10 
years greater than in ALS without parkinsonism (Qureshi et al., 1996). The most common 
extrapyramidal signs are bradykinesia and rigidity; which usually respond poorly to the levodopa 
treatment. The clinical course does not differ from that expected in ALS without parkinsonism.  
The association between ALS and PD, has been further highlighted by clinical (Belin et al., 2015), 
genetic (Körner et al., 2013) and neuroimaging (Cistaro et al., 2014) evidences, in humans and in 
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preclinical models (Ingre et al., 2015). Studies on ALS patients and on animal models of the disease 
have shown the presence of pathogenetic processes and clinical signs classically found in PD patients, 
such as intraneuronal inclusions (Desai and Swash, 1999), deficit in the axonal transport, neurotoxic 
effects due to the radical species (Johri and Beal, 2012) and endoplasmic reticulum (ER) stress (Monti 
et al., 2016). Insoluble aggregates of disease-related proteins can be deposited as intraneuronal 
inclusions, which are histopathological hallmarks of both diseases (Roy et al., 2005). 
Neuropathological evidence of neuronal loss, together with neurofilamentous and Lewy body 
inclusions in the basal ganglia, has been demonstrated in some ALS patients (Desai and Swash, 1999; 
Erol et al., 2015). Neuroimaging studies in ALS patients revealed a progressive reduction in the 
expression of the post-synaptic D2 receptor at the striatum level and a moderate reduction in the DA 
transporter (DAT) (Vogels et al., 2000). Imaging studies revealed a progressive dopaminergic deficit 
in ALS patients, even in the absence of extrapyramidal signs (Zoccolella et al., 2002). This suggests 
that the extrapyramidal system is involved in ALS, too (Park et al., 2011; Fathinia et al., 2012). 
Furthermore, necropsy studies have shown neuronal loss in the SN and globus pallidus of ALS patients 
(Yokota et al., 2006). In addition, in recent years, positron emission tomography (PET) and single 
photon emission computed tomography (SPECT) studies revealed a progressive midbrain 
dopaminergic deficit in ALS patients, even in the absence of extrapyramidal signs (Beal, 1998). Beside 
toxic proteins, there is overwhelming evidence of impaired mitochondrial dysfunction, axonal 
transport defects and neurotoxic effects of free radicals as a causative factor (Johri and Beal, 2012). 
ALS patients with mutation on TARDBP gene (Seilhean et al., 2009) or with repetition of an 
esanucleotide of the C9ORF72 gene or patients carrying mutations in the ANG gene developed also 
PD symptoms (Chiò et al., 2012). In addition, genetic mutations involved in familial forms of PD, for 
example a missense mutation (E163K) in the PARK7 gene (encoding for DJ-1), has been found also 
in ALS patients, causing mitochondrial dysfunction and cognitive impairment (Annesi et al., 2005) 
(Table 1.5).  
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Table 1.5: Summary of the known ALS-PD related genes. 
Gene Clinical features 
FUS 
(ALS) 
Upper and lower motor neuron disorder, with a typical age at onset between 40 and 50 years. 
Bulbar signs, frontotemporal dementia and parkinsonism.  
ANG 
(ALS) 
Upper and lower motor neuron disorder, with a typical age at onset between 30 and 60 years. 
Bulbar signs and parkinsonism. 
TARDBP 
(ALS) 
Upper and lower motor neuron disorder, with a typical age at onset between 40 and 60 years. 
Bulbar signs, frontotemporal dementia and parkinsonism. Characterized by a good L-dopa 
responsiveness. 
VCP 
(ALS) 
Motor neuron disease, with a typical age at onset between 20 and 40 years. Characterized by 
myopathy, cardiomyopathy and peripheral neuropathy, but presenting also frontotemporal 
dementia, pyramidal signs and parkinsonism. 
CHMP2B 
(ALS) 
Upper and lower motor neuron disorder, with a typical age at onset between 40 and 60 years. 
Bulbar signs, respiratory insufficiency and parkinsonism. 
C9ORF72 
(FTDALS) 
Motor neuron disease, with a typical age at onset between 50 and 60 years. Worsened by 
frontotemporal dementia, cognitive impairment and parkinsonism. Patients do not respond to 
L-dopa therapy. Routine brain MRI shows prominent frontal lobe atrophy. 
SOD1 
(ALS) 
Upper and lower motor neuron disorder, resulting in fatal paralysis. Presence of ubiquitin-
positive inclusions within surviving motor neurons and deposition of pathologic aggregates. 
Some patients show Parkinsonian traits. 
PARK7 
(PD) 
PD characterized by resting tremor, postural tremor, bradykinesia, muscular rigidity, anxiety 
and psychotic episodes. Onset before 40 years, slow progression and initial good response to 
levodopa. Traits reminiscent of ALS-parkinsonism/dementia complex (Guam disease).  
LRRK2 
(PD) 
PD characterized by bradykinesia, rigidity, resting tremor, postural instability, neuronal loss in 
the SN, and the presence of neurofibrillary MAPT (tau)-positive and Lewy bodies.  Some 
patients show traits that recall ALS. 
TRPM7 
(ALS-PD dementia 
complex) 
Neurodegenerative disorder characterized by signs and symptoms typical of both PD and ALS. 
Often associated with dementia. 
 
These findings suggest that PD and ALS share common pathogenic mechanisms. Mitochondrial 
dysfunction, oxidative stress and neurotoxic effects of free radicals have been supposed to be involved 
in neuronal death of both diseases. In addition, other pathogenic mechanisms have been proposed in 
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these disorders, including glutamatergic neuro-excitotoxicity, as well as apoptotic neuronal death 
(Tatton et al., 1997). 
 
Biomarker discovery of neurodegenerative diseases 
The study of central nervous system (CNS) diseases is hampered by the availability of biological 
models that can recapitulate the pathogenetic process. In neurodegenerative diseases, proteomics 
analysis of post-mortem tissues is strongly limited by (i) the scarce availability of autoptic specimens, 
(ii) the fluctuation of protein levels identified in autopsy samples, due to rapid post-mortem changes 
in the brain and (iii) the advanced stage of the disease normally affecting donors (Plum et al., 2015). 
More information comes from cellular or animal models of neurodegenerative disorders that can 
mimic a specific aetiology or a specific pathogenetic mechanism (Plum et al., 2015). Several proteomics 
studies reported so far in association with neurodegenerative diseases focused on biomarker discovery 
(Pal et al., 2014). A biomarker is a characteristic that can be objectively measured and evaluated as an 
indicator of normal biological processes, pathogenic processes, or pharmacological responses to a 
therapeutic intervention. Biomarkers may help the diagnosis, the correlation with the progression of 
the disease, the therapy assessment or evidence the susceptibility to a disease. Biomarkers present in 
body fluids (e.g., saliva, blood) and PBMCs are ideal, because they can be measured by simple, non-
invasive and non-expensive tests. CSF is considered the ideal source for identifying biomarkers in 
neurodegenerative diseases because there is no barrier between CSF and the brain. However, CSF is 
not as easily accessible as other body fluids, whose collection, unlike CSF, is considered almost non-
invasive. This limits large-scale validation studies and thus the introduction into clinical practice. 
PBMCs are considered an appropriate cellular model for the search of peripheral markers both for 
diagnostic purposes and for a better understanding of neurodegenerative disorders, like PD and ALS 
(Nardo et al., 2011). Immune cells may mirror at the periphery dysfunctions occurring at the central 
level, in particular those due to a genetic background. For instance, mutations in the Parkin gene 
render PBMCs more susceptible to DA and iron-mediated apoptosis (Fasano et al., 2008). Moreover, 
the dogma of the immune privilege of CNS has been challenged, based on following observations: i) 
immune system patrols the CNS through continuous migration of leukocytes, ii) the immune system, 
through T-Lymphocyte-sustained autoimmune mechanisms, may promote neuroprotective response, 
iii) the adaptive immune system affects cognitive performances and behaviour and iv) immune system 
may contribute to neuronal damage, as suggested by the demonstration of chronic neuroinflammatory 
process in the brain of PD patients (Fasano et al, 2008).  
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Mitochondria 
Mitochondria are double membranes-enclosed cytoplasmic organelles, whose dysfunction is 
commonly associated to neurodegenerative disorders. The structure of mitochondria can be divided 
in four components: outer mitochondrial membrane (OMM), intermembrane space (IMS), inner 
mitochondrial membrane (IMM) and mitochondrial matrix. The inner membrane is highly folded, 
forming tubular or lamellar structures called cristae, where the complexes of the respiratory chain are 
embedded. Mitochondria are intimately involved in cellular homeostasis. Indeed, they provide energy 
in form of ATP to the cell, play a key role in the biosynthesis of several macromolecules (such as 
nucleotides, lipids, heme, and iron-sulfur clusters) and regulate the intracellular Ca2+ homeostasis 
(Vakifahmetoglu-Norberg et al., 2017). As mitochondria are essential for a plethora of cellular 
processes, the regulation and the maintenance of mitochondrial function are very important for the 
cell.  
 
Mitochondrial dynamics  
Mitochondria are very dynamic organelles that forms complex networks. The mitochondrial network 
changes continuously in response to the activation of a specific signalling pathway or the presence of 
a particular metabolic stimulus. Fusion and fission are involved in the mitochondrial network 
dynamics.  
Mitochondrial fusion allows for the exchange of components between mitochondria, thus enabling 
the maintenance of their functional state (Chen and Chan, 2006). This process is made possible by 
three different proteins, Mitofusin 1 (MFN1), Mitofusin 2 (MFN2) and Dynamin-like 120 kDa protein 
(OPA1) (Figure 1.5). MFN1 and MFN2 are integral OMM proteins with GTPase activity that are 
responsible for the fusion of the OMM (Dimmer and Scorrano, 2006). The first step of fusion is 
mediated by the formation of homotypic (MFN1-MFN1 or MFN2-MFN2) or heterotypic (MFN1-
MFN2) complexes (Koshiba et al., 2004). The turnover of MFN1 and MFN2 proteins depends on 
the recruitment of the AAA-ATPase p97 that permits the degradation of the ubiquitinated MFNs 
through the proteasome (Pallanck, 2010). It has been demonstrated that deletion of MFN1 or MFN2 
causes mitochondrial fragmentation and poor mitochondrial function (Perier and Vila, 2012). OPA1 
is an integral GTPase protein that is responsible for the fusion of the IMM (Chan, 2006). This protein 
is imported in the IMS, where it is processed by several proteases, such as PARL, YME1L and OMA1 
(MacVicar and Langer, 2016), thus leading to the formation of both long (L-OPA1) and short (S-
OPA1) protein forms. In physiological conditions, a correct balance between L-OPA1 and S-OPA1 
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is maintained to preserve the mitochondrial network morphology (Song et al, 2009). However, 
mitochondrial depolarization causes the activation of OMA1 protease, which determines the 
accumulation of the S-OPA1 (Head et al., 2009). This process leads to the inhibition of the IMMs 
fusion, thus causing mitochondrial fragmentation (Song et al, 2009). OPA1 is also involved in the 
protection against apoptotic cell death. Indeed, this protein plays a key role in the maintenance of 
cristae structure and junctions, thus preventing the release of cytochrome c from mitochondria 
(Ramonet et al., 2013). Moreover, OPA1 knock down leads to Bax translocation, release of 
cytochrome c and caspase activation (Olichon et al., 2003). 
 
 
Figure 1.5: Both MFN1 and MFN2 are responsible for the fusion of the OMM, while OPA1 plays a key role in the fusion 
of the IMM.  
 
Mitochondrial fission is important to allow the proper cellular distribution of these organelles and the 
degradation of damaged mitochondria through mitophagy (Otera and Mihara, 2011). This process is 
made possible by the GTPase activity of the cytosolic protein dynamin-1-like protein (DRP1). Indeed, 
once this GTPase protein localises on mitochondria, DRP1 oligomerizes into ring-like structures and 
constricts mitochondria thanks to GTP hydrolysis (Ingerman et al., 2005). The recruitment of DRP1 
to the OMM depends on specific post-translational modifications. For example, fission is triggered 
when calcineurin dephosporilates DRP1 protein, while is prevented when PKA phosphorylates the 
conserved residue Ser-637 of DRP1. The recruitment of DRP1 on the OMM requires also the 
presence of specific mitochondrial receptors (Parone et al., 2008). The most characterized receptor 
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that interacts with DRP1 is Mitochondrial fission 1 protein (FIS1) (Karren et al., 2005) (Figure 1.6). 
There are also other mitochondrial membrane proteins that interact with DRP1, thus contributing to 
the fission process. For example, MFF proteins can recruit DRP1 independently for Fis1 and its 
overexpression determines mitochondrial fragmentation (Otera et al., 2010). Eventually, MiD49 and 
MiD51 are involved in the fission process through their capacity to recruit DRP1 on the OMM 
(Palmer et al., 2011). 
 
 
Figure 1.6: FIS1 is a mitochondrial membrane receptor involved in the recruitment of DRP1 protein. Once DRP1 localizes 
and oligomerizes on the OMM, it constricts mitochondria thanks to the hydrolysis of GTP molecules.  
 
Mitophagy is an important quality control process that allows for the recognition and the consequent 
lysosomal degradation of damaged mitochondria (Youle and Narendra, 2011). The missed 
mitochondrial disposal causes the accumulation of dysfunctional mitochondria (Egan et al., 2011) that 
can lead to cell death. The most characterized mitophagy mechanism is the PINK1/Parkin pathway. 
Under basal conditions, the precursor of PINK1 is synthesized in the cytosol and imported into the 
OMM via translocase of outer mitochondrial membrane complex (TOM). Full-length PINK1 is 
further transferred into the IMM through the translocase of inner mitochondrial membrane (TIM) 
complex in a membrane potential dependent manner. Here, PINK1 is processed by the mitochondrial 
processing peptidase (MPP), that cleaves the MTS sequence, resulting in a ~60-kDa PINK1 form. 
This MPP-cleaved form of PINK1, which spans the IMM, is then further cleaved by the rhomboid 
protease of the IMM, presenilin associated rhomboid-like protease (PARL), to give rise to the 52-kDa 
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mature form. PINK1 is then degraded through the proteasome. This pathway keeps endogenous 
PINK1 levels very low in polarized mitochondria to prevent mitophagy of healthy mitochondria 
(Eiyama and Okamoto, 2015) (Figure 1.7). 
 
 
Figure 1.7: In healthy mitochondria, the precursor of PINK1 (64 kDa) is imported into the OMM via TOM and further 
transferred into IMM through TIM complex in a membrane potential dependent manner. Here, 64-kDa PINK1 is 
processed by the MPP. This form of PINK1 is then cleaved by PARL, to give rise to the 52-kDa mature form, and 
subsequently degraded by mitochondrial peptidases and by the proteasome. 
 
On the contrary, the import of PINK1 and its proteasomal degradation are inhibited, when 
mitochondria are damaged and lose their membrane potential (e.g., after treatment with protonophors 
as Carbonyl cyanide m-chlorophenyl hydrazine (CCCP)). The inhibition of PINK1 degradation causes 
the accumulation of this protein onto the OMM. This process leads to the mitochondrial recruitment 
of the E3-ubiquitin ligase Parkin, which catalyses the covalent attachment of ubiquitin moieties onto 
specific mitochondrial proteins (e.g. MFNs, VDACs, Miro and TOMM70) (Pickrell and Youle, 2015) 
(Figure 1.8). The recruitment of Parkin to mitochondria depends on the phosphorylation and 
consequent activation of this protein by PINK1 (Ordureau et al., 2014), on VDAC proteins (Sun et 
al., 2012) and on MFN2 (Chen and Dorn, 2013). Once the OMM proteins are ubiquitylated, several 
autophagy receptors are recruited to damaged mitochondria, to bind the ubiquitin-tagged OMM 
proteins (Figure 1.8). The impairment of PINK1/Parkin mitophagy axis could lead to the 
accumulation of dysfunctional mitochondria that may contribute to dopaminergic cell death, due to 
the increased production of ROS and the enhanced release of mitochondrial apoptogenic factors 
(Fernández-Moriano et al., 2015). 
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Figure 1.8: In depolarized mitochondria, PINK1 accumulates onto the OMM, thus recruiting Parkin. Parkin catalyzes the 
covalent attachment of ubiquitin moieties onto specific mitochondrial proteins. This process leads to the selective 
engulfment of damaged organelles by the autophagosome. 
 
Mitochondrial proteome 
The majority of mitochondrial proteins are encoded by nuclear genes, synthesized in the cytosol and 
eventually imported to the appropriate mitochondrial sub-compartment through several multimeric 
translocation machines (e.g. TOM and TIM) (Kang et al., 2017). The mitochondrial DNA (mt-DNA) 
has 37 genes that encode subunits of the respiratory chain, tRNAs and rRNAs (Scarpulla et al., 2012).  
Several human diseases are associated with mutations of mitochondrial proteins encoded by 
mitochondrial genome, or by nuclear chromosomes, or mutation in proteins that, interacting with 
mitochondria, regulate mitochondrial homeostasis (Gorman et al., 2015; Su et al., 2018). Therefore, 
the study of the mitochondrial proteome associated with specific physiological or pathological 
conditions increased. Indeed, the detection of the molecular landscape underlying mitochondrial 
dysfunction could represent new opportunities to investigate the pathogenesis of several diseases 
(Picard et al., 2016). The Human Proteome Organization (HUPO) has promoted in recent years the 
mitochondrial human proteome project (mt-HPP), whose main goal is to understand the function of 
the mitochondrial proteome and its crosstalk with the proteome of other organelles. By combining 
proteomics and computational biology, it would be possible to systematically consider mitochondrial 
proteins encoded by the mt-DNA, by nuclear DNA and protein imported into mitochondria or simply 
associated to them (Monti et al., 2018). The simultaneous consideration of all mitochondrial proteins 
and their first interactors led to the generation of the functional mitochondrial human proteome 
network (Fasano et al., 2016) that can be used to map proteins derived from proteomics studies. In 
particular, the mapping of proteome alterations related to diseases where mitochondrial dysfunctions 
are involved (e.g., PD) may evidence the driver mitochondrial molecular factors and pathways. 
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1.2 
Scope of the thesis 
 
 
 
 
AD, PD and ALS are complex neurodegenerative disorders, whose aetiology and pathogenesis have 
not completely characterized. Many biochemical, environmental and genetic mechanisms have been 
proposed to play a role in the neuronal damage and loss in both diseases. Moreover, PD and ALS 
share common pathogenetic mechanisms. Indeed, the frequency of extrapyramidal symptoms in ALS 
patients is significantly higher than in the general population. Due to the complexity of these diseases, 
a systems biology approach would be appropriate to dissect their pathogenesis. By combining 
bioinformatics tools and proteomics analysis, it would be possible to highlight biochemical processes 
shared by neurodegenerative diseases and disease-specific pathways, which may justify the 
degeneration of different neuron populations. Finally, a focus on the mitochondrial interactome and 
proteome may elucidate important steps of PD degenerative process. 
To this purpose, in the first project (Meta-Neuro project, Meta-analysis of Neurodegenerative 
diseases) developed in the present thesis, a meta-analysis of the literature of all the proteomic 
investigations of neuronal alterations in PD, ALS and AD as control (non-motor neurodegenerative 
disease) was performed. The main objective was to obtain a comprehensive snapshot of molecular 
factors involved in PD by the analysis of proteomics and genetics data. Moreover, with the aid of the 
over-representation analysis, we wanted to highlight biochemical pathways specifically involved in PD 
pathogenetic process. Eventually, protein networks were generated, based on physical or functional 
interactions, in order to identify cellular components and macro-complexes involved in PD 
pathogenesis only. 
To further develop the results obtained by the first project, we decided to characterize differences in 
the PBMCs proteome of patients with ALS, PD and ALS patients with parkinsonian signs (ALS-PD) 
(ProLyPALS project, Proteomics of Lymphocytes in Parkinson’s disease and Amyotrophic Lateral 
Sclerosis). The main goals were the verification of the outcome of the Meta-Neuro project and the 
discovery of novel molecular factors specifically involved in one of the two pathologies. Indeed, the 
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characterization of ALS-PD patients may evidence proteins and pathways, which lead to the 
manifestation of both diseases. To this purpose, a 2-DE analysis of PBMCs samples was used to 
identify proteins that are specifically involved in PD or ALS, and proteins that are altered by both 
pathogenetic processes. To interpret these data and solve false positive and false negative issues, a 
systems biology approach was used to unravel the involvement of biochemical pathways responsible 
for the degeneration of different neuron populations. 
Several molecular pathways implicated in PD aetiology converge on mitochondria. Mitochondrial 
dysfunction could affect neuronal survival. To focus on the main mitochondrial processes involved 
in PD, an updated version of the functional mitochondrial human proteome network was generated 
and used to map PD-specific proteins obtained by the meta-analysis (MitoNet project, Mitochondrial 
Network). All the high-quality information collected in the neXtProt database (the reference database 
for the HPP) were used to visualize the mitochondrial interactome. PD-specific proteins mapped on 
the network were used to identify pathways altered at the mitochondrial level.  
The last project developed in this thesis (DynaMoParD project, Dynamic Model of Parkinson’s 
Disease) is focused on the characterization of mitochondrial state and dynamics in cellular models of 
mitochondrial impairment in PD. To this purpose, SH-SY5Y human neuroblastoma cells treated with 
several mitochondrial toxins (i.e., DA, rotenone or MPP+) at different time points were used to retrieve 
data about key molecular factors involved in mitochondrial dynamics, with the final goal of generating 
a dynamic mathematical model of the “PD mitochondrion”. Altered DA homeostasis seems to be an 
important cellular pathogenetic mechanism involved in neurodegeneration in PD. In this context, it 
is possible to use the SH-SY5Y neuroblastoma cell line to mimic the improper handling of this 
neurotransmitter by the administration of exogenous DA in the culture medium. Moreover, rotenone 
and MPP+ are commonly used toxins in PD research due to their ability to induce parkinsonism 
through the inhibition of complex I. As a reference model of mitophagy induction, the treatment with 
the uncoupler CCCP was used in all experimental designs as a positive control.  
.
  
 
 
PART II 
Meta-Neuro 
 
Meta-analysis of Neurodegenerative diseases  
 
 
 43 
 
 
2.1 
Materials and Methods 
 
 
 
 
 
Input lists generation 
A meta-analysis of the literature was performed and all quantitative proteomic studies of neuronal 
alterations in PD, ALS, and AD were retrieved. The search was conducted in PubMed database 
(https://www.ncbi.nlm.nih.gov/pubmed/), using the following query: “proteom* [Title/Abstract] 
AND Parkinson* [Title/Abstract]), (“proteom* [Title/Abstract] AND Amyotrophic lateral Sclerosis* 
[Title/Abstract]) (“proteom* [Title/Abstract] AND Alzheimer* [Title/Abstract]”. We included all 
English language investigations found in the database and published within the end of 2015. All papers 
about therapies and biomarkers in peripheral fluids (such as: saliva, plasma, blood) were manually 
filtered out and only full-text original articles focused on the development of diseases in the CNS were 
considered. All protein IDs found to be differentially abundant in the disease state were retrieved 
manually and three input lists were generated (“PD_Proteins”, “ALS_Proteins” and “AD_Proteins”). 
No further filtering of results was applied by our analysis. For proteins obtained from non-human 
organisms (such as D. melanogaster and C. elegans), their orthologs, as reported in the Uniprot database 
(www.uniprot.org), were considered for the further analysis. Furthermore, the proteins IDs were 
converted to the corresponding gene symbol, as annotated in Uniprot database. 
Genetic information was taken from the curated DisGeNET database (http://disgenet.org, v4 
released April 15th 2016) (Piñero et al., 2015), using the following search terms: PD (umls:C0030567), 
ALS (umls:C0002736), and AD (umls:C0002395). All genes involved in the three diseases were 
retrieved and three input lists generated (“PD_Genes”, “ALS_Genes” and “AD_Genes”). 
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Bioinformatics analysis 
Venn diagram (http://bioinformatics.psb.ugent.be/webtools/Venn/) was used to compare the 
protein input lists (“PD_Proteins”, “ALS_Proteins” and “AD_Proteins”). Therefore, proteins were 
divided into two groups, “disease-specific” proteins (only-PD_Proteins, only- ALS_Proteins, and 
only-AD_Proteins) and “in common among different diseases” proteins. To compare the protein and 
gene input lists, InteractiVenn (http://www.interactivenn.net/) (Heberle et al., 2015) was used and 
PD specific genes and proteins (PD_Proteins-Genes) were identified.  
An ORA of “only-PD_Proteins” list and of “PD_Proteins”, “ALS_Proteins” and “AD_Proteins” 
lists was performed using the “Analyze tool” in Reactome (http://www.reactome.org/) (Fabregat et 
al., 2018) and Panther in GO BP (http://www.geneontology.org/) (The GO Consortium, 2017) 
database. For both analyses only, categories with a p value <0.05 were considered as significant. In 
order to compare the results obtained after the analysis of the input lists, we used GOView 
(http://www.webgestalt.org/GOView/) (Wang et al., 2017). GOView is a web-based application, 
which allows users to compare and visualize multiple GO term lists in a directed acyclic graph (DAG), 
able to reveal relationships among the terms. 
The web portal BioProfiling.de was used to build networks (http://www.bioprofiling.de) (Antonov 
2011). This tool covers almost all the available information about signalling and metabolic pathways 
(databases: Reactome and KEGG) and physical PPI (database: IntAct). Accordingly, the protein input 
lists previously generated ("_Proteins") were analysed with the PPI spider tool (Antonov et al., 2009). 
The p value provided, computed by Monte Carlo simulation, refers to the probability to get a model 
of the same quality for a random gene list of the same size (Antonov 2011). The significant D1 
networks (all nodes belong to the input list), p < 0.01, were considered to further interpret and discuss 
proteomics results. The direct interactor networks were exported as .xgmml files and edited using 
Cytoscape 3.2.0 (http://www.cytoscape.org/) (Shannon et al., 2003). Then, the three networks were 
merged to exclude nodes shared by different diseases and to identify “only-PD_Nodes”, later 
extracted in a new interaction network. To perform network topology analysis of the enriched 
networks, we used the NetworkAnalyzer Cytoscape application. It performs analysis of biological 
networks providing distributions of more complex network parameters, including node degrees, 
average clustering coefficients, topological coefficients, and shortest path lengths. Several network 
topology parameters such as the diameter of a network, the average number of neighbours, and the 
number of connected pairs of nodes were also computed (Assenov et al., 2008). Again, the GO 
Consortium was used to perform the ORA (GO terms).  
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Western blot analysis of Substantia Nigra samples 
Mesencephalic tissues from five sporadic PD patients and five age-matched controls (defined by the 
Brain Bank as non-demented, since they did not show any sign of dementia at the time of death) 
(Table 2.1) were obtained from the Netherlands Brain Bank (NBB), Netherlands Institute for 
Neuroscience, Amsterdam. A written consent for a brain autopsy was obtained from all donors. 
Eventually, clinical information for each subject was obtained from the NBB. 
Table 2.1: Characteristics of PD patients and gender and age-related control subjects (CTRL). 
NBB number Sex Age Diagnosis 
2007-013 M 61 PD 
2009-003 M 62 CTRL 
2007-029 M 67 PD 
1999-116 M 78 CTRL 
2006-062 M 87 PD 
2009-001 M 88 CTRL 
2009-045 F 59 PD 
2001-004 F 64 CTRL 
2009-078 F 88 PD 
1999-111 F 88 CTRL 
Notes: NBB: Netherlands Brain Bank; M: Male, F: Female; CTRL: control subjects, PD: Parkinson’s disease 
 
The tissue specimens (approximately 12 mg) were lysed in 500 μl of tissue lysis buffer (50 mM Tris-
HCl pH 7.4, 150 mM NaCl, 1% Triton, 2 mM ethylenediaminetetraacetic acid (EDTA) 1 mM 1,4-
dithiothreitol (DTT), 1x phosphatase inhibitors (Roche), 1× phenylmethylsulfonyl fluoride (PMSF), 
1× protease inhibitor cocktails (PIC). The tissues were manually lysed using a Potter homogenizer and 
then incubated on ice for 30 minutes. The samples were sonicated on ice (0.5 cycles, 15 pulses, twice). 
After this procedure, the lysates were centrifuged at 18000×g for 15 minutes at 4°C in order to collect 
the supernatants in new tubes.  
Total protein concentration was quantified using the bicinchoninic acid (BCA) method (Thermo 
Fisher Scientific). Equal amounts of proteins, previously incubated in Laemmli loading buffer, were 
resolved in 10% sodium dodecyl sulfate PAGE (SDS, TGX Stain-Free FastCast Acrylamide Kit, 10%, 
BioRad). The fluorescent stain was activated by UV light, following manufacturer’s instructions.  
Then, proteins were transferred to polyvinylidene difluoride (PVDF) membranes (Millipore) at 1.0 
mA/cm2, 1.5 hours (TE77pwr, Hoefer) and the fluorescent signal acquired (GelDoc-Ite Imaging 
System; UVP). Membranes were then saturated for 2 hours at room temperature (RT) in tris-buffered 
saline with 0.05% tween 20 (TBST) containing 5% skimmed milk powder. Eventually, blots were 
probed with antibodies against: TALDO1 (Abcam ab67467,1:500) and β-actin (GeneTex GTX23280, 
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1:8000) in 5% milk-TBST overnight at 4°C. Blots were incubated with anti-mouse (Millipore 12-349, 
1:1500) peroxidase-conjugated secondary antibody in 5% milk-TBST. Enhanced chemiluminescence 
substrate (Millipore Corporation) was used in order to visualize the peroxidase signals. Images (16 bit 
grayscale) were acquired with the G:BOXChemi XT4 (Syngene) system and analysed using the ImageJ 
software (https://imagej.nih.gov/ij/) (Schneider et al., 2012), normalizing each TALDO1 signal for 
the β-actin signal.  
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2.2 
Results 
 
 
 
 
 
Protein lists generation 
All the proteomics investigations of PD, AD and ALS disease models were collected performing a 
meta-analysis of the literature. The input lists were generated using all information about proteins 
altered by the three diseases extracted from full-texts of selected articles (Table 2.2). 762, 420 and 139 
papers were identified in PubMed about proteomics investigations in AD, PD and ALS, respectively. 
The studies retained (healthy/disease comparisons and quantitative proteomics studies) were 40 for 
AD, 46 for PD and only nine for ALS (Supplementary Table 2.1). The three input lists generated were 
AD_Proteins (928 proteins), PD_Proteins (1155 proteins) and ALS_Proteins (387 proteins) (Table 
2.2). 
Table 2.2: Number of PubMed hits and selected articles obtained by the meta-analysis procedure and number of proteins 
in each input list. 
 PubMed hits 
Healthy/disease comparisons and 
quantitative proteomic studies 
_Proteins 
AD 762 40 928 
PD 420 46 1155 
ALS 139 9 387 
 
Over-representation analysis of “_Protein” lists 
In order to understand which cellular pathways were mainly affected by the three diseases examined, 
an ORA was performed on the “_Proteins” input lists using the GO BP enrichment tool of the GO 
consortium. Only significant categories (p value <0.05) were considered information (Tables 2.3). The 
“apoptotic process” served as an internal control, since alterations in the apoptotic pathway resulted 
to be present in all the three conditions (PD, AD, and ALS), as expected for neurodegenerative 
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disorders. Similarly, the ORA revealed the alteration of protein transport as a pathway involved in the 
three diseases (“protein targeting” and “regulation of protein transport”). On the other hand, disease-
specific pathways were identified. Indeed, pathways converging on mitochondria (“mitophagy” and 
“mitochondria localization”), on the proteasome system (“proteolysis involved in cellular protein 
catabolic process”) and on the production of oxidative stress (“response to oxygen radical”) seemed 
to play a pivotal role in the pathogenesis of PD (Table 2.3). By contrast, cytoskeleton organization, 
ion homeostasis and lipid biosynthetic process resulted to be altered in AD, while aberrant RNA 
processing appeared to be mainly involved in ALS pathogenesis (“rRNA metabolic process”, “ncRNA 
metabolic process” and “mRNA splicing via splicesome”) (Table 2.3). 
 
Table 2.3: Summary table of the most significant results of the GO Biological Processes analysis of “_Proteins” input lists, 
after GoView filtering.for the further analysis. Given the huge amount of results obtained, GOView was used to select 
and sum up the most relevant  
AD_Proteins PD_Proteins ALS_Proteins 
Apoptotic process 
Electron transport chain 
Axon guidance 
Intracellular protein transport 
Protein targeting 
Signalling pathway (Fc receptor, NIK/NF-kappaB) 
 
Cell cycle phase 
Establishment of protein localization to endoplasmic reticulum 
DNA damage response 
Nuclear-transcribed mRNA catabolic process, nonsense-mediated decay 
Negative regulation of neuron apoptotic process 
Establishment of synaptic vesicle localization 
Mitochondrial membrane organization 
Mitochondrial transport 
Signalling pathway (ERBB, Fc epsilon, fibroblast growth factor receptor, 
insulin receptor, epidermal growth factor receptor) 
 
G2/M transition of mitotic cell 
cycle 
 G2/M transition of mitotic cell cycle 
Cellular potassium and sodium ion 
homeostasis 
Microtubule cytoskeleton 
organization 
Proteolysis involved in cellular protein 
catabolic process 
Mitochondrion localization 
Mitophagy 
Signalling pathway (ephrin receptor, 
tumor necrosis factor, canonical Wnt) 
rRNA metabolic process 
ncRNA metabolic process 
Nuclear transport 
RNA transport 
 
Physical interaction network  
Starting from the protein input lists, direct interactor networks were generated (Supplementary Figure. 
2.1). Then, the three networks were merged (Supplementary Figure 2.2) and “only-PD_Nodes” (129 
nodes) were extracted in a new network shown in Figure 2.1. This network highlights the alteration 
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of proteins involved in the regulation of proteolysis (light blue nodes), a process mainly guided by the 
proteasome complex. 
 
 
Figure 2.1: Significant networks built by PPI spider (p < 0.01), using IntAct database as the reference set. D1 model of 
only-PD_Nodes. Colours indicate gene functional roles according to the GO classification. 
 
In order to investigate which cellular macro complexes were involved in PD, NetworkAnalyzer was 
used. The size of nodes was adjusted according to their degree: the bigger the node, the higher the 
number of edges (Figure 2.2). At the same time, to identify the cellular localization of the complexes, 
an ORA was performed using the category CC of the GO Consortium. Three complexes included in 
the network are highlighted in Figure 2.2: “respiratory chain complex”, “proteasome complex” and 
“chaperonin containing T complex” (CCT complex) together with “protein phosphatase 2a complex” 
(PPP2A complex). 
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Figure 2.2: D1 model of only-PD_nodes after analysis with NetworkAnalyzer and ORA, using GO consortium CC. 
 
Analysis of macro complexes 
Eventually, to assess how complexes were involved in PD pathogenesis, they were separately analysed. 
Quantitative information on each protein were retrieved from original papers. Since it was impossible 
to compare papers using different scales and normalization methods, all quantitative data reported in 
the paper were used to categorize variations as up- or down-regulations. Proteins reported as 
consistently up-regulated in PD are the red nodes of the network, while down-regulated ones are green 
nodes. Yellow nodes represent contradictory results (different studies showed opposite variations) 
(Figure 2.3). Alterations in protein levels are reported in Supplementary Table 2.2. Figure 2.3A shows 
two closely related complexes, the chaperonins CCT complex and the phosphatases PPP2A complex. 
In the CCT complex, all the chaperonins were found to be down-regulated, except for CCT5. This 
protein is down-regulated when SNCA is over-expressed (Gui et al., 2012) as well as in MPTP-treated 
mice (Jin et al., 2005). Conversely, it is up-regulated in mouse neuroblastoma cell lines (Burté et al., 
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2011) and in PINK1 knockout mice (Triplett et al., 2015). With reference to the respiratory chain 
(Figure 2.3B), the components were altered in different directions, depending on the disease model 
considered (three yellow nodes: UQCRH, CYC1, and UQCRC1). Furthermore, the components of 
the regulatory (19S) subunit of the proteasome complex (Figure 2.3C) were all down-regulated, while 
members of the catalytic (20S) subunit were all up-regulated. 
 
 
Figure 2.3: Protein complexes specifically involved in PD. Nodes are coloured based on their confidence of being up- 
(red) or down-regulated (green) in the disease state. Yellow nodes are proteins whose level is presented as down-regulated 
in some papers and up-regulated in others. (A) shows the chaperonins CCT complex and the phosphatases PPP2A 
complex, (B) shows the complex III of the respiratory chain and (C) represents the proteasome complex. 
 
Parkinson’s disease-specific biochemical pathways and gene 
ontologies 
In order to identify proteins that were unique to a specific disease, the three “_Proteins” lists were 
analysed (Figure 2.4). 675 proteins resulted to be altered in PD only (only-PD_Proteins input list). On 
the other hand, PD and ALS shared 69 proteins, while AD and ALS showed only 29 proteins in 
common. 
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Figure 2.4: Venn diagram of the three input lists. Venn diagram showing the number of disease-specific proteins and 
proteins shared by more than one disease. 
 
To identify the over-represented pathways when only PD-specific proteins were considered, an ORA 
of only-PD_Proteins input list (675 IDs) was performed. To this purpose, GO BP and Reactome 
were used as reference databases. Again, “mitophagy” and apoptotic process (“regulation of 
apoptosis”) were found to be over-represented. Moreover, “translation” and “metabolism of amino 
acid and derivates” were significant ORA results (Table 2.4).  
 
Table 2.4: Summary table of the most significant results of the GO Biological Processes and Reactome analysis of “only 
PD_Proteins” input list. 
Go Consortium Biological Process Reactome 
Vesicle-mediated transport, 
Regulation of apoptotic process, 
Regulation of cell motility, 
Protein complex assembly, 
Signalling pathways (e.g. MAPK cascade, NIK/NF-kappaB 
signalling, Wnt signalling pathway), 
Regulation of protein catabolic process, 
Actin cytoskeleton organization, 
Modulation of synaptic transmission, 
Mitochondrion organization, 
Translation, 
Nuclear-transcribed mRNA catabolic process nonsense-
mediated decay, 
SRP-dependent cotranslational protein targeting to 
membrane 
Cellular response to heat stress, 
DNA replication, 
Laminin interactions, 
Nonsense-Mediated Decay (NMD), 
Mitophagy (PINK1/Parkin mediated Mitophagy), 
Metabolism of aminoacid and derivates, 
Translation, 
Regulation of apoptosis, 
Signalling pathway (e.g. MAPK family signalling 
cascade, signalling by Wnt, signalling by Hedgehog), 
Membrane trafficking 
 
Identification of Parkinson’s disease-specific proteins and genes  
In order to identify both proteins and genes exclusively associated to PD, genetic information was 
extracted from the curated database DisGeNET, and three additional input lists called AD_Genes, 
PD_Genes, and ALS_Genes were obtained (Table 2.5).  
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Table 2.5: Numbers of IDs of “_Proteins” and “_Genes” input lists. “_Genes” input lists were obtained using DisGeNET 
as reference database. 
 Input lists 
 “_Proteins” “_Genes” 
AD 928 1663 
PD 1155 766 
ALS 387 799 
 
The “_Proteins” and the “_Genes” input lists were compared using the InteractiVenn tool (Figure 
2.5).  
 
 
Figure 2.5: Venn diagram showing disease-specific genes and proteins and those shared by different diseases. The arrow 
shows the overlap between the PD_Proteins list and the PD_Genes list. 
 
As a result, 25 IDs were present in both “PD_Proteins” and “PD_Genes” input lists and not present 
in any other protein or gene list (Table 2.6). Therefore, these IDs have been associated to PD both by 
genetics and proteomics analyses. 
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Table 2.6: Gene Symbol and description of 25 IDs that were present both in “PD_Proteins” and “PD_Genes” input lists. 
Gene Symbol Description 
ALDH1A1 Retinal dehydrogenase 1 
AP1M1 AP-1 complex subunit mu-1 
B2M Beta-2-microglobulin 
CD200 OX-2 membrane glycoprotein 
DDC Aromatic-L-amino-acid decarboxylase 
DLG2 Disks large homolog 2 
FBN1 Fibrillin-1 
FBP1 Fructose-1,6-bisphosphatase 1 
GAD1 Glutamate decarboxylase 1 
GCH1 GTP cyclohydrolase 1 
GLUD2 Glutamate dehydrogenase 2, mitochondrial 
HSPA1L Heat shock 70 kDa protein 1-like 
MANF Mesencephalic astrocyte-derived neurotrophic factor 
NOD2 Nucleotide-binding oligomerization domain-containing protein 2 
NQO2 Ribosyldihydronicotinamide dehydrogenase [quinone] 
PDXK Pyridoxal kinase 
RPL14 60S ribosomal protein L14 
RPL23A 60S ribosomal protein L23a 
RPL6 60S ribosomal protein L6 
RPS8 40S ribosomal protein S8 
SFXN2 Sideroflexin-2 
SNRPF Small nuclear ribonucleoprotein F 
TALDO1 Transaldolase 1 
UBE2S Ubiquitin-conjugating enzyme E2 S 
WFS1 Wolframin 
 
Verification of Transaldolase 1 as a Parkinson’s disease protein 
As a proof of principle, one protein in the list of the 25 PD unique IDs was selected to verify its up-
regulation in PD affected tissues, as suggested by the bioinformatic analysis. 
Meta-Neuro: Results 
 
55 
 
Transaldolase 1 (TALDO1) abundance was checked in SN samples obtained from five sporadic PD 
patients and five matched control subjects (CTRL). Western blot analysis revealed that protein level 
of TALDO1 were higher in the affected tissue of sporadic PD patients, as reported in the literature 
(Alberio et al., 2012; Licker et al., 2014) (Figure 2.6). 
 
 
Figure 2.6: Western blot analysis of 10 SN samples (five PD patients and five control subjects (CTRL)). (A) A 
representative Western blot, showing Transaldolase 1 and β-Actin, used as a loading control. (B) Bars report the relative 
change of Transaldolase 1 signals (normalized to the related β-actin signal) in PD patients with respect to control subjects, 
arbitrarily set to 1. Values are the mean ± SEM of three technical replicates (*, p < 0.05). 
  
 
 
PART III 
ProLyPALS 
 
       Proteomics of Lymphocytes in Parkinson’s disease and 
Amyotrophic Lateral Sclerosis  
 
 
 
 57 
 
 
3.1 
Materials and Methods 
 
 
 
 
 
Study subjects 
Sixty-nine subjects were enrolled by the Parkinson's Disease and Amyotrophic Lateral Sclerosis 
Centres at the Department of Neuroscience, University of Torino, and by the Neurology Division at 
the Department of Translational Medicine, University of Eastern Piedmont. Every subject was 
associated to an alphanumeric code to ensure that his/her identity was not disclosed to investigators. 
Among the patients enrolled for the study, 20 subjects were newly diagnosed (de-novo) PD patients, 
while 49 were ALS patients. Among them, 20 subjects were de-novo ALS patients (ALS), 20 were 
ALS patients already under riluzole treatment (ALS_r) without parkinsonian signs, while nine patients 
were ALS patients with parkinsonian symptoms and signs (ALS-PD), usually under riluzole treatment. 
MDS-UPDRS was used for PD diagnosis, while ALS diagnosis was evaluated using the ALSFRS 
system (Table 3.1).  
Table 3.1: Summary of the clinical information collected.  
PD ALS ALS_r ALS-PD 
Clinical neurological examination 
MDS-UPDRS 
MR encephalopathy 
SPECT with DAT scan 
 
Clinical neurological examination 
ALSFRS 
DNA analysis for the major known genes involved in ALS  
(SOD1, FUS, TARDBP, C9ORF72) 
 Dose of riluzole 
For each subject, information about age, sex, height and weight (at the time of blood collection), smoke or alcohol use, 
work and physical activity, diagnosis, familiarity with other neurologic pathologies, therapies, exposition to substances 
or environment particularly dangerous and any other recent pathologies were also collected. 
Note: MDS-UPDRS: Movement Disorder Society (MDS) of the Unified Parkinson's Disease Rating Scale; MR: Magnetic Resonance; 
SPECT: Single Photon Emission Computed Tomography; ALSFRS-R: ALS Functional Rating Scale-Revised. 
 
Gender and age distributions were similar in different groups. Supplemental Table 3.1 reports 
demographic and clinical data for all enrolled subjects (for a summary see Table 3.2). Subjects suffering 
from inflammatory or infectious diseases and subjects that took drugs capable of interfering with 
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PBMCs at the time of enrolment were excluded from the study. All patients signed an informed 
consent before being recruited for the present study, following approval by the Institutional Review 
Boards of the University Hospitals where subjects were enrolled.  
 
Table 3.2: Summary of enrolled patients in the study. 
  PD 
(20) 
ALS 
(20) 
ALS_r 
(20) 
ALS-PD 
(9) 
Age at the withdrawal ± SD 
(years) 
63.3±10.1 67.4±10.4 64.8±9.8 69.8±7.7 
Male% 45% 65% 50% 67% 
Unmedicated 20 20 0 3 
Riluzole 
50 mg/d 0 0 4 0 
50 mgx2/d 0 0 16 6 
ALSFRS score 0 37.6±7.3 30.3±8.4 29.2±7.5 
Motor MDS-UPDRS score 36.3±10.4 0 0 0 
Note: d: daily. 
 
Peripheral blood mononuclear cells isolation 
All subjects underwent a venous blood sampling (16 ml) from the antecubital vein, between 9 a.m. 
and 10 a.m., after an overnight fast.  
Blood was collected into a CPT-tube with sodium citrate (BD Bioscience) and it was centrifuged (1500 
g, 20 minutes, RT) to separate plasma, PBMCs (layer over the gel barrier) and erythrocytes/neutrophils 
(layer under the gel barrier). Then, the PBMCs layer was transferred into a new tube and centrifuged 
again (10 minutes at 600 g, RT).  
The resulting pellet was washed twice with 10 mL of PBS (w/o Ca2+ and Mg2+). Lastly, samples have 
been divided into 4 aliquots of 1 mL each and then pelleted at 500-1000 g for 10 minutes. Pellets were 
immediately frozen and stored at -80°C. 
 
Two-dimensional electrophoresis and image analysis 
PBMCs were resuspended in 100 µl UTC (7M urea, 2M thiourea and 4% 3-[(3-cholamidopropyl) 
dimethylammonio]-1-propanesulfonate (CHAPS)) with a protease/phosphatase inhibitors cocktail 
(Sigma-Aldrich). Cells were left in this solution for 30 minutes to allow a complete cell lysis, sonicated 
(10 pulses at 0.5 cycle and 80 amplitude, and 10 pulses at 0.5 cycle and 100 amplitude) and centrifuged 
(13000 g for 30 minutes, RT) to precipitate cellular debris.  
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Protein concentration was determined according to Bradford. Total proteins (500 μg) were separated 
through 2-DE using 18 cm IPG DryStrips with a nonlinear 3–10 pH gradient (GE Healthcare) 
followed by 12.5% SDS-PAGE. The resulting maps were stained with Ru(II) tris(bathophenanthroline 
disulfonate) (Serva). Images were acquired (12-bit grayscale) with the GelDoc-It Imaging System 
(UVP) and analysed with ImageMaster 2D Platinum (GE Healthcare). A total of about 400 spots were 
detected in gels and included in the analysis.  
 
Statistical analysis 
Spot volumes were normalized over the sum of the volume of those spots present in all gels. The 
spots present in less than 65% of the gels were excluded from the further analysis. Then, the biological 
variability of the subjects in each group was assessed by Pearson linear correlation and Q-Q plots. 
After a logarithmic transformation data were processed to eliminate confounding factors: gender 
(Wilcoxon test, p value < 0.01), age at the withdrawal (Pearson test, p value < 0.01) and riluzole-
sensitivity (Student's T-test, p value < 0.01), controlling that riluzole-sensitivity was not correlated to 
disease severity (ALSFRS score). We generated a single group (ALS_all) with all ALS patients (ALS 
and ALS_r).  
For the feature selection, relative volumes were analysed by the non-parametric Wilcoxon test to find 
differences (p < 0.2) in patients with PD with respect to ALS subjects (ALS_all). 
Predictive model for the classification of PD patients with respect to ALS subjects was built by linear 
discriminant analysis (LDA) of the spots identified as described above. In this case, missing values 
were replaced by the mean value of the spot volume of the group or, if the mean was lower than the 
98th percentile, by the minimum value observed in the group.  
For each subject that has to be predicted by the model, a likelihood score (Predscore) was calculated 
by linear combination of relative spot volumes according to the following equation: 𝑃𝑟𝑒𝑑𝑠𝑐𝑜𝑟𝑒 =  ∑ 𝑐𝑖 ∗  𝑉𝑜𝑙𝑖𝑖  
Simplified models were obtained by progressively removing spots with the lowest discriminating 
weight (W), calculated according to the equation:  𝑊 = |𝑐𝑖 ∗ (𝑉𝑜𝑙𝑖,𝐴𝐿𝑆_𝑎𝑙𝑙 −  𝑉𝑜𝑙𝑖,𝑃𝐷)| 
where ci is the LDA coefficient for spot i and 𝑉𝑜𝑙𝑖,𝐴𝐿𝑆_𝑎𝑙𝑙 −  𝑉𝑜𝑙𝑖,𝑃𝐷 is the absolute separation of the 
mean values of spot i in ALS subjects (ALS_all) and PD. Each predictive model has been tested with 
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the leave-one-out (predicting one subject excluded from the model construction) and K-fold methods 
(testing the prediction of 10 patients, randomly eliminated before the construction of the model (k = 
6)). The performance of predictive models has been quantified by measuring the area under the ROC 
curve. 
Finally, the LDA model which allowed us to predict subject groups with the best sensitivity and 
specificity was chosen as reference model to predict the ALS-PD patients. The spots deriving from 
that model were selected to be excised for protein identification. Eventually, we used them to 
discriminate groups of ALS-PD patients by a principal component analysis (PCA) and classify them 
as ALS or PD.  
All procedures for data analysis and graphics were written in R, an open-source environment for 
statistical computing (Figure 3.1). 
 
 
Figure 3.1: Summary of statistical analysis steps.  
 
In-gel digestion, mass spectrometry and protein identification 
Spots corresponding to proteins of interest were excised manually. Spots were reduced (10 mM DTT 
in 100 mM NH4HCO3 for 45 minutes at 56°C) and then alkylated (55 mM IAA in 100 mM NH4HCO3 
for 30 minutes at RT). Spots were dehydrated using CH3CN for 5 minutes. Dry spots were reswollen 
with a solution of 10 ng/μL trypsin (Modified Porcine Trypsin, sequencing Grade, Promega, 
Madisonin in 100 mM NH4CO3) and digested overnight at 37°C. Upon digestion, peptides obtained 
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from each spot were extracted with a solution of Trifluoroacetic acid (TFA) and CH3CN. The 
supernatants were collected in a fresh tube and vacuum dried.  
The peptide mixtures were analysed by LC-MS/MS, using LTQ XL-Orbitrap ETD equipped with a 
HPLC NanoEasy-PROXEON (Thermo Fisher Scientific). Protein identification was manually 
performed by searching the National Centre for Biotechnology Information non-redundant database 
using the Mascot Ion Search program (http://www.matrixscience.com). The following parameters 
were set: specific trypsin digestion, up to one missed cleavage; fixed carbamidomethylation of 
cysteines, partial oxidation of methionines, partial protein N-terminal acetylation, partial N-terminal 
pyro-carbamidomethylation, peptide mass tolerance ± 10 ppm, fragment mass tolerance ± 0.6 Da, 2+ 
to 3+ peptide charge, species restriction to human. All identified proteins had a Mascot score 
corresponding to a statistically significant (p < 0.05) confident identification according to Fisher's test. 
At least 2 different peptides had to be assigned. Peptide and protein identifications corresponding to 
keratins or trypsin were not considered. 
 
Bioinformatics analysis  
The web portal String (https://string-db.org/) (Szklarczyk et al., 2017) was used to build networks. 
The database covers most of the available information regarding signalling and metabolic pathways 
(Biocarta, BioCyc, GO, KEGG, and Reactome) and physical protein-protein interactions (BIND, 
DIP, GRID, HPRD, IntAct, MINT, and PID). Accordingly, the spots deriving from the LDA model 
were used to generate the network. The provided PPI enriched p value is a major of the connectivity 
of nodes and verifies whether the proteins of the input list have more interactions among themselves 
than what would be expected for a random set of proteins of similar size, drawn from the genome. 
Such an enrichment indicates that the proteins are at least partially biologically connected, as a group. 
The significant network (p < 0.01) was further considered to interpret and discuss proteomics results. 
The network was exported as a. txt file and visualized and modified by Cytoscape 3.6.1 
(http://www.cytoscape.org/) (Shannon et al., 2003). The ORA of nodes of the network was carried 
out using the Reactome database (http://www.reactome.org/) (Fabregat et al., 2018).  
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3.2 
Results 
 
 
 
 
 
Two-dimensional electrophoresis profiling of PBMCs proteins 
Human PBMCs expression profiles of patients (PD, ALS, ALS_r and ALS-PD) were obtained by 2-
DE. A total of about 400 spots were detected in gels and 50 of them were present in all gels.  
The sum of these common spots was plotted (Supplemental Figure 3.1) to verify a normal distribution, 
which allows for the use of this value for normalization purposes. A total of 324 spots were detected 
in 65% of gels and included in the analysis. After the visualization of the distribution of missing values 
(Supplemental Figure 3.2), a threshold of 24, as the maximum number of gels in which a spot was not 
detected, was considered acceptable. This corresponds to the presence of each spot in at least 65% of 
the gels. Then, the biological variability of the subjects in each group was evaluated. Pairs of 2-DE 
gels from different subjects in the same group were compared by Pearson linear correlation of 
corresponding spot volumes after logarithmic transformation (Supplemental Figure 3.3). All 
comparisons between gel pairs showed a linear behavior. Therefore, all gels were retained, and spot 
volumes used for the analysis. 
69 maps were screened to identify proteins whose changes were linked to possible confounding 
factors, as gender, age and drug treatments. 7 spots showed significant differences by the Wilcoxon 
test (p<0.01) between male and female patients (Supplemental Figure 3.4). 21 spots presented 
significant (p<0.01) Pearson linear correlation between spots volume and age of patients at the 
withdrawal (Supplemental Figure 3.5). Both groups of spots were eliminated from further analysis. 
Then, 13 spots showed significant differences by the Student’ T test (p<0.01) between ALS patients 
treated (ALS_r) or not (ALS) with riluzole (Supplemental Figure 3.6). The level of these spots did not 
correlate with the ALSFRS score (Supplemental Table 3.2). Thus, all riluzole-sensitive spots were 
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excluded from further analyses. Thus, it was possible to merge ALS and ALS_r groups into a new 
category (ALS_all). 
 
Features (spots) selection 
By comparing 2-DE maps from 20 PD patients and 40 ALS subjects (ALS_all), 54 protein spots 
(Wilcoxon test, p<0.2) were selected as the emergent properties and considered for the subsequent 
analysis (grey and black dots in Figure 3.2). The nine black dots represent protein spots showing 
different levels in the two groups, with a p value lower than 0.05 (Wilcoxon test, p<0.05). 
 
 
Figure 3.2: Volcano plot of all the spots. White dots have a p value (Wilcoxon test) higher than 0.2. Gray dots have a p 
value comprised between 0.2 and 0.05. Black dots are significant for the Wilcoxon test with a p value lower than 0.05. The 
two vertical lines evidence differences of 2 folds between ALS_all and PD.  
 
54 spots were used to construct a LDA between ALS_all and PD groups. 50 iterative models were 
generated, in which the spot with the lowest weight was eliminated. The cross-validation of the model 
was performed in two different ways: the leave-one-out process (Supplemental Figure 3.7) and the K-
fold process (Supplemental Figure 3 .8). The model which permitted to predict patients of the test set 
with the best sensitivity and specificity (sensitivity = 95% and specificity = 100%) was chosen as the 
reference one (Figure 3.3), and the 33 spots used to generate the model were selected. 
 
ProLyPALS: Results 
 
64 
 
 
Figure 3.3: Leave-one-out (A, B) and K-fold (C, D) cross-validation of the selected model (33 spots). A and C represent 
graphs of prediction scores of each patient. B and C represent the ROC curve. In “blue” ALS_all patients and in “orange” 
PD patients.  
 
The Predscore (based on the linear combination of 33 spots) was used to predict ALS-PD patients 
(Figure 3.4; Table 3.3). This model classified 4 subjects as ALS patients and 5 subjects as PD patients. 
 
 
Figure 3.4: Prediction of the ALS-PD patients, based on the selected model of 33 spots validated through K-fold method. 
ALS_all patients in “blue”, PD in “orange” and ALS-PD patients in “light blue”. 
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Table 3.3: Classification of the ALS-PD patients. 
Patient ID Classified as: 
ALS-PD 1 PD 
ALS-PD 2 ALS 
ALS-PD 3 PD 
ALS-PD 4 PD 
ALS-PD 5 ALS 
ALS-PD 6 ALS 
ALS-PD 7 ALS 
ALS-PD 8 PD 
ALS-PD 9 PD 
 
Proteins identification 
Proteins corresponding to the 33 selected spots were excised (Figure 3.5) and identified by LC-MS/MS 
as reported in Table 3.4.  
 
 
Figure 3.5: Spots excised for MS analysis are evidenced on a representative 2-DE map. 
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Table 3.4: Identification of protein spots. 
SPOTS N° GENE UNIPROT ID PROTEIN KDa PI 
472 SOD1 P00441 Superoxide dismutase [Cu-Zn] 15.9 5.7 
491 NME1 P15531 Nucleoside diphosphate kinase A 17.2 5.8 
503 HSPA8 P11142 
Heat shock cognate 71 kDa protein 
(fragment) 
70.9 5.4 
510 PFDN5 Q99471 Prefoldin subunit 5 17.3 5.9 
516 FGA P02671 Fibrinogen alpha chain (fragment) 95 5.7 
551 PGAM1 P18669 Phosphoglycerate mutase 1 28.8 6.7 
566 ACTB P60709 Actin, cytoplasmic 1 41.7 5.29 
578 PRDX3 P30048 
Thioredoxin-dependent peroxide 
reductase, mitochondrial 
27.7 7.7 
604 CAPZB P47756 F-actin-capping protein subunit beta 31.3 5.4 
614 PNP P23492 Purine nucleoside phosphorylase 32.1 6.5 
644 TUBB2A Q13885 Tubulin beta chain 49.7 4.8 
653 MSN P26038 Moesin 67.8 6.1 
654 MSN P26038 Moesin 67.8 6.1 
656 MSN P26038 Moesin 67.8 6.1 
659 LMNB1 P20700 Lamin-B1 66.4 5.1 
664 ACTB P60709 Actin, cytoplasmic 1 (fragment) 41.7 5.29 
687 PKM P14618 Pyruvate kinase PKM (fragment) 57.9 7.9 
711 PKM P14618 Pyruvate kinase PKM 57.9 7.9 
714 FGG P02679 Fibrinogen gamma chain 51.5 5.4 
722 PKM P14618 Pyruvate kinase PKM (fragment) 57.9 7.9 
723 TUBB1 Q9H4B7 Tubulin beta-1 chain 50.3 5 
726 VCL P18206 Vinculin (fragment) 124 5.5 
727 FGB P02675 Fibrinogen beta chain 56 8.5 
729 SERPINB1 P30740 Leukocyte elastase inhibitor (fragment) 42.7 5.9 
734 ENO1 P06733 Alpha-enolase 47.2 7 
741 TUBA1C Q9BQE3 Tubulin alpha-1C chain 49.9 4.9 
760 WDR1 O75083 WD repeat-containing protein 1 69.2 6.2 
773 FGB P02675 Fibrinogen beta chain 55.9 8.5 
774 MSN P26038 Moesin 67.8 6.1 
796 PDIA3 P30101 Protein disulfide-isomerase A3 56.8 5.9 
819 TUBB1 Q9H4B7 Tubulin beta-1 chain 50.3 5 
837 TLN1 Q9Y490 Talin-1 (fragment) 269.8 5.8 
872 ACTN1 P12814 Alpha-actinin-1 103 5.5 
In bold/blue, protein spots showing different levels in the two groups with a p value lower than 0.05 (Wilcoxon test, p<0.05). 
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A focus on amyotrophic lateral sclerosis patients with parkinsonian 
signs 
Using 33 spots, a PCA was performed to verify whether ALS-PD patients were classified as ALS or 
PD by our model. The first component (PC1) accounted for 25.4% of variance (Supplemental Figure 
3.8). To focus on more relevant spots in determining the classification of ALS-PD patients, we 
considered the PC1 value of the 33 spots. We arbitrarily decided to consider spots with |PC1|>0.2 
(see Table 3.5.) and verify in which direction they influenced the classification of ALS-PD patients. 
 
Table 3.5: Spots with |PC1|>0.2. 
SPOTS N° GENE UNIPROT ID |PC1| SIMILAR TO 
516 FGA P02671 0.220329 ALS 
551 PGAM1 P18669 0.26505 PD 
614 PNP P23492 0.31735 PD 
664 ACTB P60709 0.219239 ALS 
687 PKM P14618 0.27921 PD 
729 SERPINB1 P30740 0.24897 ALS 
734 ENO1 P06733 0.303292 PD 
741 TUBA1C Q9BQE3 0.21397 ALS 
760 WDR1 O75083 0.27932 PD 
773 FGB P02675 0.290507 PD 
872 ACTN1 P12814 0.23861 PD 
In bold/blue, protein spots showing different levels in the two groups with a p value lower than 0.05 (Wilcoxon test, p<0.05). 
 
Starting from the 33 proteins previously identified, a network-based analysis was performed, using the 
String database as a reference set. With this approach, a direct interactor network was generated 
(Figure 3.6), including 23 proteins. 
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Figure 3.6: Direct interactor network obtained using String as reference database. Nodes with thicker border represent 
proteins showing different levels in the two groups with a p value lower than 0.05. 
 
Since ALS-PD patients are primarily ALS patients, we wanted to visualize which protein signature 
determined their difference with ALS patients with no extrapyramidal signs and caused the 
classification of some of them as PD. To this purpose, ALS-PD classified as ALS or as PD were 
compared with ALS patients (ALS_all). The results are reported on the network in Figure 3.7. 
PGAM1, ENO1, FGA, FGB, ACTN1, PKM, WDR1 and TUBA1C (bigger nodes, Figure 3.7A) were 
proteins that contributed the most to the classification (|PC1|>0.2). In Figure 3.7A, it is possible to 
visualize data of ALS-PD patients classified as ALS. ACTN1, PKM, WDR1 and TUBA1C probably 
contributed the most for the classification of this group as ALS, since their levels are homogenous 
with respect to the ALS group. Conversely, PGAM1, ENO1, FGB, FGA, PDIA3, TUBB1 (yellow or 
blue nodes, Figure 3.7A) represent proteins that showed the greatest difference of expression with 
respect to ALS patients (fold change (ALS-PD vs. ALS) >1.5), witnessing the difference of comorbid 
patients also at the molecular level. For ALS-PD patients classified as PD, PGAM1 and WDR1 had 
|PC1|>0.2 and a fold change <0.5 (Figure 3.7B), again contributing the most to the classification 
model. 
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Figure 3.7: Direct interactor network, obtained using String as reference database. Nodes with thicker borders represent 
proteins showing different levels in the ALS and PD groups, with a p value lower than 0.05. Bigger nodes represent 
proteins with |PC1| >0.2. Color code is correlated with protein abundance and indicates the fold change in the 
comparison ALS-PD vs. ALS. (A) ALS-PD patients classified as ALS, (B) ALS-PD patients classified as PD. 
 
Afterwards, the IDs list of the network nodes was used to perform an ORA, using Reactome as 
reference database. In Table 3.6, the top 25 over-represented pathways are reported. All pathways 
significantly (FRD<0.001) over-represented were reported in Supplemental Table 3.3. 
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Table 3.6. the top 25 over-represented pathways, using Reactome as reference database. 
Pathway Name 
Entities Reactions 
Found Total Pvalue FDR Ratio 
Prefoldin mediated transfer 
of substrate to CCT/TriC 
6 28 1.25E-10 2.58E-08 1.72E-04 
Cooperation of Prefoldin 
and TriC/CCT in actin and 
tubulin folding 
6 36 5.57E-10 5.74E-08 5.15E-04 
Platelet degranulation 8 137 2.14E-09 8.65E-08 9.45E-04 
Signalling by high-kinase 
activity BRAF mutants 
6 46 2.38E-09 8.65E-08 5.15E-04 
MAP2K and MAPK 
activation 
6 47 2.70E-09 8.65E-08 6.87E-04 
Signalling by moderate 
kinase activity BRAF 
mutants 
6 48 3.06E-09 8.65E-08 6.01E-04 
Response to elevated 
platelet cytosolic Ca2+ 
8 144 3.15E-09 8.65E-08 0.001202 
Paradoxical activation of 
RAF signalling by kinase 
inactive BRAF 
6 49 3.46E-09 8.65E-08 6.01E-04 
Hemostasis 14 806 5.60E-09 1.23E-07 0.028086 
Recycling pathway of L1 6 54 6.14E-09 1.23E-07 0.001202 
Signalling by RAS mutants 6 61 1.26E-08 2.27E-07 6.87E-04 
Signalling by BRAF and 
RAF fusions 
6 68 2.39E-08 3.90E-07 4.29E-04 
HSP90 chaperone cycle for 
steroid hormone receptors 
(SHR) 
6 69 2.60E-08 3.90E-07 0.001031 
Immune System 22 2638 3.20E-08 4.48E-07 0.126256 
RHO GTPases activate 
IQGAPs 
5 35 3.62E-08 4.70E-07 4.29E-04 
Gene and protein 
expression by JAK-STAT 
signalling after Interleukin-
12 stimulation 
6 74 3.92E-08 4.70E-07 0.003092 
L1CAM interactions 7 129 3.97E-08 4.76E-07 0.004638 
Cellular responses to stress 11 511 4.33E-08 4.77E-07 0.015803 
Interleukin-12 signalling 6 85 8.82E-08 8.82E-07 0.00481 
Oncogenic MAPK 
signalling 
6 87 1.01E-07 1.01E-06 0.00292 
Interleukin-12 family 
signalling 
6 97 1.90E-07 1.69E-06 0.009791 
Gap junction trafficking 5 50 2.09E-07 1.69E-06 0.001718 
Cellular responses to 
external stimuli 
11 598 2.11E-07 1.69E-06 0.021816 
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4.1 
Materials and Methods 
 
 
 
 
 
Input list generation  
All proteins with high quality (gold label) annotated as mitochondrial in subcellular location and/or 
GO Cellular Component sections of the neXtProt database (https://www.nextprot.org/ release 2018-
01-17) were collected and two input lists were generated (SUB_LOC list and GO_CC list). SUB_LOC 
list and GO_CC list were compared using Venn diagram (http://bioinformatics.psb.ugent.be/cgi-
bin/liste/Venn/calculate_venn.htpl). MITO list was created unifying the SUB_LOC list and the 
GO_CC list.  
 
Identification of mitochondrial missing proteins  
To highlight missing proteins, MITO list was analysed using Protein Evidence (PE) information 
retrieved from the neXtProt database. Proteins with evidence at transcript level (PE2), evidence for 
homology (PE3) and predicted (PE4) were collected and the MISSING list was generated. To 
demonstrate the existence of missing proteins (IDs of MISSING list) PubMed and the Global 
Proteome Machine database GPMdb (gpmdb.thegpm.org) (Craig et al., 2004) were used. 
 
The functional mitochondrial human proteome network generation 
To obtain a comprehensive mitochondrial network, data were extracted from neXtProt, using the 
advanced search functionality based on SPARQL language on the neXtProt SNORQL interface 
(http://snorql.nextprot.org/) (as detailed in Supplemental data 4.1). All gold protein-protein 
interactions for proteins in the MITO list were retrieved in the protein interaction section 
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(Supplemental data 4.2). Moreover, binary interactions were manually retrieved from the free text 
annotations and reported in the network table.  
The functional mitochondrial human proteome network (MITO network) was generated using 
Cytoscape 3.6.1 (http://www.cytoscape.org/) (Shannon et al., 2003). In this network, nodes represent 
proteins (mitochondrial proteins and their first interactors), while edges represent high quality protein-
protein interaction data. 
 
Bioinformatics analysis 
Sub-cellular and sub-mitochondrial location 
To classify other cellular localizations (Table 4.1) and the sub-mitochondrial localization (Table 4.2) 
of mitochondrial proteins of the MITO network, the advanced search of the neXtProt database was 
used. All gold data of the subcellular location and GO Cellular Component sections were retrieved 
(Supplemental data 4.3).  
Table 4.1: Uniprot and GO Cellular Component code of sub-cellular locations. 
Sub-cellular localization Uniprot code GO Cellular Component code 
Cytoplasm  SL-0086 GO_0005737 
Endoplasmic reticulum SL-0095 GO_0005783 
Golgi apparatus SL-0132 GO_0005794 
Lysosome SL-0158 GO_0005764 
Nucleus SL-0191 GO_0005634 
Mitochondrion SL-0173 GO_0005739 
 
Table 4.2: Uniprot and GO Cellular Component code of sub-mitochondrial locations 
Sub-mitochondrial localization Uniprot code GO Cellular Component code 
Inner membrane SL-0168 GO_0005743 
Inter membrane space SL-0169 GO_0005758 
Matrix  SL-0170 GO_0005759 
Membrane  SL-0171 GO_0031966 
Outer membrane SL-0172 GO_0005741 
 
Proteins relevant for a particular condition 
Using the MITO network, it is possible to highlight mitochondrial proteome alterations involved in a 
specific disease. To find biochemical pathways specifically involved in PD, only-PD_Proteins input 
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list (see Chapter 2.2, paragraph Physical Interaction Network) (Monti et al., 2018) was mapped on the 
MITO network. Mapped nodes were extracted and an over-representation analysis was performed 
using the “Analyze tool” in Reactome (Fabregat et al., 2018) and Panther in GO BP 
(http://www.geneontology.org/) (The GO Consortium, 2017) database. Arbitrarily, only GO 
Biological Processes with fold enrichment > 5 were considered (Macron et al., 2018). These limits 
allowed us to focus on specific ontologies (end nodes of ontology trees) and eliminate more general 
macro GO. For both analyses only, categories with FDR<0.001 were considered as significant.  
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4.2 
Results 
 
 
 
 
 
Generation of the MITO list 
All gold proteins annotated as mitochondrial in subcellular location and GO Cellular Component 
sections of the neXtProt database were retrieved. Uncertain protein (PE5, 12 mitochondrial proteins) 
were neglected from the further analysis. Mitochondrial sub-cellular location list (SUB_LOC list, 1219 
IDs) and mitochondrial GO Cellular Component list (GO_CC list, 1193 IDs) were generated. The 
SUB_LOC list and GO_CC list shared 999 mitochondrial proteins, while 194 proteins were present 
only in GO_CC list and 220 mitochondrial proteins were SUB_LOC list-specific (Figure 4.1). All 
mitochondrial proteins annotated as such in neXtProt database were used to generate a new input list, 
the MITO list (SUB_LOC list U GO_CC list, 1413 IDs).  
 
 
Figure 4.1: Mitochondrial IDs Venn diagrams. The Venn diagram shows the source of mitochondrial IDs in the MITO 
list (retrieved by neXtProt database) and the number of proteins shared by the SUB_LOC list (retrieved by the sublocation 
section) and the GO_CC list (retrieved by the GO Cellular Component section).  
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Protein evidence level of mitochondrial proteins 
Using Protein Evidence (PE) data retrieved from the neXtProt database, proteins of the MITO list 
were classified (Table 4.3) in order to identify “missing proteins”. “Missing proteins” as defined by 
the HUPO HPP consortium are neXtProt PE2-4 entries. Proteins of MITO lists annotated as PE2 
(evidence at the transcript level) or PE3 (inferred from homology) or PE4 (predicted) were used to 
generate a new list called MISSING list (containing 23 IDs) (Table 4.3). 
Table 4.3: PE2, PE3 proteins of the MITO list. All data were collected from neXtProt database (release 2018-01-17). 
Entries in the 
neXtProt database 
PE2 
(evidence at transcript level) 
1660 
PE3 
(Inferred from homology) 
452 
PE4 
(Predicted) 
74 
MITO list 
(1413 IDs) 
20 3 0 
Gene Name 
ACSM4, ACSM6, ANKRD37, ATP5G2, 
ATP5G3, COX7B2, COX8C, GDF5OS, 
MCCD1, METTL12, MTRNR2L5, PRELID2, 
SIAH3, SLC25A34, SLC25A45, SLC25A47, 
SLC25A52, TDH 
ATP5EP2, KIF28P, 
UQCRHL 
 
 
The proteins of the MISSING list were examined. Using data retrieved from the literature, it was 
possible to identify the existence of Methyltransferase-like protein 12 (METTL12). METTL12 is a 
protein involved in the regulation of citrate synthase activity. Indeed, the methylation of Lys 395 
inhibits citrate synthase (Małecki et al., 2017). This post-translational modification is blocked by 
oxaloacetate and by S-adenosylhomocysteine. Moreover, the methylation of Lys-368 of citrate 
synthase by METTL12 probably influences protein-protein interactions in the metabolism of the citric 
acid cycle (Małecki et al., 2017; Rhein et al., 207). Due to these new data, the PE status of this protein 
has been updated by UniProtKB (2018_01 release) and its status will be upgraded to PE1 in the next 
neXtProt release. As concerns PE3 proteins, Kinesin-like protein KIF28P (KIF28P) was inferred 
from mouse and rat, while Cytochrome b-c1 complex subunit 6-like, mitochondrial (UQCRHL) was 
inferred from yeast and mouse. On the other hand, ATP synthase subunit epsilon-like protein, 
mitochondrial (ATP5EP2) was defined as a pseudogene but one of its peptides was identified by MS 
in the context of a phosphoproteome analysis in human samples (Yu et al., 2007). 
 
The functional mitochondrial human proteome network  
Starting from the MITO list, using the high-quality (gold) protein-protein interaction information 
from neXtProt, a network was generated. The resulting functional mitochondrial human proteome 
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network (MITO network) had 3395 nodes: mitochondrial proteins (yellow nodes) were 825, while 
2570 nodes were first non-mitochondrial interactors (blue nodes) (Figure 4.2).  
 
Figure 4.2: The functional mitochondrial human proteome network. Yellow nodes represent mitochondrial proteins 
(encoded by the mitochondrial genome or translocated to the mitochondrion, if indicated as mitochondrial in the sub 
location and/or GO Cellular Component sections of the neXtProt database). Blue nodes represent gold interactors of the 
mitochondrial proteins, as obtained by querying the protein interaction sections of the neXtProt database.  
 
Sub-cellular and sub-mitochondrial location of mitochondrial nodes 
All the mitochondrial nodes (yellow nodes in Figure 4.2) of the MITO network were analysed in terms 
of other sub-cellular locations, in order to understand how many mitochondrial proteins were 
exclusively mitochondrial. Only the six most represented cellular components (Cytoplasm, Golgi 
Apparatus, Lysosome, Endoplasmic Reticulum, Mitochondrion, Nucleus) were considered and all 
gold data were retrieved in the same sections of the neXtProt database. 36 proteins (4%) were 
exclusively mitochondrial, whereas the majority of the proteins had other cellular locations (Figure 
4.3). Cytoplasm (93% of mitochondrial proteins were also localized in the cytoplasm) and nucleus 
(41% of mitochondrial proteins were also localized in the nucleus) were the most represented other 
cellular locations for mitochondrial proteins (Figure 4.3).  
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Figure 4.3: Graphical representation of multiple sub-cellular locations. Colour code is explained at the bottom. The size 
of the category square is proportional to the number of proteins in that group, which is written inside each square. 
Rectangles are placed progressively from the largest and more represented category on the left to the smallest and less 
represented one on the bottom-right. Category squares describing multiple locations are filled with white (mitochondrion) 
and coloured stripes (other location).  
 
Moreover, 376 proteins had a “generic mitochondrion” annotation in neXtProt subcellular location 
or GO Cellular Component sections, while 449 other mitochondrial nodes had more precise sub-
mitochondrial annotations: 138 proteins were localized in the mitochondrial matrix, 103 were inner 
membrane mitochondrial proteins, 92 were localized in the outer membrane and 16 were localized in 
the inter membrane space (Figure 4.4).  
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Figure 4.4: Graphical representation of sub-mitochondrial locations. Colour code is explained at the bottom. The size of 
the category square is proportional to the number of proteins in that group, which is written inside each square. Category 
squares describing multiple locations are filled with different colours. Rectangles are placed progressively from the largest 
and more represented category on the left to the smallest and less represented one on the bottom-right.  
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Focus on the mitochondrial impairment in Parkinson’s Disease 
675 proteins of the only-PD_Proteins list (see Chapter 2.2, Physical Interaction Network) (Monti et 
al., 2018) were analysed using the MITO network (Figure 4.5).  
 
 
Figure 4.5: PD specific proteins mapped onto the MITO network. Yellow nodes encode for mitochondrial proteins, while 
blue nodes encode for first interactors.  
 
208 PD-related proteins (31%) were mapped on the network, highlighting the central role of 
mitochondria in this pathology. An ORA was performed using Reactome and GO BP as reference 
databases. Reactome results highlighted the central role of mitophagy (“Pink/Parkin Mediated 
Mitophagy”, FDR 3.92×10-4 and “Mitophagy”, FDR 8.02×10-4) and of “mitochondrial protein 
import” (FDR 5.24×10-4) (Supplemental Table 4.1). On the other hand, the GO BP mainly involved 
was “mitochondrial transport” (FDR 1.94×10-8, Fold Enrichment 8.81). An interesting result was the 
over-representation of the GO BP “regulation of neurotransmitter transport” (FDR 7.08×10-4, Fold 
Enrichment 6.91) (Supplemental Table 4.1). 
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5.1 
Materials and Methods 
 
 
 
 
 
Cell culture and treatments 
The human neuroblastoma SH-SY5Y cells (ECACC, Cat No. 94030304; Lot No. 11C016) were 
maintained at 37°C under humidified conditions and 5% CO2 in high glucose Dulbecco’s Modified 
Eagle’s Medium (DMEM) (Euroclone) supplemented with 10% Fetal Bovine Serum (FBS) 
(Euroclone), 100 U/mL penicillin (Euroclone), 100 g/mL streptomycin (Euroclone) and 2 mM L-
glutamine (Euroclone). Cells were seeded 24 hours before treatments. Cells were then treated with 
mitochondrial toxins (Table 5.1) for 3, 6, 9 and 24 hours (time-course).  
To eliminate the peroxide dioxide spontaneously generated in the extra-cellular milieu, catalase (700 
U/ml) was added to DMEM in treatments with dopamine (DA (CAT)) or with MPP+ (MPP+ (CAT)). 
A treatment with MPP+ alone was added to verify that catalase did not influence cellular and molecular 
responses. Eventually, SH-SY5Y cells were treated with CCCP, or ROT or an equal volume of vehicle, 
DMSO. 
Table 5.1: Experimental conditions. 
Treatments Concentration 
SH-SY5Y (control) - 
1-methyl-4-phenylpyridinium (MPP+) 2.5 mM 
Catalase (CAT) 700 U/mL 
Dopamine and Catalase (DA (CAT)) 250 µM (700 U/mL) 
1-methyl-4-phenylpyridinium and catalase (MPP+(CAT)) 2.5 mM (700 U/mL) 
Dimethyl sulfoxide (DMSO) 20 µM 
Rotenone and Dimethyl sulfoxide (ROT (DMSO)) 500 nM (20 µM) 
Carbonyl cyanide m-chlorophenyl hydrazine and Dimethyl sulfoxide 
(CCCP (DMSO)) 
20 µM (20 µM) 
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Citotoxicity assay 
Cell viability was investigated using the neutral red (NR) uptake assay. Cells were seeded in 24-well 
plates at 105 cells per well and cultured for 24 hours at 37 °C before the assay. Cells were exposed to 
different experimental conditions (Table 5.1), for several time points, 3, 6, 9 and 24 hours. At the end 
of the treatment, the conditioned medium was removed, and cells were incubated with freshly 
prepared NR solution (50 μg NR/ml in culture medium) for 3 hours at 37 °C. Then cells were rapidly 
washed with a fixative (1% CaCl2 and 1.3 % formaldehyde) and subsequently lysed with the extraction 
solution (50% ethanol and 1% acetic acid). After 30 minutes incubation at RT, aliquots of the resulting 
solutions were transferred to cuvettes and the absorbance was recorded at 540 nm. Results were 
expressed as a percentage of control. All experiments were run in triplicate. Statistical significance was 
assessed by the Welch-corrected t test. 
 
Quantitative Western blot analysis 
1 ×105 SH-SY5Y cells were seeded in T25 flasks and cultured for 24 hours at 37 °C before treatments. 
At the end of the treatments, cells were detached with trypsin-EDTA, collected by centrifugation (300 
× g, 4 °C, 7 minutes) and washed with ice-cold PBS. Cells were lysed using RIPA buffer (0.1% SDS 
50 mM Tris-HCl pH 7.6, 150 mM NaCl, 1% sodium desoxycholate, 1% NP-40) and incubated on ice 
for 30 minutes. Afterwards, lysates were centrifuged at 15000 × g for 40 minutes at 4°C and 
supernatants collected. 60 μg of proteins were incubated in Laemmli loading buffer and then resolved 
by 10% or 16% SDS-PAGE. Then, proteins were transferred to PVDF membranes at 1.0 mA/cm2, 
1.5 hours (TE77pwr, Hoefer). Membranes were then saturated for 2 hours at RT in TBST containing 
5% skimmed milk powder. Eventually, blots were probed with antibodies against several proteins 
(Table 5.2) in 5% milk-TBST overnight at 4°C. 
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Table 5.2: Primary and secondary antibody used in quantitative Western blot analysis. 
Protein Primary antibody dilution Secondary antibody Secondary antibody dilution 
OPA1  1:250 (HPA036927, Sigma Aldrich) 
Anti-rabbit  
1:2500 (#AP132P, Millipore 
Corporation) 
MFN1  1:1000 (sc-50330, Santa Cruz 
Biotechnology) 
PINK1 1:1000 (#6946, Cell Signaling) 
VDAC1 1:1000 (ab15895, Abcam) 
COX5β  1:1000 (#C4498, Sigma-Aldrich) 
ACT  1:10000 (GTX23280, GeneTex) Anti-mouse  1:10000 (12-349, Millipore 
Corporation) 
 
Blots were incubated with peroxidase-conjugated secondary antibodies, as reported in Table 5.2, in 
5% milk-TBST. Enhanced chemiluminescence substrate (Millipore Corporation) was used in order to 
visualize the peroxidase signals. Images (16 bit grayscale) were acquired with the G:BOXChemi XT4 
(Syngene) system and analysed using the ImageJ software (https://imagej.nih.gov/ij/) (Schneider et 
al., 2012), normalizing each protein signal for the β-actin signal. 
Results were expressed as a percentage of control. All experiments were run in triplicate. Statistical 
significance was assessed by the Welch-corrected t test. 
  
Measurement of mitochondrial membrane potential (Δψm) 
SH-SY5Y cells were seeded in 24-well plates (1×105 cells/well) and cultured for 24 hours at 37 °C 
before treatments. Cells were treated for 24 hours. To evaluate the mitochondrial membrane potential, 
medium was removed and replaced with fresh DMEM with 100 nM Mitotracker Red CMXRos 
(chloromethyl-X-rosamine, Life Technologies), which accumulates into the matrix of mitochondria 
with intact mitochondrial membrane potential. After 20 minutes of incubation at 37 °C, medium 
containing Mitotracker was replaced with fresh PBS and cells were fixed with 4% paraformaldehyde 
for 20 minutes. Nuclei were stained with 300 nM 4',6-diamidino-2- phenylindole (DAPI) for 5 minutes 
(Life Technologies). Coverslips were mounted with ProLong Gold Antifade mountant (Thermo 
Fisher Scientific) and cells imaged using a laser-scanning confocal microscope (Leica TCS SP5) 
through a 63×/1.40 NA oil-immersion objective (HCX PL APO lambda blue). Z-stacks with 0.2 μm 
step size were acquired with sequential excitation at 1024 x 1024 pixels resolution and 1.5× or 2× 
magnification, 2 frames average. Eventually, image processing and analysis were performed using the 
ImageJ software. For each whole field of view (fov), Mitotracker signal intensities were calculated 
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measuring integrated density values after a reduction of background signal by rolling ball algorithm 
(200 pixel radius). The corrected intensity was normalized with respect to the number of cells, as 
defined by nuclear staining with DAPI.  
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5.2 
Results 
 
 
 
 
 
Cytotoxicity assays  
To evaluate the effect of mitochondrial toxins (see Table 5.1) on SH-SY5Y cells, a cytotoxicity assay 
was performed using NR. Results are reported as the mean percentage of viable cells, obtained by the 
ratio of the absorbance at 540 nm of treated cells with respect to the related control, in at least three 
independent experiments. From 6 hours of treatment on, dopamine (DA(CAT)), MPP+ (MPP+ and 
MPP+ (CAT)), Rotenone (ROT(DMSO)), and CCCP (CCCP(DMSO)) caused a significant decrease 
of cell viability (about 40%) (Figure 5.1). On the contrary, exposure to catalase (CAT) for 3 and 6 
hours induced a slight increase of cell viability (Figure 5.1)  
 
 
Figure 5.1: Cell viability of SH-SY5Y cells. Relative cell viability after 3, 6, 9 and 24 hours of treatments with several 
mitochondrial toxins. *, p<0.05; **, p<0.01. 
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Molecular characterization of mitochondrial network alterations 
To evaluate protein level of OPA1, MFN1, PINK1, VDAC1 and COX5β, SH-SY5Y cells were treated 
with several mitochondrial toxins (see Table 5.1) and quantitative Western blot analysis was 
performed.  
In order to evaluate whether mitophagy was impaired by DA, MPP+ and rotenone, PINK1 protein 
levels were evaluated. As shown in Figure 5.2, PINK1 protein was detectable only in SH-SY5Y cells 
treated with CCCP treatment (from 6 hours of treatment and subsequent time points), used as a 
positive control. 
 
Figure 5.2: Representative Western blot of the effect of DA, MPP+, rotenone and CCCP treatments on PINK1 
accumulation at different time points. 
 
To investigate effects on the mitochondrial mass induced by toxic treatments, Western blot 
quantification of cytochrome c oxidase subunit 5 β (COX5β), localized in the inner mitochondrial 
membrane, and voltage-dependent anion-selective channel protein 1 (VDAC1), localized in the outer 
mitochondrial membrane, was carried out.  
As COX5β is concerned, no significant variation was highlighted after rotenone and MPP+ treatments 
(MPP+ with or without catalase). Conversely, after 24 hours of DA treatment, samples showed 
reduced levels of COX5β. Also, CCCP treatment reduced COX5β level (≈50 % reduction after 6 
hours and subsequent time points) (Figure 5.3). 
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Figure 5.3: Effect of treatments on COX5β. Top: Relative quantification of COX5β. Bars represent the mean of three 
independent experiments on SH-SY5Y cells treated for 3,6, 9 and 24 hours. Error bars represent SEM of three 
experiments. *, p<0.05; **, p<0.01. Bottom: Representative Western blot of the effect of DA, MPP+, rotenone and CCCP 
treatments on COX5β at 24 hours. 
 
As VDAC1 is concerned, 24 hours DA treatment caused the reduction of its levels of approximately 
60%. On the other hand, 24 hours MPP+ treatments induced an increase of VDAC1 level (Figure 5.4). 
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Figure 5.4: Effect of treatments on VDAC1. Top: Relative quantification of VDAC1. Bars represent the mean of three 
independent experiments on SH-SY5Y cells treated for 3,6, 9 and 24 hours. Error bars represent SEM of three 
experiments. *, p<0.05; **, p<0.01. Bottom: Representative Western blot of the effect of DA, MPP+, rotenone and CCCP 
treatments on VDAC1 at 24 hours. 
 
Abundance and modifications of OPA1 and MFN1 in all experimental conditions were considered, 
since their role in influencing mitochondrial dynamics. After CCCP treatment, down-regulation of 
MFN1 was observed. Three hours of CCCP treatment induced a reduction of 50% of MFN1 protein 
level. Conversely, other treatments did not have any effect on MFN1 (Figure 5.5). 
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Figure 5.5: Effect of treatments on MFN1. Top: Relative quantification of MFN1. Bars represent the mean of three 
independent experiments on SH-SY5Y cells treated for 3,6, 9 and 24 hours. Error bars represent SEM of three 
experiments. *, p<0.05; **, p<0.01. Bottom: Representative Western blot of the effect of DA, MPP+, rotenone and CCCP 
treatments on MFN1 at 24 hours. 
 
As OPA1 is concerned, from 9 hours on, DA and MPP+ treatments lowered its levels (50% reduction 
of both the long L-OPA1 and the short S-OPA1 forms at 24 hours; Figure 5.6). On the other hand, 
CCCP induced the disappearance of L-OPA1 (Figure 5.6). 
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Figure 5.6: Effect of treatments on OPA1. Top: Bars represent the mean of three independent experiments on SH-SY5Y 
cells treated for 3, 6, 9 and 24 hours. Error bars represent SEM of three experiments. *, p<0.05; **, p<0.01. Bottom: 
Representative Western blot of the effect of DA, MPP+, rotenone and CCCP treatments on OPA1 at 24 hours. Two 
forms are visible, the longest form (L-OPA1) and the shortest (S-OPA1).  
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Effect on mitochondrial membrane potential (Δψm) after treatments 
In order to determine the effect of treatments on mitochondrial function, living cells were stained 
with Mitotracker Red CMXRos, which accumulates in mitochondria with an intact membrane 
potential. Treatment of SH-SY5Y cells with DA, MPP+, rotenone and CCCP for 24 hours induced a 
comparable loss of the mitochondrial membrane potential (≈50-60% reduction) (Figure 5.7, 
Supplemental Figure 5.1) 
 
 Figure 5.7: Effect of treatments on Δψm. Bars represent the mean of seven fields of SH-SY5Y cells treated for 24 hours. 
Error bars represent SEM of seven fields of view. Statistical test will be performed after data collection from at least three 
biological replicates.  
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6.1 
Discussion 
 
 
 
 
 
Neurodegenerative disorders, such as AD, PD and ALS are multi-factorial in nature, involving several 
genetic mutations (in coding or regulatory regions) and epigenetic and environmental factors 
(Landgrave-Gómez et al., 2015). The main clinical manifestation (movement disorders, cognitive 
impairment and/or psychiatric disturbances) depends on the neuron population being primarily 
affected. Complex and multifactorial neurodegenerative diseases can be investigated using a holistic 
approach that can give a global view about the pathogenetic process and shed light on specific and 
generic pathways of neurodegeneration (Fasano et al., 2017). Proteomics offers a global molecular 
snapshot of proteins and consequently of processes that may influence neuronal death. The proteome 
in fact provides a dynamic view of what is happening in the system under investigation, because the 
expression of proteins, their abundance, their localization in tissues or cells, the type and amount of 
their post-translational changes depend from the environment and from the cellular physiological state 
(Santos and Lindner, 2017). Therefore, all the projects presented in this thesis, by combining 
bioinformatics tools with proteomics, aimed at highlighting biochemical processes shared by different 
neurodegenerative diseases and disease-specific pathways, which may justify the degeneration of 
dopaminergic neurons in PD. Finally, a focus on the mitochondrial interactome and proteome 
intended to elucidate important specific steps of the degenerative process in PD. 
 
The Meta-Neuro Project 
To identify specific biochemical processes involved in the loss of dopaminergic neurons in PD, all 
papers containing proteomics experiments about neuronal modifications in PD, ALS (motor disorder 
caused by motor neurons death), and AD (non-motor neurodegenerative disease, used as control) 
were considered, including papers on human tissues, animal models and cellular models, and excluding 
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papers about pharmacological effects of particular molecules or peripheral biomarkers. The strength 
of the meta-analysis approach is to consider at the same time the results of many studies, derived from 
different models, thus filtering out experimental bias and highlighting really relevant mechanisms. 
However, this approach has some shortcomings. First, only quantitative proteomics studies were 
included (post-translational modifications were excluded from the analysis). To solve this issue, 
proteomics data were merged with information coming from a genetic database (DisGeNET). 
Another weakness is the few proteomics information about ALS (9 papers) compared to those of PD 
(46 papers) and AD (40 papers). Consequently, the molecular snapshot obtained for ALS was more 
incomplete than those generated for PD and AD.  
To identify disease-specific pathways and biochemical processes shared by the three 
neurodegenerative diseases, an ORA on the “_Proteins” input lists was performed, using the GO 
consortium. By the comparison of over-represented pathways, it was possible to identify processes 
common to all three diseases that were general hallmarks of cell death. Indeed, the ORA underlined 
the over-representation of the apoptotic process (used as a kind of positive control), oxidative stress 
and ROS damage and electron transport chain (ETC). The respiratory chain, especially in pathological 
conditions, can be a source of ROS. A high level of ROS causes a damage to various cellular 
components and ultimately results in the activation of apoptosis (Li et al., 2013). Regarding ALS 
specific-pathways, the involvement of RNA processing was particularly evident. Metabolism (“rRNA 
metabolic process”, “ncRNA metabolic process”), transport (“nuclear transport”, “Nuclear import”, 
and “RNA transport”) and splicing (“mRNA splicing”) were ALS specific over-represented GO. 
Alteration of RNA metabolism in ALS was already described. First of all, the majority of the genetic 
mutations observed in familial ALS (TARDBP, FUS, ANG and SETX) can impact directly on either 
gene transcription, pre-mRNA splicing, ribonucleoprotein complex formation, transport, RNA 
translation or degradation (Strong, 2010). Moreover, it was observed that neurofilament aggregates 
are due to a selective disturbance in the steady state levels of their mRNA. Indeed, mRNA of low 
molecular weight neurofilament proteins (68 kDa) is suppressed, while the mRNA of intermediate 
molecular weight (160 kDa, NFM) or high molecular weight neurofilaments (200 kDa, NFH) are more 
stabilized. NFM and NFH generate aggregates (Menzies et al., 2002).  
By contrast, cytoskeleton organization, ion homeostasis and lipid biosynthetic process resulted to be 
altered only in AD. Although alteration at the mitochondrial level (membrane organization and 
mitochondrial transport) were over-represented in AD and PD, notably, “mitophagy” was involved 
in PD only. Alteration of the mitochondrial quality control and the consequent mitochondrial 
impairment have been widely associated to apoptosis directly triggered by these organelles (“apoptotic 
mitochondrial changes”) (Perkins et al., 2009).  
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The analysis of the three “_Proteins” lists displayed a major overlap between PD and ALS compared 
to the comparison of AD and ALS. There is an extensive evidence that supports the close relationship 
between ALS and PD at the clinical (Belin et al., 2015), genetic (Körner et al., 2013) and neuroimaging 
(Cistaro et al., 2014) levels, in humans and in preclinical models (Ingre et al., 2015). On the contrary, 
ALS and AD comorbidity has never been reported. Indeed, the molecular overlapping in our analysis 
resulted to be scarce. 
To identify PD-specific proteins, all the proteins shared by AD and ALS were eliminated and an “only-
PD_Proteins” list was generated. Twentyfive of these proteins were also found in the DisGeNET 
database. They probably constitute major molecular hallmarks of PD, since they were never found to 
be altered in the other two pathologies and were reported both at the proteomic and the genetic levels. 
Among these PD hallmarks, transaldolase was identified. Transaldolase has already been identified in 
T-lymphocytes as part of a protein signature, able to discriminate PD patients from control subjects 
and patients affected by atypical parkinsonism (Alberio et al., 2012). Therefore, this protein may mirror 
at the peripheral level an alteration occurring in the CNS (Licker et al., 2014). Moreover, since this 
evidence was only based on one paper in the literature (Licker et al., 2014), the up-regulation of the 
protein was verified in five SN specimens of PD patients, with respect to five control subjects. As a 
proof-of-principle of our bioinformatics analysis, the increased level of the protein was confirmed in 
the experimental analysis. Although it is difficult to speculate about the link between a single protein 
and a complex, multifactorial disease, transaldolase is involved in the pentose phosphate pathway that 
regulates mitochondrial homeostasis in the presence of enhanced oxidative stress (Perl et al., 2011). 
The ORA of the “only- PD_Proteins” list highlighted the importance of mitophagy (GO pathways 
analysis) and some signal transduction cascades, such as the Wnt signalling pathway (L’Episcopo et 
al., 2014).  
Eventually, PD-specific protein complexes were unravelled. The analysis of PD specific networks 
evidenced four protein complexes: the proteasome 26S, the ETC complex III, the CCT complex, and 
the PPP2A complex. Quantitative information about proteins of these complexes were retrieved from 
original papers. Since it was impossible to compare papers using different scales and normalization 
methods, variations were categorized as up- or down-regulations. In the proteasome complex, it was 
possible to identify a different action of the PD pathogenetic process on the expression of members 
of the catalytic subunit (proteasome 20S, all up-regulated) and of the regulatory subunit (proteasome 
19S, all down-regulated). The involvement of the ETC dysfunction in PD has always been related to 
complex I (Amo et al., 2014), nevertheless, considering all the results together it was possible to 
highlight also the role of complex III. In the ETC complex III, proteins were reported to be regulated 
in different directions by the original papers, probably because of the use of different models (Morais 
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et al., 2014). This may indicate different alterations in the respiratory chain due to different 
perturbations. Another PD-specific complex was composed by chaperonins (CCT complex) that play 
an active role in the protection of dopaminergic neurons (Imai et al., 2003). All the proteins of the 
CCT complex were reported as down-regulated in the papers considered in the meta- analysis, 
probably indicating an overwhelming of their re-folding/protective capacities. Some of these 
chaperonins are direct interactors of the PPP2A complex. PPP2A is a protein complex composed by 
structural (A), regulatory/targeting (B), and catalytic (C) subunits. This phosphatase controls Akt 
phosphorylation and thus macro autophagy (Klionsky et al., 2016), the activity of tyrosine hydroxylase 
(Hua et al., 2015) and α-syn aggregation (Wu et al., 2012).  
 
The ProLyPALS Project 
PD and ALS probably share common pathways of neurodegeneration even though occurring in 
different cell types, as evidenced in the literature and by the meta-analysis of the Meta-Neuro project 
discussed above. As a matter of fact, the frequency of extrapyramidal symptoms in ALS patients is 
significantly higher than in the general population. ALS patients showing parkinsonian signs and 
symptoms (ALS-PD) may evidence altered protein levels and pathways, responsible of the 
manifestation of both diseases. From a genetic point of view, they may present mutations in genes 
previously linked with ALS or PD only (Körner et al., 2013). It has been demonstrated that the 
mutation of several genes (VCP, CHMP2B, PFN1, and C9ORF72 for example) induced high 
susceptibility to develop forms of comorbidity between ALS and PD (Seilhean et al., 2009; Chiò et al., 
2012; Gilbert et al., 2010). Thus, there are several commonly altered mechanisms between these two 
pathologies and ALS-PD patients demonstrate this strong association.  
To verify alterations retrieved by the meta-analysis and to find new potential molecular factors 
specifically involved in comorbidity of these two pathologies, a 2-DE analysis of PBMCs samples of 
patients with ALS, PD and ALS patients with parkinsonian signs (ALS-PD) was performed and a 
systems biology approach was used to unravel the involvement of biochemical pathways responsible 
for the degeneration of different neuronal populations.  
2- DE analysis allowed to investigate hundreds of proteins simultaneously, providing information 
about molecular weight, pI, quantity, and possible post-translational modifications. In particular, 
protein hydrolysis was highlighted and the change in abundance of several proteins was attributed to 
an increase in their degradation. For example, FGA molecular weight is 95 kDa, whereas in our study 
a spot corresponding to a fragment of this protein was identified at 10 kDa.  
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The cellular source exploited in the present project were PBMCs. Their easiness of sampling permits 
large-scale validation studies for biomarkers search. They are mainly composed by T-lymphocytes, 
which patrol what is happening at the central level (Fasano et al., 2008). T-lymphocyte proteome 
changes may be a valid tool to classify PD and ALS patients. In fact, it has been demonstrated that 
they reflect the functional impairment of SN dopaminergic neurons (Pacheco et al., 2009) and the 
same alterations in the level of enzymes involved in the oxidative phosphorylation reported in the 
spinal cord of PD patients (Ladd et al., 2014). In addition, they have also been used as reporters of 
pathogenetic events involved in ALS (Nardo et al., 2009). Indeed, PBMCs displayed traits such as 
intracellular calcium dysregulation (Curti et al., 1996) and glutamatergic dysfunction (Poulopoulou et 
al., 2005) typical of ALS patients. For these reasons, PBMCs were the best cellular model that could 
be recovered from patients without invasive samplings. However, the particular sensitivity of 
circulating cells to other inflammatory states and drug therapies needs a word of caution during 
patients enrolment and in interpreting results. In fact, only subjects who did not report an 
inflammatory pathology in the 15 days before the blood collection were enrolled.  
The pharmacological therapy is a confounding factor and therefore its effect was eliminated and 
carefully consider in recruitment criteria. ALS-PD subjects at the time of withdrawal were either in 
treatment or not with riluzole. This is the reason why both ALS patients under drug treatment (ALS_r) 
and subjects newly diagnosed and not yet in treatment with riluzole (ALS) were recruited. The effect 
of drug treatment on lymphocytes’ proteome was largely demonstrated in the literature. For example, 
L-DOPA and DA agonists induce modifications in the proteome of T-lymphocytes (Alberio et al., 
2012). No one of the ALS-PD subjects enrolled were in treatment with drugs for PD and therefore 
only PD patients recently diagnosed and not yet under pharmacological treatment were recruited. 
Once the effect due to riluzole was eliminated, all ALS patients were considered as a homogeneous 
group (ALS_all). As a consequence, the group resulted more comparable with the ALS-PD group for 
the categories “years from the diagnosis” and “severity of the pathology”.  
A power analysis was performed to decide the correct number of subjects to be enrolled for each 
group, in order to highlight differences of 65% in protein levels. Considering the variability among 
subjects, 20 patients were recruited for each group. However, the comorbidity between ALS and PD 
is quite a rare pathology. Therefore, all the patients visited in the last year at the PD and ALS Centres 
of the Department of Neuroscience of the University of Torino have been enrolled. The small number 
of ALS-PD patients was overcome by our analysis, because we used ALS and PD patients for the 
construction of a discriminating model and ALS-PD patients as a test set. A supervised analysis was 
used to classify the enrolled subjects. However, the Wilcoxon test with a permissive p value (p<0.2) 
and without the correction for multiple testing was used to select features to be used in the 
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construction of a discriminating model (LDA). In addition, the substitution of missing values of the 
spots selected was performed only after the univariate test, to avoid data manipulation and the 
introduction of biases. Final model, constructed with the spot selected by the Wilcoxon test, was 
validated by the k-fold method (the more robust one) in an iterative way. The model that demonstrated 
the best sensibility and specificity (sensibility = 97.5% and specificity = 100%) in the cross-validation 
was chosen as the reference one, and the 33 spots used to generate the model were selected.  
The prediction classified five ALS-PD patients as PD and four subjects as ALS patients. This was 
quite surprising since ALS-PD patients are subjects that firstly present ALS and develop PD signs 
only in a second moment. However, their classification as PD subjects can be due to several factors: 
early appearance of parkinsonism, severity of parkinsonian signs, familiarity with PD, mutations in 
genes commonly involved in PD. To this purpose, the results of the analysis will be merged with other 
data from patients (such as the genetic screening for the classical PD genes, DATscan analysis of ALS-
PD patients and MDS-UPDRS score), in order to better justify the ALS-PD classification.  
In addition, several features were analysed in detail. For example, it is largely known that mutations in 
Cu,Zn-superoxide dismutase-1 (SOD1) are causative for familial forms of ALS (Saccon et al., 2013). 
Anyway, it is quite surprising that the levels of this protein contributed to the multivariate classification 
of ALS patients in PBMCs samples, even in comparison with another neurodegenerative disease. 
Several selected spots resulted to correspond to fibrinogen. In a proteomics study on total 
lymphocytes from PD patients, it was demonstrated that two different isoforms of gamma fibrinogen 
either correlated with the disease state or with the disease duration (Mila et al., 2009). Instead, total 
beta fibrinogen levels were found to be reduced in T-lymphocytes of PD patients (Alberio et al., 2012). 
Again, all forms of fibrinogen were down-represented in PBMCs of PD patients (down-regulation of 
beta and gamma fibrinogen and up-regulation of a cleaved form of alpha-fibrinogen), even if 
compared with ALS patients’ samples. Another interesting result is the involvement of several 
glycolytic enzymes, Phosphoglycerate mutase 1, Alpha-enolase and Pyruvate kinase, in the 
classification of ALS-PD patients. Also, ORA highlighted the involvement of glycolysis (Reactome 
pathway analysis). It has recently been demonstrated that in PD patient PBMCs, mitochondrial 
dysfunction is associated with a concomitant increase in the glycolytic flux, independently for the 
glucose uptake or the monocyte activation (Smith et al., 2018). Moreover, others selected spots were 
proteins of the cytoskeleton (TUBB1, TUBB2A, ACTB, TUBA1C) or proteins associated to 
cytoskeleton (MSN, VCL, ACTN1, CAPZB and WDR1). An altered expression of cytoskeletal 
proteins was recently reported also by a RNA-seq analysis of PBMCs of sporadic and familiar ALS 
patients (Gagliardi et al., 2018).  
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The MitoNet Project 
All data obtained from previously discussed projects highlighted that several molecular pathways 
implicated in PD aetiology converge on mitochondria. To focus on the main mitochondrial processes 
involved in PD, an updated version of the functional mitochondrial human proteome network was 
generated and used to map PD-specific proteins obtained by the meta-analysis. The neXtProt database 
(official HPP database) was used as reference to retrieve all high-quality proteins annotated as 
mitochondrial in subcellular location and GO Cellular Component sections. Only gold annotations 
were considered, in order to be more robust in the definition of mitochondrial proteins. In this way, 
proteins synthesized in mitochondria, proteins imported into the mitochondrion and proteins 
transiently associated or imported only in particular conditions were considered. NeXtProt PE5 
entries were neglected from the analysis because they are uncertain protein predictions that may 
correspond to erroneous translations of pseudogenes, long non-coding RNA or other kinds of non-
coding elements. 1413 IDs were annotated as “Gold” mitochondrial proteins in neXtProt database 
and were used to generate the updated version of the functional mitochondrial human proteome 
network (Fasano et al., 2016). To create this tool, a network-based analysis was performed, using the 
high-quality protein-protein interaction information from neXtProt (Lane et al., 2014). Mitochondrial 
proteins that were retrieved thanks to annotations in subcellular location and GO Cellular Component 
sections may not be exclusively mitochondrial, since other cellular locations may be reported. Indeed, 
according to the Human Protein Atlas, more than half of the human proteome has multiple subcellular 
localizations, either simultaneously occurring within a cell or alternatively occurring at different stages 
of the cell cycle (Thul et al., 2017). Indeed only 4% (36) of proteins were exclusively mitochondrial, 
whereas the majority of them had other cellular locations (93% of mitochondrial proteins were also 
localized in the cytoplasm and 41% of mitochondrial proteins were also localized in the nucleus). 
These localizations may also be due to the fact that nuclei and cytoplasm are the major contaminants 
when isolating mitochondria (Alberio et al., 2017). Nevertheless, it is well known that many proteins 
translocate from the nucleus to mitochondria and viceversa following several stimuli, contributing, for 
example, to mitochondrial biogenesis and functionality during stress and aging (Lionaki et al., 2016). 
The functional mitochondrial human proteome network was used to focus on mitochondrial protein 
complexes or biochemical pathways potentially involved in PD. 675 proteins have already been related 
specifically to PD (“only-PD_Proteins” list of the Meta-Neuro project). 31% of PD-related proteins 
mapped on the functional mitochondrial human proteome network, highlighting the central role of 
mitochondria in this pathology. Moreover, using this approach, it was possible to eliminate all proteins 
that were not mitochondrial (or associated with this organelle) and identify only mitochondrial 
pathways altered by PD pathogenesis. To this purpose, an ORA was performed. Mitophagy 
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(“Pink/Parkin Mediated Mitophagy” and “Mitophagy”) and “mitochondrial protein import” were 
over-represented. Mutations in PINK1 and Parkin genes have been associated with familial forms of 
PD. Nevertheless, several pieces of evidence suggest that dysfunctional, depolarized mitochondria are 
not properly disposed also in the sporadic forms of the disease, thereby contributing to bioenergetic 
failure and oxidative stress (Bondi et al., 2015; Zilocchi et al., 2018). Moreover, the alteration of 
proteins involved in the protein import into the mitochondrion is probably due to mitochondrial 
membrane potential loss (Pickles et al., 2018). An interesting result was the over-representation of the 
“regulation of neurotransmitter transport” (using as reference GO BP database). It has already been 
proposed that synapse dysfunction is an early and leading event in determining neuronal degeneration 
and loss in PD (Monti et al., 2015).  
 
The DynaMoParD Project 
The final aim of the present project will be the generation of a dynamic model of the “PD 
mitochondrion”, to describe mathematically what happens in mitochondria of PD patients. The 
proposed model will focus on a particular type of cellular model of PD (human neuroblastoma cells 
treated with mitochondrial toxins). The model will adopt a fuzzy logic-based formalism that will 
provide a temporal simulation of the system. To this purpose, preliminary data were collected about 
several proteins involved in mitochondrial dynamics, such as mitophagy, fusion and fission. Next steps 
will be the generation of many other wet results and their integration, to generate membership 
functions of the fuzzy-model, with the final aim to use the virtual “PD mitochondrion” as a simulation 
platform. 
Mitochondria play important roles in many cellular activities (e.g., energy production, metabolism, 
aging and cell death) (Itoh et al., 2013). Neurons contain many mitochondria to satisfy their high 
request of ATP (Kageyama et al., 2013). Mitochondria are maintained as short tubular structures, 
which are highly dynamic and move, divide, and fuse by fission and fusion pathways. Mitochondrial 
fission is mediated by DRP1, a soluble cytosolic protein that assembles into spiral filaments around 
mitochondrial tubules. MFF, FIS1 are OMM proteins and have been proposed as DRP1 receptors. 
Several different post-translational modifications, including phosphorylation, ubiquitination and 
sumoylation of DRP1 regulate its interactions with mitochondria (Wilson et al., 2013). The Drp1 spiral 
has been proposed to constrict mitochondrial tubules through conformational changes, driven by 
GTP hydrolysis (Wilson et al., 2013). Mitochondrial fusion is mediated by MFNs (MFN1 and MFN2) 
and OPA1. MFNs are localized in the OMM, fuse the mitochondrial membranes of adjacent tubules 
through homotypic and heterotypic interactions (Song et al., 2009). OPA1 is localized in the IMM and 
interacts with MFNs to form intermembrane protein complexes that couple the fusion of outer 
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membranes to that of the inner membranes (Song et al., 2009). Loss of either MFNs or OPA1 leads 
to a similar mitochondrial fragmentation phenotype, suggesting that both outer and inner membrane 
fusion processes are affected. The dynamic behaviour of mitochondria allows the segregation of 
damaged mitochondria via the fission process and exchange of material between healthy mitochondria 
via the fusion process (van der Bliek et al., 2013). Additionally, mitophagy is triggered in the presence 
of severely damaged or superfluous mitochondria. Damaged mitochondria are isolated from the 
mitochondrial network and sequestered in autophagosomes to be delivered to lysosomes for 
degradation (Youle and Narendra, 2011). One of the most studied mechanisms for mitophagy in 
mammalian cells is the PINK1/Parkin-mediated mitophagy pathway. Briefly, a loss of Δψm is thought 
to be sufficient to induce PINK1 accumulation in the OMM, PINK1-induced phosphorylation of 
ubiquitin and parkin, and parkin-mediated ubiquitination of OMM proteins (including VDAC1) (Gao 
et al., 2015).  
Many neurodegenerative diseases are associated with alterations in the fission and fusion of 
mitochondria (Cho et al., 2009). However, the impairment of the mitochondrial quality control could 
be the primary cause of the PD pathogenesis (Polyzos and McMurray, 2017). 
To retrieve data about molecular factors involved in mitochondrial dynamics (fusion and fission) and 
mitophagy, different cellular models of mitochondrial impairment were used. In particular, human 
neuroblastoma cells (SH-SY5Y) were treated i) with inhibitors of ETC complex I ( 500 nM rotenone 
and 2.5 mM MPP+) (Langston et al., 1984), ii) by the administration of exogenous DA (250 µM) in 
the culture medium to mimic the altered DA homeostasis that seems to be an important cellular 
pathogenetic mechanism involved in PD (Alberio et al.,2014; Bondi et al., 2015); and iii) with the 
uncoupler CCCP (20 µM), used as a reference model of PINK1/Parkin mitophagic pathway induction 
(Narendra et al., 2010). The optimal concentration of toxins (DA, MPP+, rotenone and CCCP) was 
determined by the neutral red assay, in order to obtain comparable levels of cell death after 24 hours 
exposure to all toxins. 
SH-SY5Y treated with CCCP for 24 hours showed depolarized mitochondria. Moreover, all molecular 
alterations observed can be explained in light of inhibited fusion and induced mitophagy. Indeed, 
MFN1 was down- regulated, thus preventing the fusion of the OMMs (Bondi et al., 2015), PINK1 
was accumulated and several mitochondrial proteins (such as COX5β) were reduced, as a consequence 
of mitochondrial elimination by mitophagy. Transmission electron microscope (TEM) images of this 
toxic model confirmed this view, showing the presence of many vacuoles and mitochondria fused 
with phagosomes (Zilocchi et al., 2018).  
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On the other hand, SH-SY5Y treated for 24 hours with DA, MPP+ or Rotenone showed a different 
behaviour. A similar mitochondrial depolarization was observed, comparable to the Δψm loss induced 
by CCCP, however, this event seemed not to be followed by a proper disposal of depolarized 
mitochondria. Indeed, the number of mitochondria was not lowered.  Moreover, human 
neuroblastoma cells treated with DA or MPP+ or rotenone did not show significant alterations in 
MFN1 protein levels, thus suggesting that fusion of the OMM was not blocked. Moreover, both long 
and short forms of OPA1 decreased. These data suggest an impairment of the IMM fusion. Moreover, 
PINK1 did not accumulate on the OMM (impairment of mitophagy). As concerns COX5β levels, a 
protein of the IMM normally used as mitochondrial marker, was reduced after MPP+ and DA 
treatments (Bondi et al., 2015; Zilocchi et al., 2018). Levels of the OMM protein VDAC1 were 
analyzed. Indeed, besides its role in energetic metabolism, VDAC1 is also involved in the regulation 
of calcium homeostasis and in the mitochondria-mediated apoptosis (Naghdi and Hajnóczky, 2016). 
Moreover, it has been proposed that VDACs play an essential role in recruiting Parkin to defective 
mitochondria, in order to eliminate them through mitophagy, even if their actual role in triggering this 
process seems to be controversial (Narendra et al., 2010). VDAC1 protein level was decreased after 
DA treatment (Alberio et al., 2014), probably degraded by mitochondrial proteases, as already 
suggested (Di Pierro et al., 2016). By contrast, MPP+ treatment caused an increase of VDAC1 level. 
Taken together, these data provide a static snapshot of cellular events activated or inhibited after toxic 
treatments. To overcome this drawback, a fuzzy model was constructed (Figure 6.1).  
 
 
Figure 6.1: Network map of the model of mitochondrial dynamics (fusion and fission) and mitophagy. Circles represent 
metabolites and ions, rounded rectangles represent proteins and rectangles represent pathways or cellular processes. Blue 
nodes represent model's output, while yellow nodes represent model’s input. 
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The fuzzy model of mitochondrial dynamics and mitophagy was formalized as a graph (represented 
in Figure 6.1) composed of 17 nodes. The components were divided in 3 categories: molecules and 
ions (circles in Figure 6.1), pathway and cellular processes (rectangles in Figure 6.1), and proteins 
(rounded rectangle in Figure 6.1). - while edges represented the known positive and negative 
regulations among these components. Associated with each node, a set of membership functions was 
defined to represent multiple states of the nodes; in order to describe the interactions existing among 
them, a set of fuzzy logic rules was also defined for each node. The input nodes of the model are 
Complex I inhibitor (MPP+ and rotenone), DA and CCCP. These nodes were not regulated by any 
other node and their value must be specified by the user for each simulation. 
At this moment only preliminary data were collected and this information is not enough to define 
membership functions (IF <antecedent> THEN <consequent>). Thus, it will be necessary to collect 
many other experimental data after the different mitochondrial insults (i.e., DA, rotenone, MPP+ and 
CCCP) at different time points (3, 6, 9 and 24 hours). In particular, for each time point, it will be 
necessary to obtain experimental information about protein level of VDAC1, COX5β, MFN1, OPA1-
L, OPA1-S and PINK1 (by Western blot analysis); mRNA level of VDAC1, PINK1 and OPA1 (by 
Real time PCR); Δψm (by mitotracker staining), calcium ion flux to mitochondria (using recombinant 
aequorin targeted to mitochondria), ROS level (through 2′ 7′-dichlorofluorescein diacetate) and 
intracellular concentration of toxins. This last point will be fundamental. Indeed, the intracellular 
concentration of toxins represents the input of the dynamic model. To obtain an estimation of toxin 
intakes, which is a function of time, a computer simulation using cellular survival data will be used. 
This would be possible because we observed a biological effect (cell death) as a function of time and 
we assume that cell death depends on the intracellular toxin concentrations. To verify the obtained 
values, as a proof of principle, the intracellular concentration of DA will be experimentally evaluated 
by a spectrophotometric method. The absorbance at 600 nm of dopamine coordinated with Fe(III) 
will be monitored over time using a spectrophotometer. Therefore, the intracellular concentration of 
dopamine will be determined by lysing cells, adding Fe(III) and interpolating absorbance values with 
a calibration curve previously generated (Guo et al., 2009). 
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6.2 
Conclusion 
 
 
 
 
Neurodegenerative disorders, such as PD and ALS, represent a wide spectrum of pathologies 
characterized by the death of specific neuronal subtypes. The main clinical manifestation (movement 
disorders, cognitive impairment, and/or psychiatric disturbances) depends on the neuron population 
being primarily affected. ALS and PD aetiology and pathogenesis have not been completely 
characterized. To identify general and disease-specific patterns of neurodegeneration, a meta-analysis 
of the literature of all proteomics investigations about PD and ALS was performed. Regarding the 
ALS specific-pathways, the involvement of RNA processing was particularly evident: mRNA 
metabolism, transport, and splicing were all over-represented ontologies. Instead, PD-specific 
proteins were those involved in cellular response to stress, mitochondrion organization, mitophagy 
and protein synthesis. 
Nevertheless, there is also an extensive evidence that demonstrates the close relationship between 
ALS and PD. Indeed, the frequency of extrapyramidal symptoms in ALS patients is significantly higher 
than in the general population. ALS patients showing parkinsonian signs and symptoms (ALS-PD) 
may evidence altered protein levels and pathways, which lead to the manifestation of both diseases. 
To characterize ALS patients who display parkinsonian signs, proteomics analysis of PBMCs of ALS-
PD, ALS and PD patients was performed. This approach highlighted common alterations among 
ALS-PD subjects and ALS or PD patients. In particular, several proteins that have already associated 
to PD or ALS contributed to the multivariate classification of ALS-PD patients in PBMCs samples, 
such as SOD1 (involved in genetic form of ALS), FGG (correlated with PD state or with the disease 
duration) and FGB (protein levels already found to be reduced in T-lymphocytes of PD patients). 
Another interesting result was the alteration observed in the glycolytic process in ALS-PD patients. 
Indeed, it has already been reported that in PBMCs of PD patients, mitochondrial dysfunction causes 
an abnormal activation of glycolysis. 
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Again, mitochondria seem to have a pivotal role in PD pathogenesis. Although many 
neurodegenerative diseases are associated with alterations at the mitochondrial level, the impairment 
of the mitochondrial quality control seems to lead PD pathogenesis, since several molecular pathways 
implicated in PD aetiology converge on mitochondria. To focus on the main mitochondrial processes 
involved in PD, PD-specific proteins obtained by the meta-analysis were mapped on the functional 
mitochondrial human proteome network. This analysis highlighted that 31% of PD-specific proteins 
were mitochondrial proteins or associated with mitochondria. Moreover, ORA highlighted the central 
role of mitophagy, mitochondrial protein import and mitochondrial transport in PD. 
Considering all the results so far obtained, it will be interesting to generate a dynamic model to describe 
what happens in mitochondria of PD patients. To this purpose, preliminary data were collected about 
several proteins involved in mitophagy, fusion and fission pathways, in cellular models of 
mitochondrial impairment due to mitochondrial toxins related to PD. Next goal will be to obtain more 
molecular information about mitochondrial dynamics and elimination. All these data will be used to 
generate membership functions of a fuzzy-model of the “PD mitochondrion”, to be further used as 
a simulation platform. For instance, this model could be used to understand what happens at the 
mitochondrial level during PD pathogenesis and to simulate the action of drugs on the nodes to revert 
the process. For example, the reduced activity of PINK1 is linked to PD pathogenesis. Using this 
model, it could be possible to investigate the action of drugs able to activate PINK1 and estimate their 
rescue potential. However, this model has some limitations. First of all, it could be used only to 
evaluate the mitochondrial behaviour in neuronal cells after the treatment with mitochondrial toxins. 
Moreover, this model takes into account only three mitochondrial processes (mitophagy, fusion and 
fission), while mitochondrial network is involved in many other pathways. Additionally, only the 
PINK1/Parkin mitophagic process has been considered, while it has already been demonstrated that 
other proteins are involved in mitochondrial disposal (such as BNIP3).    
To conclude, the main aim of this thesis was to identify the pathways involved specifically in PD 
pathogenesis using proteomics and bioinformatics. Proteomics provides a global snapshot at the 
molecular level, thus allowing for the identification of processes that regulate the pathogenetic process. 
In the last decade, the proteomic community focused its attention on neurodegenerative diseases. 
However, a relevant limitation so far observed was the lack of proper controls, aimed at filtering out 
aspecific pathways of neurodegeneration/neuroinflammation. Therefore, the solution proposed in the 
present thesis was the use of other neurodegenerative diseases as a “control”, to remove all pathways 
that are involved in generic processes of neuronal death. Another limitation of proteomics studies on 
neurodegenerative disorders is the static view they convey. Indeed, investigated models are usually 
considered at a single time point, with no consideration for systems dynamics. Conversely, to obtain 
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a comprehensive image of altered processes in neurodegeneration, it would be important to observe 
how specific molecular factors and pathways are dysregulated during disease progression. 
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Supplementary Table 2.1. PMIDs of studies used to generate “_Proteins” input lists. Colours indicate the organism used in 
the proteomics analysis. Blue: Homo Sapiens, Red: Mus musculus and Green: other organisms.  
 PMID 
AD 
11747211, 15756939, 15797529, 16519965, 17050040, 17111439, 17309106, 18648492, 18648646, 19241155, 
20061648, 21237293, 21368863, 21388376, 21699958, 21883897, 21954051, 22559202, 22634250, 22926577, 
23050487, 23154051, 23211594, 23231993, 23276639, 23391701, 23424162, 23457027, 23512986, 23537733, 
23963966, 24306222, 24606058, 24893329, 25108202, 25457556, 25756589, 25818006, 25958317, 26059363 
PD 
15526345, 15755676, 15790536, 16150055, 16565515, 16889417, 17203978, 17490626, 17532186, 17705834, 
18173235, 18226537, 18270577, 18338827, 18353766, 18384645, 18782562, 19498008, 19725078, 20155936, 
20334438, 20403401, 20563739, 20594931, 20977677, 21136655, 21296869, 21296869, 21322648, 21960009, 
21988495, 22315971, 22410244, 22445325, 23562983, 24040246, 24449343, 24675778, 24737941, 24806433, 
24834013, 24841483, 25626353, 25683516, 25865804, 26468903 
ALS 17979159, 17196550, 16847061, 15863242, 15501831, 19357085, 12475980, 25743254 
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Supplementary Table 2.2. Summary of the protein level variations in PD complexes. ↓ indicates a down-regulation of the protein in PD, ↑ indicates up-regulation of 
proteins in PD. 
 Gene Symbol Expression Pubmed ID Model used 
Respiratory chain 
UQCRB ↓ 24449343 Human SN 
UQCRC1 
↓ 24841483 Striatum in unilateral 6-OHDA-rat model 
↑ 22445325 α-synuclein overexpression in SH-SY5Y cells 
UQCRC2 
↓ 22410244 Human SN 
↓ 18338827 Ventral midbrain in MPTP-treated L1cam transgenic mice (1 day) 
↑ 18338827 Ventral midbrain in MPTP-treated L1cam transgenic mice (7 days) 
UQCRH 
↑ 21960009 Nigrostriatal area in A53T and wt α-synuclein mice 
↓ 15790536 SN in mice treated chronically with MPTP for 5 weeks 
UQCRSF1 
↑ 20403401 SN in 6-OHDA rat model 
↓ 18270577 Striatum in MPTP macaque model 
↑ 16565515 Human SN 
CYC1 
↑ 18173235 Striatum in MPTP and METH mice models 
↓ 15790536 SN in mice treated chronically with MPTP for 5 weeks 
CCT complex 
TCP1 
↑ 16150055 Cortical and striatal tissue of PARK2 knockout mice 
↑ 25865804 mutant parkin (Q311R and A371T) overexpression in SH-SY5Y cells 
CCT4 
↑ 18338827 Ventral midbrain in MPTP-treated L1cam transgenic mice (1 day) 
↑ 18173235 Striatum in MPTP mice model 
↑ 18173235 Striatum in METH mice model 
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 Gene Symbol Expression Pubmed ID Model used 
CCT complex 
CCT5 
↓ 22445325 α-synuclein overexpression in SH-SY5Y cells 
↑ 21322648 MPTP-treated N2a cells 
↓ 15790536 SN in mice treated chronically with MPTP for 5 weeks 
↑ 25626353 Whole brain in PINK1 knockout mice 
CCT6A ↑ 18338827 Ventral midbrain in MPTP-treated L1cam transgenic mice (1 day) 
CCT7 
↑ 22445325 α-synuclein overexpression in SH-SY5Y cells 
↑ 18338827 Ventral midbrain in MPTP-treated L1cam transgenic mice (1 day) 
PPP2A complex 
PPP2CA ↓ 24449343 Human SN 
PPP2CB 
↑ 16150055 Cortical and striatal tissue in PARK2 knockout mice 
↑ 26468903 α-synuclein fibrils-exposed SH-SY5Y cells 
PPP2R4 
↓ 20403401 SN in 6-OHDA rat model 
↑ 20403401 SN in 6-OHDA rat model 
PPP2R5A ↓ 15790536 SN in mice treated chronically with MPTP for 5 weeks 
Proteasome complex 
PSMB1 ↑ 21296869 Parkin-expressing SH-SY5Y cells treated with CCCP 
PSMB3 ↑ 21296869 Parkin-expressing SH-SY5Y cells treated with CCCP 
PSMB5 
↑ 21296869 Parkin-expressing SH-SY5Y cells treated with CCCP 
↑ 16150055 Cortical and striatal tissue in PARK2 knockout mice 
PSMA1 
↑ 22315971 Co-expression of wt or mutated LRRK2 and Tau in C. elegans 
↑ 21296869 Parkin-expressing SH-SY5Y cells treated with CCCP 
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 Gene Symbol Expression Pubmed ID Model used 
Proteasome complex 
PSMA3 
↑ 21960009 Nigrostriatal area in A53T and wt α-synuclein mice 
↑ 21296869 Parkin-expressing SH-SY5Ycells treated with CCCP 
PSMA7, PSMA5 
↑ 21296869 Parkin-expressing SH-SY5Ycells treated with CCCP 
↓ 18338827 Ventral midbrain in MPTP-treated L1cam transgenic mice (1 day) 
PSMC2 
↓ 20403401 SN in 6-OHDA rat model 
↓ 22445325 α-synuclein overexpression in SH-SY5Y cells 
PSMC1 ↓ 15790536 SN in mice treated chronically with MPTP for 5 weeks 
PSMC3 ↓ 18338827 Ventral midbrain in MPTP-treated L1cam transgenic mice (1 day) 
UCHL5 ↓ 17705834 Rotenone-treated MES cells 
USP14 ↑ 18173235 Striatum in MPTP and METH mice models 
6-OHDA: 6-hydroxydopamine, LRRK2: Leucine-rich repeat kinase 2, MES cells: dopaminergic neuronal cell line, METH: methamphetamine, MPTP:1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine, N2a 
cells: murine neuroblastoma cell line, PARK2: Parkin gene, PINK1: PTEN-induced putative kinase 1, SH-SY5Ycells: human neuroblastoma cell line.   
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Supplementary Table 3.1. Gender and age distributions. 
Patients Genetic analysis Riluzole ALSFRS Score Gender Birth date 
ALS_r1 wt 50mgx2/d 28 M 1954 
ALS_r2 wt 50mgx2/d 33 M 1959 
ALS_r3 wt 50mg/d 29 F 1943 
ALS_r4 C9orf72 50mg/d 16 F 1949 
ALS_r5 SOD1 50mgx2/d 25 F 1950 
ALS_r6 wt 50mgx2/d 26 M 1941 
ALS_r7 wt 50mgx2/d 40 M 1953 
ALS_r8 wt 50mg/d 39 M 1951 
ALS_r9 wt 50mgx2/d 37 M 1943 
ALS_r10 wt 50mgx2/d 31 F 1941 
ALS_r11 wt 50mgx2/d 44 M 1960 
ALS_r12 wt 50mgx2/d 29 F 1940 
ALS_r13 wt 50mgx2/d 21 M 1941 
ALS_r14 wt 50mgx2/d 24 F 1943 
ALS_r15 wt 50mgx2/d 16 F 1965 
ALS_r16 wt 50mg/d 42 F 1955 
ALS_r17 wt 50mgx2/d MISS F 1964 
ALS_r18 wt 50mgx2/d 22 M 1943 
ALS_r19 C9orf72 50mgx2/d 37 F 1946 
ALS_r20 N.D. 50mgx2/d 36 M 1976 
ALS1 wt NO 43 M 1943 
ALS2 wt 50mgx2/d 45 M 1960 
ALS3 wt 50mgx2/d 40 M 1947 
ALS4 wt 50mgx2/d 39 M 1947 
ALS5 wt 50mgx2/d 39 F 1946 
ALS6 N.D. NO 45 M 1948 
ALS7 wt NO 25 F 1974 
ALS8 wt 50mgx2/d 43 M 1948 
ALS9 wt 50mgx2/d 33 M 1952 
ALS10 wt 50mgx2/d 37 M 1962 
ALS11 wt 20ml/d 41 F 1934 
ALS12 wt NO 25 F 1960 
ALS13 wt 50mgx2/d 25 M 1940 
ALS14 N.D. NO 37 M 1946 
ALS15 N.D. 50mgx2/d 47 M 1946 
ALS16 wt 50mgx2/d 40 M 1953 
ALS17 wt 50mgx2/d 47 M 1959 
ALS18 wt 50mgx2/d 31 F 1938 
ALS19 wt 50mgx2/d 42 F 1943 
ALS20 wt 50mgx2/d 28 F 1931 
PD1    M 1943 
PD2    F 1946 
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Patients Genetic analysis Riluzole ALSFRS Score Gender Birth date 
PD3    F 1946 
PD4    F 1943 
PD5    M 1947 
PD6    M 1947 
PD7    M 1958 
PD8    F 1961 
PD9    M 1971 
PD10    F 1969 
PD11    M 1966 
PD12    F 1966 
PD13    M 1951 
PD14    F 1963 
PD15    F 1942 
PD16    M 1946 
PD17    F 1950 
PD18    F 1958 
PD19    M 1940 
PD20    F 1948 
ALS-PD1 wt 50mgx2/d 27 M 1936 
ALS-PD2 wt 50mgx2/d 41 F 1951 
ALS-PD3 wt NO 38 F 1939 
ALS-PD4 N.D. NO 34 M 1944 
ALS-PD5 N.D. 50mgx2/d 29 F 1958 
ALS-PD6 wt 50mgx2/d 19 M 1942 
ALS-PD7 wt 50mgx2/d 20 M 1941 
ALS-PD8 N.D. 50mgx2/d 29 M 1956 
ALS-PD9 wt MISS 26 M 1952 
 
Supplemental Table 3.2. Coefficients of linear correlations of riluzole-sensitive spots with ALSFRS score. 
Spots N° Coefficients 
ALSFRS 
Pearson 
correlation 
498 0.037 p = 0.814 
507 -0.138 p = 0.415 
567 -0.130 p = 0.380 
580 0.003 p = 0.986 
603 0.073 p = 0.648 
624 0.212 p = 0.208 
631 0.356 p = 0.016 
648 0.101 p = 0.513 
649 -0.075 p = 0.619 
681 0.105 p = 0.476 
684 -0.297 p = 0.047 
728 0.207 p = 0.167 
787 -0.014 p = 0.935 
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Supplemental Table 3.3. All pathways significantly (FRD<0.001) over-represented using Reactome as reference database. 
Pathway Name 
Entities Reactions 
Found Total Ratio Pvalue FDR Found Total Ratio 
Prefoldin mediated transfer of substrate to 
CCT/TriC 
6 28 0.002019 1.25E-10 2.58E-08 2 2 1.72E-04 
Cooperation of Prefoldin and TriC/CCT in 
actin and tubulin folding 
6 36 0.002596 5.57E-10 5.74E-08 6 6 5.15E-04 
Platelet degranulation 8 137 0.009878 2.14E-09 8.65E-08 2 11 9.45E-04 
Signaling by high-kinase activity BRAF 
mutants 
6 46 0.003317 2.38E-09 8.65E-08 4 6 5.15E-04 
MAP2K and MAPK activation 6 47 0.003389 2.70E-09 8.65E-08 4 8 6.87E-04 
Signaling by moderate kinase activity BRAF 
mutants 
6 48 0.003461 3.06E-09 8.65E-08 4 7 6.01E-04 
Response to elevated platelet cytosolic Ca2+ 8 144 0.010383 3.15E-09 8.65E-08 2 14 0.001202 
Paradoxical activation of RAF signaling by 
kinase inactive BRAF 
6 49 0.003533 3.46E-09 8.65E-08 4 7 6.01E-04 
Hemostasis 14 806 0.058115 5.60E-09 1.23E-07 31 327 0.028086 
Recycling pathway of L1 6 54 0.003894 6.14E-09 1.23E-07 7 14 0.001202 
Signaling by RAS mutants 6 61 0.004398 1.26E-08 2.27E-07 4 8 6.87E-04 
Signaling by BRAF and RAF fusions 6 68 0.004903 2.39E-08 3.90E-07 4 5 4.29E-04 
HSP90 chaperone cycle for steroid hormone 
receptors (SHR) 
6 69 0.004975 2.60E-08 3.90E-07 9 12 0.001031 
Immune System 22 2638 0.190208 3.20E-08 4.48E-07 22 1470 0.126256 
RHO GTPases activate IQGAPs 5 35 0.002524 3.62E-08 4.70E-07 2 5 4.29E-04 
Gene and protein expression by JAK-STAT 
signaling after Interleukin-12 stimulation 
6 74 0.005336 3.92E-08 4.70E-07 3 36 0.003092 
L1CAM interactions 7 129 0.009301 3.97E-08 4.76E-07 10 54 0.004638 
Cellular responses to stress 11 511 0.036845 4.33E-08 4.77E-07 34 184 0.015803 
Interleukin-12 signaling 6 85 0.006129 8.82E-08 8.82E-07 3 56 0.00481 
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Pathway Name 
Entities Reactions 
Found Total Ratio Pvalue FDR Found Total Ratio 
Oncogenic MAPK signaling 6 87 0.006273 1.01E-07 1.01E-06 20 34 0.00292 
Interleukin-12 family signaling 6 97 0.006994 1.90E-07 1.69E-06 3 114 0.009791 
Gap junction trafficking 5 50 0.003605 2.09E-07 1.69E-06 7 20 0.001718 
Cellular responses to external stimuli 11 598 0.043118 2.11E-07 1.69E-06 34 254 0.021816 
Chaperonin-mediated protein folding 6 99 0.007138 2.14E-07 1.72E-06 6 19 0.001632 
GRB2:SOS provides linkage to MAPK 
signaling for Integrins 
4 20 0.001442 2.46E-07 1.72E-06 2 2 1.72E-04 
Microtubule-dependent trafficking of 
connexons from Golgi to the plasma membrane 
4 21 0.001514 2.98E-07 2.09E-06 1 2 1.72E-04 
Protein folding 6 105 0.007571 3.02E-07 2.11E-06 15 28 0.002405 
Gap junction trafficking and regulation 5 54 0.003894 3.05E-07 2.14E-06 7 24 0.002061 
p130Cas linkage to MAPK signaling for 
integrins 
4 22 0.001586 3.58E-07 2.15E-06 3 3 2.58E-04 
Transport of connexons to the plasma 
membrane 
4 22 0.001586 3.58E-07 2.15E-06 1 3 2.58E-04 
Post-chaperonin tubulin folding pathway 4 24 0.00173 5.05E-07 3.03E-06 9 9 7.73E-04 
COPI-independent Golgi-to-ER retrograde 
traffic 
5 62 0.00447 6.00E-07 3.11E-06 2 7 6.01E-04 
Platelet activation, signaling and aggregation 8 288 0.020766 6.22E-07 3.11E-06 22 114 0.009791 
Formation of tubulin folding intermediates by 
CCT/TriC 
4 29 0.002091 1.07E-06 5.34E-06 2 2 1.72E-04 
Translocation of SLC2A4 (GLUT4) to the 
plasma membrane 
5 78 0.005624 1.83E-06 9.17E-06 3 15 0.001288 
Integrin alphaIIb beta3 signaling 4 39 0.002812 3.43E-06 1.71E-05 20 24 0.002061 
Integrin signaling 4 39 0.002812 3.43E-06 1.71E-05 20 24 0.002061 
Gap junction assembly 4 39 0.002812 3.43E-06 1.71E-05 3 16 0.001374 
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Pathway Name 
Entities Reactions 
Found Total Ratio Pvalue FDR Found Total Ratio 
COPI-mediated anterograde transport 5 106 0.007643 8.07E-06 3.23E-05 2 12 0.001031 
Carboxyterminal post-translational 
modifications of tubulin 
4 51 0.003677 9.80E-06 3.92E-05 6 6 5.15E-04 
Factors involved in megakaryocyte 
development and platelet production 
6 193 0.013916 9.88E-06 3.95E-05 5 43 0.003693 
Platelet Aggregation (Plug Formation) 4 53 0.003821 1.14E-05 4.56E-05 20 27 0.002319 
Intraflagellar transport 4 55 0.003966 1.32E-05 5.27E-05 6 12 0.001031 
Kinesins 4 67 0.004831 2.84E-05 1.13E-04 2 14 0.001202 
Golgi-to-ER retrograde transport 5 147 0.010599 3.83E-05 1.53E-04 4 18 0.001546 
MHC class II antigen presentation 5 147 0.010599 3.83E-05 1.53E-04 1 26 0.002233 
RHO GTPases Activate Formins 5 148 0.010671 3.96E-05 1.58E-04 9 27 0.002319 
The role of GTSE1 in G2/M progression after 
G2 checkpoint 
4 82 0.005912 6.19E-05 1.86E-04 3 10 8.59E-04 
ER to Golgi Anterograde Transport 5 163 0.011753 6.24E-05 1.87E-04 2 39 0.00335 
RAF/MAP kinase cascade 6 270 0.019468 6.42E-05 1.93E-04 4 39 0.00335 
MAPK1/MAPK3 signaling 6 277 0.019973 7.39E-05 2.22E-04 4 46 0.003951 
Regulation of TLR by endogenous ligand 3 31 0.002235 7.54E-05 2.26E-04 1 12 0.001031 
Common Pathway of Fibrin Clot Formation 3 34 0.002452 9.90E-05 2.97E-04 4 29 0.002491 
Axon guidance 8 582 0.041964 1.01E-04 3.03E-04 13 297 0.025509 
Recruitment of NuMA to mitotic centrosomes 4 96 0.006922 1.13E-04 3.40E-04 1 2 1.72E-04 
COPI-dependent Golgi-to-ER retrograde traffic 4 106 0.007643 1.65E-04 4.96E-04 2 11 9.45E-04 
Glycolysis 4 108 0.007787 1.77E-04 5.32E-04 3 24 0.002061 
MAPK family signaling cascades 6 328 0.02365 1.85E-04 5.55E-04 4 86 0.007386 
Mitotic Anaphase 5 207 0.014925 1.90E-04 5.70E-04 3 11 9.45E-04 
Mitotic Metaphase and Anaphase 5 208 0.014997 1.94E-04 5.81E-04 3 12 0.001031 
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Pathway Name 
Entities Reactions 
Found Total Ratio Pvalue FDR Found Total Ratio 
Signaling by Interleukins 8 640 0.046146 1.94E-04 5.81E-04 4 491 0.042171 
Intra-Golgi and retrograde Golgi-to-ER traffic 5 217 0.015646 2.36E-04 5.81E-04 4 48 0.004123 
Transport to the Golgi and subsequent 
modification 
5 218 0.015719 2.41E-04 5.81E-04 2 60 0.005153 
Hedgehog 'off' state 4 123 0.008869 2.90E-04 5.81E-04 2 32 0.002748 
Formation of Fibrin Clot (Clotting Cascade) 3 52 0.003749 3.43E-04 6.86E-04 4 57 0.004896 
Resolution of Sister Chromatid Cohesion 4 133 0.00959 3.90E-04 7.80E-04 4 8 6.87E-04 
Glucose metabolism 4 139 0.010022 4.60E-04 9.20E-04 5 50 0.004294 
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Supplemental Table 4.1: ORA of PD sub-cluster. Reactome and GO BP were used as reference. 
Reactome GO BP 
Pathway name FDR Pathway name 
Fold 
enrichment 
FDR 
Pink/Parkin Mediated 
Mitophagy 
3.92E-04 
establishment of mitochondrion localization, microtubule-mediated 
(GO:0034643) 
30.64 1.87E-05 
Mitochondrial protein import 4.82E-04 mitochondrion transport along microtubule (GO:0047497) 30.64 1.89E-05 
Mitophagy 8.02E-04 establishment of mitochondrion localization (GO:0051654) 25.54 4.07E-05 
  mitochondrion localization (GO:0051646) 22.7 4.12E-08 
  GTP metabolic process (GO:0046039) 22.34 1.22E-05 
  guanosine-containing compound metabolic process (GO:1901068) 19.15 8.35E-07 
  protein targeting to mitochondrion (GO:0006626) 14.86 2.02E-05 
  regulation of cellular response to heat (GO:1900034) 13.62 6.61E-04 
  purine ribonucleoside metabolic process (GO:0046128) 13.13 1.06E-05 
  purine nucleoside metabolic process (GO:0042278) 12.59 1.36E-05 
  protein localization to mitochondrion (GO:0070585) 12.1 1.74E-05 
  establishment of protein localization to mitochondrion (GO:0072655) 11.67 8.78E-05 
  mitochondrial membrane organization (GO:0007006) 11.44 3.23E-08 
  aerobic respiration (GO:0009060) 11.19 1.13E-04 
  regulation of membrane permeability (GO:0090559) 10.48 1.63E-04 
  regulation of mitochondrial membrane permeability (GO:0046902) 10.21 6.71E-04 
  organelle transport along microtubule (GO:0072384) 9.93 7.82E-04 
  ribonucleoside metabolic process (GO:0009119) 9.89 6.78E-05 
  mitochondrial transport (GO:0006839) 8.81 1.94E-08 
  purine ribonucleoside triphosphate metabolic process (GO:0009205) 8.28 1.53E-08 
  respiratory electron transport chain (GO:0022904) 8.17 7.07E-04 
  ribonucleoside triphosphate metabolic process (GO:0009199) 8.06 1.91E-08 
  purine nucleoside triphosphate metabolic process (GO:0009144) 8.03 1.97E-08 
  mitochondrion organization (GO:0007005) 7.95 2.46E-16 
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Reactome GO BP 
Pathway name FDR Pathway name 
Fold 
enrichment 
FDR 
  oxidative phosphorylation (GO:0006119) 7.93 8.32E-04 
  nucleoside metabolic process (GO:0009116) 7.73 3.35E-04 
  nucleoside triphosphate metabolic process (GO:0009141) 7.38 4.54E-08 
  regulation of neurotransmitter transport (GO:0051588) 6.91 7.08E-04 
  positive regulation of cell morphogenesis involved in differentiation 
(GO:0010770) 
6.86 2.78E-04 
  macroautophagy (GO:0016236) 6.66 8.86E-04 
  response to glucose (GO:0009749) 6.57 9.64E-04 
  cellular respiration (GO:0045333) 6.55 3.86E-04 
  regulation of mitochondrion organization (GO:0010821) 6.46 1.70E-04 
  energy derivation by oxidation of organic compounds (GO:0015980) 6.33 1.36E-05 
  purine ribonucleoside monophosphate metabolic process (GO:0009167) 6.27 1.48E-05 
  cytoskeleton-dependent intracellular transport (GO:0030705) 6.27 5.36E-04 
  purine nucleoside monophosphate metabolic process (GO:0009126) 6.24 1.50E-05 
  ribonucleoside monophosphate metabolic process (GO:0009161) 5.91 2.61E-05 
  ATP metabolic process (GO:0046034) 5.88 3.48E-04 
  electron transport chain (GO:0022900) 5.77 9.53E-04 
  purine ribonucleotide metabolic process (GO:0009150) 5.55 3.06E-08 
  regulation of stress-activated MAPK cascade (GO:0032872) 5.55 2.46E-04 
  regulation of stress-activated protein kinase signaling cascade (GO:0070302) 5.52 2.55E-04 
  purine nucleotide metabolic process (GO:0006163) 5.51 1.95E-08 
  regulation of Ras protein signal transduction (GO:0046578) 5.5 2.65E-04 
  nucleoside monophosphate metabolic process (GO:0009123) 5.42 6.12E-05 
  ribose phosphate metabolic process (GO:0019693) 5.36 2.61E-08 
  ribonucleotide metabolic process (GO:0009259) 5.36 4.78E-08 
  cellular response to peptide hormone stimulus (GO:0071375) 5.27 1.72E-04 
Continue → 
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Reactome GO BP 
Pathway name FDR Pathway name 
Fold 
enrichment 
FDR 
  regulation of cell morphogenesis involved in differentiation (GO:0010769) 5.16 4.51E-05 
  apoptotic signaling pathway (GO:0097190) 5.16 9.96E-05 
  regulation of protein polymerization (GO:0032271) 5.15 9.59E-04 
  cellular response to peptide (GO:1901653) 5.11 5.02E-05 
  purine-containing compound metabolic process (GO:0072521) 5.09 4.99E-08 
  regulation of small GTPase mediated signal transduction (GO:0051056) 5.06 2.60E-05 
 
 
  
 
 
8.2 
Supplemental Figures 
 
Supplementary Figure 2.1: Physical interaction network of “_Proteins” lists. Network-based analysis of the (A) “AD_Proteins” 
list, (B) “PD_Proteins” list and (C) “ALS_Proteins” list, using the IntAct database as the reference set (PPI spider).  network 
is statistically significant (p < 0.01). 
(A) 
 
(B) 
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(C) 
 
 
 
Supplementary Figure 2.2: Merged PPI networks. Network obtained by the union of AD, PD and ALS PPI networks (View 
Supplementary Figure 1). The colour code indicates which nodes are disease-specific and which nodes are shared by different 
diseases.  
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Supplemental Figure 3.1: Distribution density of the sum of common spot volumes 
 
 
 
Supplemental Figure 3.2: Distribution of missing values. The horizontal line represents the chosen threshold of 24 missing 
values. 
 
  
Supplemental Figures 
 
146 
 
Supplemental Figure 3.3: (A) Scatter plot of a pair of gels belonging to the same group. The Pearson correlation coefficient is 
reported under the plot, together with the slope of the straight line. (B) Quantile-quantile plot for the residuals of the linear 
fit in panel A. A linear correlation between t quantiles and studentized residuals indicates that gels are comparable. 
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Supplemental Figure 3.4: 7 spots gender-sensible Box plot relative to the spots that significantly correlate with the gender by 
the Wilcoxon test ( p<0.01). In “pink” are reported female patients, while in “light blue” are represented male patients. 
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Supplemental Figure 3.5: 21 spots age-sensible Pearson correlation relative to the spots that significantly correlate (p<0.01) 
with age of patient at the withdrawal. In “yellow” are reported ALS patients, in “red” ALS_r patients, in “green” PD patients 
while in “blue” are displayed ALS-PD patients. 
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Supplemental Figure 3.6: 13 spots riluzole-sensible Box plot relative to the spots that significantly correlate by the Student T 
test ( p<0.01) with drug treatment. In “yellow” are reported ALS patients and in “red” ALS_r patients. 
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Supplemental Figure 3.7: (A) Cross-validation performed with the Leave-one-out process. (B) Cross-validation obtained by 
the k-fold method. In “black” the percentage relative to the sensibility of each model is reported, in “dark gray” the specificity 
and in “light gray” the area under the ROC curve. The dashed line indicates the 33 spot model chosen because of the best 
performance. 
A 
 
B 
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Supplemental Figure 3.8: graphical representation of PCA. The 5 ALS-PD patients classified as PD (blue spots) and the 4 
ALS-PD patients classified as ALS (red spots) were discriminate for 25.4% by PC1.
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Supplemental Figure 5.1: Representative images of SH-SY5Y cells treated for 24 hours with different mitochondrial toxins. 
Red (Mitotracker) indicates mitochondria with intact Δψm.  
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8.3 
Supplemental Data 
 
Supplemental Data 4.1: query to obtain all mitochondrial proteins. Data was extracted from neXtProt using the advanced 
search functionality based on SPARQL language on the neXtProt SNORQL interface 
select distinct ?entry ?interactant where {  
   values ?entry { #This is to replace with MITO list entries entry:NX_….  
entry:NX_…. 
      }  
       ?entry :isoform /:binaryInteraction ?interaction. 
?interaction :interactant ?interactant, :quality :GOLD.  
?interactant a :Entry. 
} 
 
Supplemental Data 4.2: query to obtain all gold protein-protein interactions from the protein interaction section. Information 
was extracted from neXtProt using the advanced search functionality based on SPARQL language on the neXtProt SNORQL 
interface 
select distinct ?entry ?comment where { 
  values ?entry { entry: #This is to replace with MITO list entries 
} 
  ?entry :isoform ?iso. 
  ?iso :interactionInfo /rdfs:comment ?comment. 
} 
 
Supplemental Data 4.3: query to obtain subcellular location data. Information was extracted from neXtProt using the advanced 
search functionality based on SPARQL language on the neXtProt SNORQL interface 
select distinct ?entry where {  
   values ?mitoloc {cv:#Uniprot code cv:GO code}  
       ?entry :isoform ?iso.  
       ?iso :cellularComponent ?loc .  
       ?loc :term/:childOf ?mitoloc .  
       ?loc :evidence / :quality :GOLD .  
       filter not exists {?loc :negativeEvidence ?_.}  
} 
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Supplemental Data 4.4: query to obtain mitochondrial with unknown function. Data was extracted from neXtProt using the 
advanced search functionality based on SPARQL language on the neXtProt SNORQL interface 
select distinct ?entry where { 
 ?entry :isoform ?iso. 
 filter not exists { ?iso :functionInfo ?_ . } 
 filter not exists { ?iso :function ?func . 
                     optional {?func :term ?fterm1 .} 
                     filter(!bound(?fterm1)) #eliminates functions from 
pathways 
                   } 
 filter not exists { 
                       ?iso :function / :term ?fterm . 
                       filter(?fterm != cv:GO_0005524 && ?fterm != 
cv:GO_0000287 && ?fterm != cv:GO_0005515 && ?fterm != cv:GO_0042802 
                              && ?fterm != cv:GO_0008270 && ?fterm != 
cv:GO_0051260 && ?fterm != cv:GO_0005509 
                              && ?fterm != cv:GO_0003676 && ?fterm != 
cv:GO_0003824 && ?fterm != cv:GO_0007165 && ?fterm != cv:GO_0035556) 
                      # eliminates proteins whose ONLY GO functions are 
one of ATP-binding, magnesium-binding, calcium-binding, zinc-binding, 
                      # nucleic acid binding, protein-binding, identical 
protein binding, protein homooligomerization, catalytic activity, signal 
transduction, 
                    } 
} 
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